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Abstract 
The vasculature has a crucial function in normal physiology, enabling the 
transport of oxygen and nutrients to cells throughout the body. In turn, endothelial cells, 
which form the inner-most lining of blood vessels, are key regulators of vascular 
function. In addition to forming a barrier which separates the circulation from 
underlying tissues, endothelial cells respond to diverse extracellular cues and produce a 
variety of biologically-active mediators in order to maintain vascular homeostasis. 
Disruption of normal vascular function is a prominent feature of a variety of 
pathological conditions. Thus, elucidating the signaling pathways regulating endothelial 
function is critical for understanding the role of endothelial cells in both normal 
physiology and pathology, as well as for potential development of therapeutic 
interventions. 
In this dissertation, we use a combination of pharmacological inhibition and 
knockdown studies, along with generation of endothelial conditional knockout mice, to 
demonstrate an important role of the Abelson (Abl) family of non-receptor tyrosine 
kinases (Abl and Arg) in vascular function. Specifically, loss of endothelial expression of 
the Abl kinases leads to late-stage embryonic and perinatal lethality in conditional 
knockout mice, indicating a crucial requirement for Abl/Arg kinases in normal vascular 
development and function. Endothelial Abl/Arg-null embryos display focal regions of 
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vascular loss and tissue damage, as well as increased endothelial cell apoptosis. An 
important pro-survival function for the Abl kinases is further supported by our finding 
that either microRNA-mediated Abl/Arg depletion or pharmacological inhibition of the 
Abl kinases increases endothelial cell susceptibility to stress-induced apoptosis in vitro. 
The Abl kinases are activated in response to treatment with the pro-angiogenic growth 
factors vascular endothelial growth factor (VEGF) and basic fibroblast growth factor 
(bFGF). We show that both VEGF- and bFGF-mediated endothelial cell survival is 
impaired following Abl kinase inhibition. 
These studies have uncovered a previously unappreciated role for the Abl 
kinases in the regulation of the angiopoietin/Tie2 signaling pathway, which functions to 
support endothelial cell survival and vascular stability. Loss of Abl/Arg expression leads 
to reduced mRNA and protein levels of the Tie2 receptor, resulting in impaired 
activation of intracellular signaling pathways by the Tie2 ligand angiopoietin-1 
(Angpt1), as well as decreased Angpt1-mediated endothelial cell survival following 
serum-deprivation stress. Notably, we found that the Abl kinases are activated 
following Angpt1 stimulation, suggesting a unique dual role for Abl and Arg in 
Angpt/Tie2 signaling, potentially modulating Tie2 downstream signaling responses, as 
well as regulating Tie2 receptor expression. 
Further, we show an important contribution of the Abl family kinases to the 
regulation of endothelial permeability responses both in vitro and in vivo. The Abl 
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kinases are activated in response to a diverse group of permeability-inducing factors, 
including VEGF and the inflammatory mediators thrombin and histamine. We show 
that inhibition of Abl kinase activity, using either the ATP-competitive inhibitor imatinib 
or the allosteric inhibitor GNF-2, protects against disruption of endothelial barrier 
function by the permeability-inducing factors in vitro. VEGF-induced vascular 
permeability similarly is decreased in conditional knockout mice lacking endothelial Abl 
expression, as well as following treatment with Abl kinase inhibitors in vivo. 
Mechanistically, we show that loss of Abl kinase activity is accompanied by activation of 
the barrier-stabilizing GTPases (guanosine triphosphatases) Rac1 and Rap1, as well as 
inhibition of agonist-induced Ca2+
Taken together, these results demonstrate involvement of the Abl family kinases 
in the regulation of endothelial cell responses to a broad range of pro-angiogenic and 
permeability-inducing factors, as well as a critical requirement for the endothelial Abl 
kinases in normal vascular development and function in vivo. These findings have 
implications for the clinical use of Abl kinase inhibitors. 
 mobilization and generation of acto-myosin 
contractility. 
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1. Background and Significance 
The vasculature plays an important role in normal physiology, enabling the 
transport of oxygen and nutrients to cells throughout the body. The endothelium, which 
forms the inner-most lining of blood vessels, functions to separate the circulation from 
the underlying tissues. While early vascular biologists thought of endothelial cells as 
forming a static barrier, “a sheet of nucleated cellophane [1],” it has become clear that 
the endothelium is actually a dynamic, multifunctional organ. Endothelial cells are key 
players in vascular function, responding to diverse extracellular cues, as well as 
producing a variety of biologically-active mediators, in order to maintain vascular 
homeostasis [2]. In addition to forming a semi-permeable barrier between tissues and 
the bloodstream, which controls the transport of solutes and immune cells into and out 
of the circulation, endothelial cells regulate vasoreactivity and act to maintain the 
vasculature in an anti-thrombotic state [2]. As disruption of vascular homeostasis is a 
key feature of a variety of pathological conditions [2,3,4], elucidating the signaling 
pathways regulating endothelial function is critical for understanding the role of 
endothelial cells in both normal physiology and pathology, as well as for potential 
development of therapeutic interventions. 
1.1 Vascular Development 
The mature vasculature exists as an extensive network of interconnected, 
hierarchically-organized blood vessels. This complex vascular network is generated 
 2 
primarily through two broad mechanisms, vasculogenesis and angiogenesis. 
Vasculogenesis is the process whereby new blood vessels are created de novo following 
endothelial cell differentiation from multipotent progenitor cells, while angiogenesis 
involves expansion of the vascular network through sprouting or splitting of existing 
blood vessels [5]. 
1.1.1 Vasculogenesis 
The cardiovascular system is the first organ system to form during vertebrate 
embryonic development [6]. The initial blood vessels are formed through the in situ 
differentiation of mesodermal precursors (angioblasts) into endothelial cells. The process 
of vasculogenesis occurs between embryonic day (E) 6 and E10 in mice [7] and is initially 
observed in the extra-embryonic yolk sac membrane, where mesodermal precursors 
cells aggregate to form blood islands. Cells on the periphery of these blood islands 
(angioblasts) differentiate into endothelial cells, while the inner cells (hematopoietic 
progenitor cells) differentiate into blood cells. Within the embryo, angioblasts similarly 
differentiate to form intra-embryonic endothelial cells. These nascent endothelial cells 
coalesce to form vascular tubes, which anastamose to form a primitive vascular network, 
known as the primary capillary plexus [6,8], a process involving alterations in 
endothelial cell morphology, as well as modulation of cell-cell and cell-matrix adhesion 
[9]. Vascular endothelial growth factor (VEGF) is a crucial regulator of vasculogenesis. 
Indeed, mouse embryos lacking expression of VEGF receptor 2 (VEGFR2; also known as 
 3 
Flk1 in mice or Kdr in humans) die between E8.5 and E9.5; these embryos lack blood 
islands and organized blood vessels and exhibit diminished populations of 
hematopoietic progenitors [10].   
1.1.2 Angiogenesis 
The initial unorganized vascular network undergoes a program of expansion, 
pruning, and remodeling in order to form a mature, functional vasculature [9]. Growth 
of the vasculature occurs through the process of angiogenesis, whereby new blood 
vessels are formed from pre-existing vessels. Angiogenic growth can occur either 
through sprouting mechanisms, in which new vessels form by branching off from 
existing vascular channels, or through non-sprouting mechanisms involving splitting of 
existing vessels (i.e., intussusception) [9]. The mechanisms regulating sprouting 
angiogenesis have been most well-characterized. 
Sprouting angiogenesis is a complex process, involving the coordinated 
regulation of a variety of endothelial cell processes, including migration, proliferation, 
survival, and capillary morphogenesis [11]. Initiation of angiogenic sprouting requires 
loosening of endothelial intercellular junctions, enabling endothelial migration in the 
direction of an angiogenic stimulus [5]. The growing vascular sprouts are each lead by a 
specialized endothelial tip cell that dynamically extends numerous filopodia, which 
enable the tip cell to respond to a variety of attractant and repellant stimuli to guide the 
extension of the nascent sprout [8]. While the leading endothelial tip cells mediate 
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directional migration of vascular sprouts, the trailing endothelial cells, known as stalk 
cells, proliferate to extend the stalk of the new vessel [12]. Endothelial tip cells also 
express the metalloproteinase MT1-MMP, which mediates degradation of the 
surrounding extracellular matrix (ECM), allowing for endothelial cell invasion and 
migration during vascular sprouting [13]. 
In addition to its role in vasculogenesis, VEGF is a particularly important 
regulator of sprouting angiogenesis. VEGF-A (VEGF), the primary pro-angiogenic 
member of the VEGF family of ligands, signals through the receptor tyrosine kinase 
VEGFR2 to promote endothelial cell proliferation, migration, and survival [14]. VEGFR2 
is highly expressed in endothelial tip cells, particularly in their filopodia [12]. VEGF 
stimulates extension of tip cell filopodia to promote directional migration and promotes 
proliferation of stalk cells. VEGF signaling is also a critical determinant of tip cell 
identity, through the modulation of Notch pathway activation [15]. VEGFR2 activation 
in tip cells leads to upregulation of the Notch ligand Dll4, which in turn activates Notch 
signaling in neighboring stalk cells, leading to downregulation of VEGFR2 and 
upregulation of the related VEGFR1. As a result, stalk cells become less responsive to 
VEGF, compared to the leading tip cells. Interestingly, tip cell selection is a dynamic 
process, influenced by relative levels of VEGF and Notch pathway activation, which 
allows for the continual modulation of angiogenic sprouting in response to extracellular 
cues [16]. 
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1.1.3 Vascular Remodeling and Maturation 
Following angiogenic expansion, remodeling of the vascular network, 
accompanied by selective pruning (regression) of excess vascular branches, results in the 
generation of a highly-organized, hierarchically-branched vascular system, with tissue-
specific vascular patterning and vessel density [17]. The establishment of blood flow, 
along with the activity of ephrin and Notch signaling pathways, contributes to the 
remodeling of the vascular network to form arteries, veins, and capillaries [8]. However, 
differential expression of arterial (ephrin-B2) and venous (EphB4 receptor) markers has 
been detected in the developing endothelium even prior to onset of circulation, 
suggesting genetic regulation of arterial versus venous specification [18]. Following the 
establishment of circulation, blood is pumped from the heart through the arterial system 
to tissue capillary beds, where exchange of gases and nutrients occur, prior to return of 
the blood to the heart via the venous circulation [8]. Interstitial fluid, which results from 
plasma leakage from the capillaries into the surrounding tissues, is returned to the 
venous circulation through the lymphatic system [19]. The lymphatic vasculature, which 
has an important role in the maintenance of fluid balance, is formed by sprouting from 
embryonic veins, regulated by signaling mediated by the VEGF family member VEGF-
C. 
Formation of a mature, functional vasculature also requires recruitment of mural 
cells, which surround the endothelial tubes and function to stabilize the vessels [20]. 
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Larger vessels are surrounded by multiple layers of contractile vascular smooth muscle 
cells, while smaller vessels are covered by varying numbers of pericytes. These 
periendothelial cells stimulate ECM production to stabilize nascent vessels, as well as 
inhibit endothelial cell proliferation and migration [5]. Mural cells also support 
endothelial cell survival, in part through the production of soluble mediators including 
angiopoietin-1 (Angpt1) [21]. The critical supportive function of these periendothelial 
cells is illustrated by the excessive vessel regression observed following disruption of 
endothelial cell-pericyte interactions in the retinal vasculature [22]. Platelet-derived 
growth factor (PDGF) signaling is an important mediator of vascular maturation. 
Endothelial cells secrete PDGF-B, which binds to the PDGF receptor β (PDGFRβ) on 
pericytes and vascular smooth muscle cells, promoting mural cell recruitment [21]. 
Genetic ablation of PDGF-B or PDGFRβ in mice impairs mural cell coverage of blood 
vessels [23], contributing to vascular abnormalities including endothelial hyperplasia, 
vessel dilation, and impaired barrier function [24], as well as microaneurysms, 
hemorrhage and edema [25,26,27,28]. 
1.2 Endothelial Cell-Cell and Cell-Matrix Adhesion 
In contrast to the angiogenic growth of the vasculature during embryonic 
development and postnatal growth, the endothelial cells of the adult vasculature are 
typically quiescent [29]. However, while quiescent, the mature endothelium is not 
simply a static barrier, but rather, an important regulator of vascular homeostasis [2]. 
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Endothelial cell-cell and cell-matrix adhesions are critical for proper vascular function, 
acting to maintain vascular structure and modulate endothelial cell growth factor 
signaling responses. The major structural components of endothelial cell-cell and cell-
matrix adhesions are shown in Figure 1.1. 
 
Figure 1.1 Structural Components of Endothelial Cell-Cell and Cell-Matrix Adhesions 
Endothelial barrier function and structural integrity are maintained by cell-cell and cell-
matrix adhesions. The two major types of endothelial cell-cell adhesions are formed by 
tight junction and adherens junction protein complexes. The primary structural 
components of tight junctions are transmembrane proteins of the claudin and occludin 
families, which are connected to the actin cytoskeleton through interaction with actin-
binding proteins including ZO-1 and AF-6/afadin. Adherens junctions are composed of 
the transmembrane protein vascular endothelial (VE)-cadherin, which binds 
intracellularly to catenin proteins (β-catenin, α-catenin, and p120-catenin) that function 
to link VE-cadherin to the underlying actin cytoskeleton, as well as regulate VE-cadherin 
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internalization. Endothelial cell-matrix adhesions are mediated by the binding of 
integrin heterodimers (α,β) to the extracellular matrix. The short cytoplasmic tails of 
integrins interact with actin-binding proteins (including talin and vinculin), adaptor 
proteins (paxillin), and signaling mediators (focal adhesion kinase, FAK) to form focal 
adhesion complexes.  
 
1.2.1 Intercellular Junctions 
The endothelium forms a critical semi-permeable barrier between tissues and the 
bloodstream. Maintenance of this barrier is a dynamic and tightly-controlled process, 
which regulates the transport of solutes and immune cells into and out of the circulation. 
While loosening of the endothelial barrier is an important aspect of both normal 
angiogenic remodeling and inflammatory responses [5,30], abnormally elevated 
vascular permeability is a key feature of a variety of pathological conditions, 
contributing to edema, increased interstitial fluid pressure, and tissue damage [31,32]. 
Endothelial cells express a number of cell surface adhesion molecules that cluster at 
interendothelial cell-cell junctions to maintain vascular integrity. The two major types of 
intercellular junctions present in endothelial cells are tight junctions and adherens 
junctions, which together regulate permeability of the endothelial barrier [33]. Along 
with the adhesion proteins that form tight junctions and adherens junctions, endothelial 
cells express several other cell adhesion molecules which localize to interendothelial 
junctions, including platelet endothelial cell adhesion molecule (PECAM-1/CD31) [33]. 
PECAM-1, which also is expressed by monocytes and neutrophils, promotes 
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transendothelial migration of leukocytes [34], likely through homophilic binding 
between endothelial cell and leukocyte PECAM-1 proteins. 
1.2.1.1 Tight Junctions 
Tight junctions are formed primarily by integral membrane proteins of the 
claudin and occludin families. Junctional adhesion molecule (JAM) proteins, which are 
transmembrane proteins of the immunoglobulin superfamily, also are found in tight 
junction protein complexes, as is the related endothelial cell-selective adhesion molecule 
(ESAM) [35]. These proteins cluster in rows to form tight junction complexes, which 
associate with complexes on the membrane of the neighboring endothelial cell to seal the 
intercellular space [36]. Tight junction components associate intracellularly with a 
variety of PDZ domain-containing proteins, including the ZO proteins (ZO-1, ZO-2, and 
ZO-3), AF-6/afadin, and the polarity regulator PAR-3 [37]. ZO proteins and AF-6 bind 
actin filaments, thus linking the tight junction protein complexes to the cortical actin 
cytoskeleton. While most tight junction components are expressed in a variety of cell 
types, the claudin family member claudin-5 is expressed specifically in endothelial cells 
[38]. Mice lacking claudin-5 die perinatally as a result of size-selective loosening of the 
blood-brain barrier [39], demonstrating the importance of tight junctions in maintaining 
endothelial barrier integrity. Notably, the frequency of tight junctions varies 
considerably between different types of vessels or vascular beds. While tight junctions 
are abundant in the blood vessels of the central nervous system, forming the highly 
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impermeable blood-brain barrier, these junctions are less numerous in regions of the 
vasculature characterized by dynamic transport of solutes or leukocytes, such as the 
post-capillary venules [33]. 
1.2.1.2 Adherens Junctions 
In contrast to tight junctions, adherens junctions, which are formed by 
transmembrane proteins of the cadherin family, are found more uniformly throughout 
the vasculature [40]. Endothelial cells express both vascular endothelial cadherin (VE-
cadherin) and neural cadherin (N-cadherin) [41]. N-cadherin does not localize to 
endothelial cell-cell junctions [42], but instead is thought to mediate association of 
endothelial cells with surrounding pericytes [43]. In contrast, VE-cadherin is the major 
structural component of interendothelial adherens junctions and is a critical regulator of 
vascular integrity and endothelial barrier function [44]. Dimerization and clustering of 
VE-cadherin at sites of endothelial cell-cell contact leads to homotypic, Ca2+-dependent 
interaction of the extracellular domains of VE-cadherin proteins on neighboring cells. 
The distal portion of the VE-cadherin intracellular domain binds to β-catenin or 
plakoglobin, which indirectly link VE-cadherin to the actin cytoskeleton through α-
catenin binding [45]. α-catenin interacts with actin filaments, as well as actin-binding 
proteins including vinculin and α-actinin [33]. However, α-catenin appears not to 
interact simultaneously with VE-cadherin protein complexes and with actin filaments 
[46], suggesting dynamic linkage of adherens junctions with the underlying actin 
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cytoskeleton. In lymphatic vessels, plakoglobin can also bind to desmoplakin, which 
mediates association of VE-cadherin with the vimentin cytoskeleton at endothelial cell-
specific desmosome-like structures known as complexus adherens [47]. The intracellular 
domain of VE-cadherin also contains a proximal binding site for p120-catenin; p120-
catenin association functions to inhibit VE-cadherin endocytosis [48].  
Genetic depletion of components of the adherens junction complex in mice has 
demonstrated the important role of these proteins in vascular development and vessel 
integrity. Endothelial β-catenin inactivation leads to embryonic lethality between E11.5 
and E13.5, with mutant embryos displaying abnormal vascular patterning and fragile, 
hemorrhagic vessels [52]. Genetic depletion of VE-cadherin, or expression of a VE-
cadherin cytosolic truncation mutant lacking the β-catenin binding-domain, led to 
embryonic death at E9.5, as a result of defective angiogenic remodeling and extensive 
vascular disintegration and regression [49]. Increased endothelial apoptosis was 
observed in VE-cadherin-deficient embryos, suggesting an important pro-survival 
function for VE-cadherin. Indeed, VE-cadherin was demonstrated to physically associate 
with VEGFR2, promoting VEGF-mediated activation of the pro-survival 
phosphoinositide 3-kinase (PI3K)/Akt pathway [49]. The VE-cadherin/VEGFR2 complex 
inhibits VEGF-induced activation of the p44/42 mitogen-activated protein kinase 
(MAPK, also known as extracellular signal-regulated kinase, Erk), leading to contact 
inhibition of VEGF-induced proliferation in confluent endothelial cells [50]. This 
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modulation of VEGF signaling occurs through VEGFR2 dephosphorylation mediated by 
the VE-cadherin-associated tyrosine phosphatase density-enhanced phosphatase-1 
(DEP-1), leading to inhibition of VEGFR2 internalization and proliferative signaling 
[50,51].  
1.2.2 Cell-Matrix Adhesions 
On the basolateral surface, endothelial cells are separated from the underlying 
interstitium by a thin ECM layer known as the basal lamina [52]. Endothelial cells 
synthesize and secrete a variety of ECM proteins, including collagen IV, fibronectin, and 
laminin [53]. Endothelial cells interact with the surrounding ECM through integrins, 
which are heterodimeric adhesion receptors composed of noncovalently associated α 
and β subunits. A number of integrin heterodimers are expressed by endothelial cells, 
including integrins α1β1, α2β1, α3β1, α5β1, α6β1, αvβ3, and αvβ5 [54]. While the short 
cytoplasmic tails of integrins lack intrinsic enzymatic activity, integrin engagement can 
stimulate intracellular signaling through the recruitment of kinases (including Src and 
focal adhesion kinase, FAK), adaptor proteins (Shc), and regulators of the actin 
cytoskeleton (Rho and Rac small GTPases; actin-binding proteins) to focal adhesion 
complexes, leading to activation of pathways regulating cell motility, morphology, 
proliferation, and survival [54,55]. Integrin signaling is essential for proper vascular 
development. Mice lacking endothelial expression of β1 integrin die by approximately 
E10.5, exhibiting defects in angiogenic remodeling and endothelial disorganization 
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[56,57,58]. β1 integrin function is also required for establishment of endothelial polarity 
and lumen formation [59]. 
In addition to regulating signaling through focal adhesion complexes, integrins 
also modulate the signaling of receptor tyrosine kinases in response to pro-angiogenic 
growth factor stimulation. Integrin αvβ3 has been shown to physically associate with 
activated VEGFR2, promoting VEGF-induced signaling and proliferation [60]. 
Moreover, function-blocking antibodies directed against either integrin αvβ3 or 
1.3 Endothelial Cell Receptor Tyrosine Kinase Signaling 
Pathways  
integrin 
αvβ5 inhibit angiogenesis induced by the angiogenic factors basic fibroblast growth 
factor (bFGF) and VEGF, respectively, through modulation of Erk activation [61,62,63]. 
In addition to cell-cell and cell-matrix adhesions, endothelial function is 
regulated in part by a variety of soluble factors, including pro-angiogenic growth factors 
such as VEGF, bFGF, and the angiopoietins (Angpt) [64,65].  These factors signal 
through receptor tyrosine kinases (RTKs) to support endothelial cell proliferation, 
survival, and migration, as well as vascular stability. Among these factors, the 
VEGF/VEGFR and angiopoietin/Tie receptor systems are relatively endothelial cell-
specific. In the following sections, I will describe the signaling pathways activated by 
VEGF and angiopoietins, as well as the role of these receptor systems in endothelial 
function both in normal physiology and pathology. 
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1.3.1 Vascular Endothelial Growth Factor (VEGF)/VEGFR Pathway 
1.3.1.1 Ligands 
Vascular endothelial growth factor (VEGF) has an important role in regulating 
angiogenesis during development, as well as during both physiological and pathological 
vascularization in adulthood [14]. The VEGF family of secreted glycoproteins includes 
five mammalian members, including VEGF-A, -B, -C, and –D and placenta growth factor 
(PlGF) [66]. Of the VEGF family members, VEGF-A (hereafter referred to as VEGF) is the 
primarily mediator of overall pro-angiogenic effects, while VEGF-C and VEGF-D 
regulate lymphangiogenesis [14,67]. VEGF exists in at least three distinct isoforms 
generated by alterative exon splicing, which are 189, 165, and 120 amino acids in length 
(in humans; the corresponding VEGF isoforms in mice are one residue shorter) [68]; 
these isoforms differ in their affinities for ECM binding [14]. Loss of a single VEGF allele 
in mice results in vascular defects and embryonic lethality [69,70], demonstrating the 
critical developmental role of this growth factor, as well as the requirement for precise 
control of VEGF expression levels for proper vascular development. Interestingly, 
intracrine signaling mediated by endothelial cell-derived VEGF is also required to 
support endothelial cell survival and maintain vascular homeostasis in vivo [71]. 
Hypoxia is an important regulator of VEGF expression [72]. Hypoxic conditions 
lead to stabilization of the transcription factor hypoxia-inducible factor-1α (HIF-1α), as 
well as the related HIF-2α protein, through inhibition of von Hippel-Lindau (VHL)-
dependent HIF ubiquitination and proteasomal degradation. HIF-1α or HIF-2α 
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heterodimerize with HIF-1β (Arnt) to induce transcription of hypoxia-responsive genes 
including VEGF. Thus, hypoxia leads to increased VEGF-induced angiogenic sprouting, 
resulting in recruitment of new blood vessels to hypoperfused tissues. VEGF expression 
also is upregulated in response to a variety of growth factors, including epidermal 
growth factor (EGF), transforming growth factor β (TGFβ), fibroblast growth factor 
(FGF), and PDGF [14]. 
1.3.1.2 Receptors 
VEGF can bind to either of two endothelial RTKs, VEGFR1 (also known as Flt1) 
and VEGFR2 (also known as Flk1 in mice or Kdr in humans) [14]. The related VEGFR3 
receptor binds to VEGF-C and VEGF-D. The VEGF receptors consist of an extracellular 
region containing seven immunoglobulin (Ig)-like domains, a single transmembrane 
domain, and an intracellular tyrosine kinase domain interrupted by a kinase-insert 
domain [73]. Binding of VEGF homodimers stimulates receptor homodimerization, 
resulting in trans-autophosphorylation of the receptor cytoplasmic domains and 
recruitment of signaling mediators. While VEGF binds to VEGFR1 with higher affinity 
than to VEGFR2, VEGF/VEGFR1 binding stimulates only modest receptor activation 
[74]. VEGFR2 thus is thought to mediate most of the pro-angiogenic effects of VEGF [75]. 
The 165 amino acid isoform of VEGF (VEGF165) also binds to the co-receptor 
neuropilin-1, which enhances VEGF/VEGFR2 binding and VEGF-induced proliferation 
and chemotaxis [76] and may regulate VEGFR2 trafficking and signaling [77]. 
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Genetic depletion of VEGFR2 in mice leads to embryonic lethality, with mutant 
embryos dying between E8.5 and E9.5 [10]. These embryos lack blood islands and 
organized blood vessels and exhibit diminished populations of hematopoietic 
progenitors, demonstrating a crucial role for VEGFR2 signaling in both vasculogenesis 
and hematopoiesis. Similarly, VEGFR1 knockout mice die during embryonic 
development but at later stages than VEGFR2 knockout mice (by E11.5), exhibiting 
abnormal vascular organization [78]. However, vascular development was normal in 
mice expressing a mutant form of VEGFR1 lacking the tyrosine kinase domain [79], 
suggesting that the role of VEGFR1 in vascular development is independent of its 
signaling activity. 
1.3.1.3 VEGFR2 Intracellular Signaling and Endothelial Cell Responses 
VEGF was first described both as a potent endothelial cell mitogen [80], as well 
as a permeability-inducing factor [81]. In fact, VEGF can stimulate a variety of pro-
angiogenic responses in endothelial cells, including survival, proliferation, migration, 
permeability, and tube formation [75]. These varied endothelial cell responses result 
from the VEGF-induced activation of a diverse network of intracellular signaling 
mediators (Figure 1.2). VEGF binding results in VEGFR2 trans-autophosphorylation at 
tyrosines (Y) 1175 and Y1214 [82], as well as tyrosines 951, 996, 1054, and 1059 [66].  
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Figure 1.2 Major VEGF Signaling Pathways 
Vascular endothelial growth factor (VEGF) homodimers bind to the receptor tyrosine 
kinase VEGF receptor 2 (VEGFR2), leading to receptor dimerization and trans-
autophosphorylation, which results in recruitment and activation of a variety of 
intracellular signaling mediators. Activation of these signaling pathways results in 
endothelial cell responses including survival, proliferation, migration, and permeability. 
See text for description of VEGF-mediated signaling. Abbreviations: Y, tyrosine; PLCγ, 
phospholipase Cγ; PKC, protein kinase C; MEK, mitogen-activated protein kinase 
kinase; Erk, extracellular signal-regulated kinase; IP3
 
, inositol-1,4,5-trisphosphate; 
MLCK, myosin light chain kinase; PI3K, phosphoinositide 3-kinase; eNOS, endothelial 
nitric oxide synthase; TSAd, T-cell specific adaptor protein;  FAK, focal adhesion kinase; 
PAK, p21-activated kinase; VE-cadherin, vascular endothelial cadherin. 
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VEGFR2 tyrosine phosphorylation results in recruitment of a variety of signaling 
proteins to the activated receptor, mediated by binding of their Src homology-2 (SH2) 
domains to autophosphorylated VEGFR2 tyrosine residues or binding to VEGFR2-
associated adaptor proteins, including Grb2, Nck, and Shc [66,75]. As previously 
described, VEGF signaling also is modulated by interaction of VEGFR2 with VE-
cadherin and integrin adhesion receptors [49,50,51,60]. 
The primary pathway by which VEGF supports endothelial cell survival is 
through activation of the PI3K [83,84]. PI3K catalyzes the production of 
phosphatidylinositol-3,4,5-trisphosphate (PIP3
Phosphorylation of VEGFR2 (Y1175) is required for activation of phospholipase 
Cγ (PLCγ) [82], which contributes to activation of downstream pathways mediating 
endothelial cell proliferation and permeability [75]. PLCγ catalyzes the formation of 
inositol-1,4,5-trisphosphate (IP
), which mediates the membrane 
recruitment of the anti-apoptotic serine/threonine kinase Akt (protein kinase B), 
contributing to Akt activation. Akt inhibits apoptosis in part through phosphorylation 
and inactivation of pro-apoptotic regulators including BAD and caspase-9 [85,86]. VEGF 
stimulation also leads to the upregulation of anti-apoptotic proteins including Bcl-2 and 
A1, as well as the inhibitor of apoptosis proteins (IAPs) survivin and XIAP [87,88]. 
3) and diacylglycerol (DAG) from phosphatidylinositol-
4,5-bisphosphate (PIP2). DAG and increased cytosolic Ca2+ levels, resulting in part from 
IP3-induced release of Ca2+ from intracellular stores, contribute to the activation of the 
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serine/threonine kinase protein kinase C (PKC), which mediates endothelial cell 
proliferation through activation of the Raf-MEK-Erk MAPK cascade [89]. 
The increased cytosolic Ca2+ levels also contribute to activation of endothelial 
nitric oxide synthase (eNOS) [75], which catalyzes the generation of nitric oxide (NO) 
from L-arginine. VEGF treatment further stimulates eNOS activation and NO 
production through Akt-mediated phosphorylation of eNOS on serine (S) 1179 (bovine 
residue; S1177 in human eNOS) [90]. eNOS activity contributes to VEGF-induced 
permeability and migration [91,92,93]. Endothelial cell-derived nitric oxide additionally 
serves an important function as a vasodilator, as well as an inhibitor of platelet 
activation and leukocyte adhesion [94]. Indeed, in vivo inhibition of VEGFR2 signaling is 
associated with increased blood pressure both in mice and in human cancer patients 
[95,96]. Increased Ca2+ levels also can contribute to activation of the Ca2+
Phosphorylation of VEGFR2 (Y951) leads to binding of the T-cell specific adaptor 
(TSAd) protein, which associates with the non-receptor tyrosine kinase Src [100]. This 
pathway has been linked to the regulation of VEGF-induced migration and permeability 
responses [100,101]. Importantly, knockout mice lacking expression of the Src family 
/calmodulin-
dependent enzyme myosin light chain kinase (MLCK) [97]. MLCK catalyzes 
phosphorylation of the myosin regulatory light chain (MLC2), which promotes acto-
myosin contractility by increasing myosin ATPase activity [98]. Inhibition of MLCK 
activity inhibited VEGF-induced endothelial permeability in vitro [99]. 
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kinases Src or Yes exhibited impaired VEGF-induced vascular permeability [102]. VEGF 
stimulation leads to Src-dependent tyrosine phosphorylation of VE-cadherin [103,104], 
which has been linked to destabilization of endothelial adherens junctions [105]. Src 
activation also has been shown to mediate endothelial permeability through 
phosphorylation of the guanine nucleotide exchange factor (GEF) Vav1, leading to the 
activation of the small GTPase Rac and its downstream target p21-activated kinase 
(PAK). PAK-mediated phosphorylation of VE-cadherin (S665) results in recruitment of 
β-arrestin, resulting in VE-cadherin internalization and dissolution of endothelial 
intercellular junctions [106]. In addition to its role in endothelial permeability, VEGF-
induced Rac activation promotes endothelial cell migration [107]. In response to VEGF, 
Src also phosphorylates FAK on Y861, which promotes its recruitment to focal adhesions 
and was suggested to contribute to VEGF-induced endothelial migration [108]. FAK 
activation similarly is required for VEGF-induced permeability in vivo [109]. 
1.3.1.4 Role in Pathology 
Although the adult vasculature is largely quiescent [29], the formation of new 
blood vessels can be stimulated as part of physiological processes including 
reproduction and wound healing [65]. While physiological angiogenesis is a tightly-
regulated process, de-regulated angiogenesis leading to abnormal, excessive vascular 
growth is a key feature of several pathological conditions including tumor 
vascularization [64]. The acquisition of the ability to stimulate angiogenesis, the 
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“angiogenic switch,” is an important step in the process of tumorigenesis [11], and in 
1971, inhibition of angiogenesis was proposed as a strategy for cancer treatment [110]. 
 Since that time, a multitude of studies have established a critical role for VEGF 
in mediating tumor vascularization [14]. VEGF is expressed in most human tumors, and 
it has been suggested that circulating VEGF levels may serve as a prognosis indicator for 
tumor progression [111]. Inhibiting the VEGF pathway has proven effective in inhibiting 
tumor vascularization and growth in numerous mouse models of cancer [14] and has 
shown clinical benefit in human cancer patients. Bevacizumab (Avastin), a humanized 
monoclonal antibody targeting VEGF-A, was the first anti-VEGF therapy to be approved 
by the United States Food and Drug Administration (FDA), after demonstration of 
improved survival in metastatic colon cancer patients treated with bevacizumab in 
combination with chemotherapy [112]. Additional anti-VEGF therapies, including the 
receptor tyrosine kinase inhibitors sunitinib, sorafenib, and pazopanib, have since been 
approved for the treatment of a variety of solid tumors [113]; these drugs inhibit 
VEGFR2 as well as other RTK targets. However, more recent reports have documented 
the development of tumor resistance to anti-angiogenic (including anti-VEGF) therapies, 
resulting from mechanisms including upregulation of alternative angiogenic factors, 
recruitment of pro-angiogenic bone marrow-derived cells, and most troublingly, 
increased tumor invasiveness [114].  
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Aberrant vascularization also is characteristic of several ocular diseases, 
including the neovascular (wet) form of age-related macular degeneration (AMD), as 
well as diabetic retinopathy [115], and can lead to severe vision loss or blindness. 
Elevated VEGF expression has been associated with these conditions [14,115], 
suggesting a role for VEGF activity in ocular neovascularization. Anti-VEGF therapies 
including bevacizumab and the related anti-VEGF humanized monoclonal antibody 
fragment ranibizumab (Lucentis) have improved clinical outcome in patients with 
neovascular AMD [116,117]. 
Elevated VEGF levels additionally can contribute to excessive, pathological 
vascular permeability [32]. Hypoxia-induced VEGF upregulation is observed following 
ischemic injury, including cerebral and myocardial ischemia [118,119]. While the 
induction of VEGF expression promotes eventual re-vascularization and recovery, VEGF 
also rapidly induces vascular permeability following ischemic events, which leads to 
edema and tissue damage [32]. Blocking VEGF pathway activity (or the activity of the 
downstream signaling mediator Src kinase) during this time period reduced tissue 
damage following stroke or myocardial infarction in mice [120,121,122]. 
Hyperpermeability is also a prominent characteristic of tumor microvessels [123], 
which may contribute to increased interstitial fluid pressure and impaired drug 
delivery, as well as tumor metastasis [124,125]. VEGF neutralization led to decreased 
vessel permeability and interstitial fluid pressure in mouse xenograft tumor models 
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[126,127]. In addition, tumor cells overexpressing VEGF displayed enhanced 
extravasation and lung metastasis in mice [128]. 
1.3.2 Angiopoietin/Tie Pathway 
The angiopoietin-Tie receptor system regulates endothelial function during both 
physiological and pathological angiogenesis, as well as vascular homeostasis in the 
quiescent vasculature [129]. While VEGF signaling is necessary for initial vasculogenesis 
[10], angiopoietin signaling is important for subsequent vascular remodeling as well as 
for interaction of the endothelium with supporting mural cells [130,131]. 
1.3.2.1 Ligands 
The angiopoietin (Angpt) family of secreted glycoproteins includes four 
members: Angpt1, Angpt2, Angpt3, and Angpt4 [129]. Of the angiopoietin ligands, 
Angpt1 and Angpt2 are the most well-characterized, while Angpt3 and Angpt4 are less-
studied interspecies orthologs expressed in mice and humans, respectively [132,133]. 
Angpt1 and Angpt2 are highly similar structurally, each consisting of an N-terminal 
superclustering domain and coiled-coil motif, which mediate oligomerization and 
multimerization, as well as a C-terminal fibrinogen-related domain through which the 
angiopoietins bind to the Tie2 receptor [134,135]. 
Angpt1 is expressed primarily by pericytes and other mural cells [131,136] and 
can also be produced by monocytes [137]. In contrast, Angpt2 is produced by 
endothelial cells during development, but Angpt2 expression is not readily detectable in 
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quiescent vessels in adult tissues [134]. However, increased Angpt2 levels are observed 
at sites of inflammation or angiogenic remodeling [135], as mRNA expression of Angpt2 
is upregulated in response to hypoxia or stimulation with cytokines or growth factors 
including VEGF [138,139]. In endothelial cells, Angpt2 protein is stored in unique 
endothelial cell-specific storage granules known as Weibel-Palade bodies [140], from 
which it can be rapidly mobilized in response to inflammatory mediators [141]. 
1.3.2.2 Receptors 
Angpt1 and Angpt2 bind to the endothelial receptor tyrosine kinase Tie2 
(tyrosine kinase with Ig-like and EGF homology domains-2), which is also known as 
TEK [134,136,142,143]. The Tie2 receptor consists of an extracellular portion including 
two N-terminal Ig-like domains followed by three EGF homology domains, a third Ig-
like domain, and three fibronectin type III domains, as well as a single transmembrane 
domain and a C-terminal intracellular region consisting of a split tyrosine kinase domain 
[144]. Endothelial cells also express the related Tie1 receptor, which has a similar 
domain structure to Tie2, with 76% sequence identity in the intracellular domain, but 
only 33% identity in the extracellular region [143,145]. The Tie receptors are also 
expressed by some hematopoietic cells [129]. Unlike Tie2, Angpt1 and Angpt2 do not 
bind directly to Tie1 [134,136], which remains an orphan receptor. However, Tie1 may 
modulate angiopoietin signaling through formation of heteromultimers with Tie2 
[146,147]. 
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Binding of Angpt1 to Tie2 induces receptor clustering, resulting in trans-
autophosphorylation of the receptor intracellular domain [136,148]. In contrast, 
treatment of endothelial cells with exogenous Angpt2 typically does not result in Tie2 
phosphorylation/activation, and Angpt2 can block Angpt1-mediated Tie2 activation 
[134]. As a result of these findings, in combination with the similar phenotypes of Tie2 
knockout mice and mice overexpressing Angpt2 [134] (discussed in section 1.3.2.3), 
Angpt2 generally has been considered to act as a Tie2 antagonist [149,150]. However, 
several studies have shown that under certain conditions, endogenous Angpt2 or 
treatment with higher concentrations of exogenous Angpt2 can activate Tie2 
[151,152,153], suggesting that Angpt2 rather functions as a context-dependent, partial 
Tie2 agonist. The differing potencies of Angpt1 and Angpt2 for mediating Tie2 
activation may result from different receptor-binding affinities [153] or ligand 
multimerization [148]. A role for Tie1 in modulating Angpt2-mediated Tie2 activation 
also has been suggested, as lower doses of Angpt2 can stimulate Tie2 phosphorylation in 
cells lacking Tie1 expression [146]. 
In addition to the Tie2 receptor, both Angpt1 and Angpt2 can directly bind to 
integrins on endothelial and non-endothelial cells [154]. Interestingly, inhibition of 
Angpt2 was recently shown to impair vessel sprouting during postnatal retinal 
angiogenesis [155]. However, retinal endothelial tip cells express low levels of the Tie2 
receptor [155], suggesting that Angpt2 promotes retinal angiogenesis independently of 
 26 
Tie2. Angpt2 can directly bind αvβ3, αvβ5, and α5β1 integrins, albeit with lower affinity 
than to Tie2, and use of neutralizing antibodies targeting these integrins impairs 
Angpt2-mediated enhancement of vascular sprouting in both in vitro and in vivo assays 
[155]. Thus, Angpt2-induced processes can be mediated by Tie2-independent but 
integrin-dependent pathways. 
1.3.2.3 Role in Vascular Development 
Genetic depletion studies in mice have revealed crucial roles for the 
angiopoietins and Tie receptors in vascular development [130,131,156,157,158]. Tie2-null 
mice die by E9.5 to E10.5, exhibiting impaired branching and remodeling of the primary 
capillary plexus [130]. Tie2-deficient mice also display morphological defects in the 
cardiac endocardium and myocardium [131,159], as well as deficient recruitment of 
supporting mural cells [159]. Doxycycline-inducible Tie2 inactivation also demonstrated 
a crucial pro-survival function of Tie2 in later stages of embryonic vascular 
development, as loss of Tie2 expression at approximately E11.5 rapidly leads to 
induction of endothelial cell apoptosis, resulting in loss of vascular integrity [160]. The 
orphan receptor Tie1 is required for normal vascular development, as Tie1 knockout 
mice die between E13.5 and shortly after birth, exhibiting defective vascular integrity, 
edema, and hemorrhage [130,158]. Mice lacking Angpt1 expression also die 
embryonically (by E12.5), with mutant embryos exhibiting phenotypes similar to those 
observed in Tie2 knockout mice, including endocardial and myocardial defects, as well 
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as immature vascular structure and defective association with periendothelial cells [131]. 
These findings suggested that Angpt1 is the primary Tie2 agonist in vivo, and 
demonstrated that the Angpt1-Tie2 pathway serves an important function in regulating 
vessel remodeling and maturation during vascular development. 
Transgenic mice overexpressing Angpt2 in the endothelium display phenotypes 
similar to, but more severe than, those seen in mice lacking Angpt1 or Tie2 expression 
[134]. Angpt2-overexpressing mice die between E9.5 and E10.5, exhibiting phenotypes 
including cardiac structural abnormalities, defective association between endothelial 
cells and underlying mesenchymal cells, and a disrupted, discontinuous vasculature 
[134]. The phenotypic similarities between these Angpt2 transgenic mice and Angpt1 or 
Tie2 knockout mice are consistent with Angpt2 functioning as a Tie2 antagonist in most 
contexts [149]. In contrast to the pronounced vascular defects and embryonic lethality 
observed upon loss of Angpt1 or Tie2, loss of Angpt2 expression in mice does not result 
in major abnormalities in embryonic vascular development [157]. However, Angpt2 
knockout mice (on a 129/J genetic background) display defects in patterning and 
function of the lymphatic vasculature, which result in severe chylous ascites and lead to 
the death of most mutant mice by two weeks of age [157]. Milder lymphatic defects are 
observed in Angpt2-null mice on the C57BL/6 genetic background, which survive to 
adulthood [161]. Interestingly, the lymphatic phenotype of Angpt2-null mice could be 
rescued by gene replacement with Angpt1, suggesting that Angpt2 likely functions as an 
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agonist in the lymphatic vasculature [157]. Mice lacking Angpt2 expression also display 
abnormal postnatal ocular vascular remodeling, including a lack of regression of the 
hyaloid vasculature and dramatically impaired retinal neovascularization. However, 
these defects are not rescued by Angpt1 expression [157]. 
In addition to its important role in vascular development, angiopoietin/Tie2 
signaling may be required to maintain quiescence and homeostasis in the adult 
vasculature [129]. Tie2 phosphorylation/activation has been detected in the vasculature 
of all adult tissues examined [162]. However, the significance of this persistent Tie2 
phosphorylation is unclear, as inducible global knockout of the Tie2 ligand Angpt1 did 
not affect late vascular development (after E13.5) or vascular homeostasis in the adult 
[163]. However, inducible Angpt1 knockout mice display increased angiogenesis and 
fibrosis in a wound-healing model, as well as exacerbated diabetic kidney microvascular 
injury [163], suggesting an important role for Angpt1 in responses to injury or stress in 
the adult vasculature. 
1.3.2.4 Tie2 Intracellular Signaling and Endothelial Cell Responses 
Angiopoietin-Tie2 signaling influences a variety of endothelial cell processes, 
including survival, migration, and permeability, as well as inflammatory responses 
[129]. Following angiopoietin binding and receptor clustering, subsequent trans-
autophosphorylation of the Tie2 intracellular domain results in recruitment and 
activation of a diverse set of signaling mediators (Figure 1.3).  
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Figure 1.3 Major Angiopoietin Signaling Pathways 
The secreted glycoprotein angiopoietin-1 (Angpt1), which is produced by perivascular 
cells including pericytes, binds to and activates the endothelial receptor tyrosine kinase 
Tie2. Angpt1 binding leads to activation of intracellular signaling pathways promoting 
endothelial cell survival and migration and inhibiting responses including permeability 
and inflammation. In contrast, angiopoietin-2 (Angpt2) predominantly is expressed by 
endothelial cells and functions as a context-dependent Tie2 antagonist or weak agonist. 
See text for description of angiopoietin (Angpt)-mediated signaling. Abbreviations: Y, 
tyrosine; PI3K, phosphoinositide 3-kinase; Grb2, growth factor receptor-bound protein 2; 
MEK, mitogen-activated protein kinase kinase; Erk, extracellular signal-regulated 
kinase; ABIN-2, A20-binding inhibitor of NFκB activation-2; NFκB, nuclear factor κB; 
Dok-R, downstream of tyrosine kinase-related protein;  PAK, p21-activated kinase; 
mDia, diaphanous-related formin-1; EC, endothelial cell. 
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Several Tie2 autophosphorylation sites have been identified, including tyrosines 
990, 1100, 1106, and 1111 (murine residues) [164,165,166]. The phosphorylated Tie2 
intracellular domain interacts with a variety of SH2 domain-containing binding 
partners, including the adaptor proteins Grb2 (growth factor receptor-bound protein 2), 
Grb7, and Grb14, the tyrosine phosphatase Shp2 (SH2-containing protein tyrosine 
phosphatase), and the p85 subunit of PI3K [165], as well as the phosphotyrosine binding 
(PTB) domain-containing docking protein Dok-R (downstream of tyrosine kinase-related 
protein) [167]. 
Tie2 signaling has an important pro-survival function in endothelial cells. Loss of 
Tie2 expression has been linked previously to impaired endothelial cell survival, with 
increased apoptosis observed after inducible repression of Tie2 expression in vivo [160], 
as well as following Tie2 knockdown in vitro [168,169]. Angpt1 treatment inhibits 
endothelial cell apoptosis induced by various cellular stresses [170,171,172]. These 
survival effects are mediated primarily by activation of the anti-apoptotic PI3K/Akt 
pathway [173,174], which results from direct recruitment of the p85 subunit of PI3K to 
phosphorylated Y1100 of Tie2 [175]. Angpt1 treatment leads to the upregulation of the 
IAP family member survivin, an effect which is dependent upon PI3K/Akt pathway 
activity [174]. Survivin upregulation may result from Akt-mediated inhibitory 
phosphorylation of the forkhead transcription factor FOXO1 (Forkhead box protein O1, 
also known as FKHR), which normally represses survivin expression in endothelial cells 
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[176]. A role for PI3K-dependent activation of the Raf-MEK-Erk MAPK pathway in 
Angpt1-mediated endothelial cell survival also has been demonstrated [177]. Activation 
of the Raf-MEK-Erk pathway additionally may be mediated through Grb2 and Shp2-
dependent recruitment of the Ras GEF Sos to Tie2, leading to Ras-mediated activation of 
the serine/threonine kinase Raf [165,178]. In contrast to VEGF, however, Angpt1 is not a 
potent endothelial cell mitogen [136], suggesting that the Erk pathway may have 
different downstream effectors in VEGF- versus Angpt1-mediated signaling. 
Interestingly, recent studies have demonstrated that Tie2-mediated activation of 
intracellular signaling pathways may be dependent upon cellular context and receptor 
localization [179,180]. Specifically, ECM-bound Angpt1 induced formation of Tie2 
signaling complexes at cell-matrix contacts in sparse or migrating endothelial cells, 
while Angpt1 stimulated Tie2 translocation to cell-cell contacts and formation of Tie2-
Tie2 trans-associated complexes in confluent endothelial cells. The activation of these 
distinct Tie2 complexes either at cell-cell or cell-matrix contacts was linked to 
preferential activation of the Akt or Erk pathways, respectively [179,180].  
Angpt1/Tie2 signaling also stimulates endothelial cell migration [181], which 
requires PI3K activation [182]. However, an additional pathway regulating Angpt1-
sitmulated migration has been identified, which is initiated by recruitment of the 
docking protein Dok-R to phosphorylated Y1106 on Tie2 [183]. Dok-R binds to the 
adaptor protein Nck, leading to the recruitment and activation of PAK, which in turn 
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promotes endothelial cell migration, likely through the regulation of cytoskeletal 
remodeling processes [184]. The Erk pathway also has been implicated in Angpt1-
induced migration [179,185]. 
Along with its pro-angiogenic functions promoting endothelial cell survival and 
migration, Angpt1/Tie2 signaling contributes to several vascular protective and anti-
inflammatory functions, including supporting endothelial barrier function [129]. Angpt1 
treatment inhibits the induction of endothelial permeability by VEGF or thrombin in 
vitro [186,187], while transgenic overexpression of Angpt1 in mice stimulates formation 
of blood vessels resistant to VEGF-induced vascular leakage [188]. Several mechanisms 
underlie Angpt1-mediated endothelial barrier maintenance. Angpt1 treatment has been 
reported to lead to increased activation of the small GTPase Rac1, along with decreased 
RhoA GTPase activation [187,189]. Rac1 is known to support endothelial barrier 
function, through remodeling of cortical actin and stabilizing adherens junctions 
[190,191,192]. In contrast, RhoA activation promotes dissolution of endothelial cell-cell 
junctions by inducing acto-myosin contractility, which is mediated by increased 
phosphorylation of the myosin regulatory light chain following activation of the RhoA 
downstream target Rho kinase (ROCK) [30,193]. The negative regulation of RhoA by 
Angpt1 requires the activity of p190 RhoGAP (GTPase-activating protein) [189]. 
Interestingly, Angpt1 also has been reported to inhibit VEGF-induced permeability 
through the activation of RhoA [194]. In this pathway, Angpt1-induced RhoA activation 
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leads to sequestration of Src kinase, an important mediator of VEGF-induced 
permeability, through association of Src with the RhoA downstream target mDia 
(diaphanous-related formin-1). These conflicting reports raise the possibility that Angpt1 
signaling may differentially regulate the activity of different RhoA GTPase pools or 
RhoA downstream effectors. Angpt1 additionally may inhibit endothelial permeability 
by inhibiting VEGF-induced influx of extracellular Ca2+ 
Angpt1 and Angpt2 similarly have opposing roles in the regulation of 
inflammatory responses. Angpt1 inhibits VEGF-induced expression of the adhesion 
proteins intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 
(VCAM-1), and E-selectin, as well as impairs VEGF-induced leukocyte-endothelial cell 
adhesion [198]. Angpt1 also inhibits the induction of tissue factor expression by 
endothelial cells following stimulation with VEGF or the inflammatory cytokine tumor 
necrosis factor (TNF)-α [199]. The anti-inflammatory effects of Angpt1 are mediated by 
interaction of tyrosine-phosphorylated Tie2 with the zinc finger protein ABIN-2 (A20-
binding inhibitor of NFκB activation-2), which inhibits nuclear factor κB (NFκB)-
[195]. In contrast to the barrier-
protective effects of Angpt1, Angpt2 is thought to destabilize the endothelial barrier. 
Angpt2 treatment leads to endothelial destabilization and detachment in three-
dimensional co-cultures of endothelial cells and smooth muscle cells [196] and 
stimulates vascular leakage in vivo [197]. Angpt2 also enhances thrombin-induced 
endothelial permeability in vitro [187]. 
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mediated expression of inflammatory genes (including ICAM-1 and VCAM-1) [200]. In 
contrast, Angpt2 is required for inflammatory responses and sensitizes the endothelium 
to TNFα [161]. Notably, inducible endothelial overexpression of Angpt2 in mice results 
in myeloid cell recruitment to various organs, even in the absence of proinflammatory 
challenge, as well as increased responses to inflammatory stimuli [201]. 
1.3.2.5 Role in Pathology 
Consistent with the opposing effects of Angpt1 and Angpt2 on endothelial 
barrier stabilization and inflammatory responses in vitro and in mice, a shift in 
angiopoietin balance, such that Angpt2 levels exceed Angpt1 levels, has been reported 
in a number of disorders involving vascular dysfunction, including diabetes, hyperoxic 
lung injury, and sepsis [202,203,204,205]. Elevated circulating Angpt2 levels have been 
documented in sepsis [206], and higher Angpt2 levels correlate with disease progression 
[135]. In addition, Angpt2 inhibition using function-blocking antibodies ameliorated 
disease progression in a mouse model of airway inflammation [207], and hyperoxia-
induced acute lung injury was impaired in Angpt2-null mice [202], suggesting a 
potential active role for Angpt2 in progression and severity of disorders involving 
vascular dysfunction. Further, overexpression of Angpt1 has shown protective effects in 
mouse models of stroke, endotoxic shock, and fibrotic renal injury [208,209,210], 
indicating that restoration of Angpt1/Angpt2 balance may result in beneficial outcomes 
in these disorders. However, Angpt2 treatment also has shown positive effects in some 
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mouse disease models, including experimental models of sepsis and ischemia 
[211,212,213], which suggests that the role of Angpt2 in pathological conditions is highly 
context-dependent.  
Both Angpt1 and Angpt2 have been implicated in tumor angiogenesis [214]. 
While not normally expressed in the quiescent adult vasculature [134], Angpt2 
expression is upregulated in the vasculature of a variety of tumors [135]. Further, 
increased expression of Angpt2 correlates with poor prognosis of several cancers [215]. 
Based upon the expression patterns of VEGF and Angpt2 during various phases of 
tumor vascularization in a rat glioma model, it has been suggested that VEGF and 
angiopoietin signaling is highly coordinated during tumor angiogenesis, with the 
destabilizing ligand Angpt2 promoting vascular sprouting in the presence of VEGF, but 
leading to vessel regression in the absence of pro-survival signals [214]. Similar VEGF-
dependent modulation of Angpt2 responses also has been observed in a rat ocular 
vascularization model [216]. Consistent with an important role for Angpt2 in tumor 
vascularization and disease progression, several studies have shown beneficial effects of 
Angpt2 inhibition (using function-blocking antibodies or peptibodies) in a variety of 
rodent tumor models, leading to decreased angiogenesis, tumor growth, and/or 
metastasis [217,218,219,220]. In addition, the Angpt1/Angpt2-neutralizing peptibody 
AMG386 demonstrated promising anti-tumor activity in combination with paclitaxel in 
a phase II clinical trial of patients with recurrent ovarian cancer [221], and AMG386 (in 
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combination with paclitaxel and carboplatin) is currently being investigated in a phase 
III trial (TRINOVA-1) for treatment of ovarian cancer. Interestingly, sustained systemic 
overexpression of Angpt2 led to disruption of vessel pericyte coverage, microvessel 
regression, and impaired tumor growth in a human colon carcinoma xenograft mouse 
model [222], suggesting that precise spatial and temporal regulation of Angpt2 
expression levels is required for its tumor-promoting effects. 
1.4 Abl Family of Non-Receptor Tyrosine Kinases 
The Abelson (Abl) family of non-receptor kinases includes two mammalian 
members, Abl (Abl1, also known as c-Abl) and Arg (Abl-related gene, also known as 
Abl2), characterized by the presence of unique C-terminal actin-binding domains [223]. 
The Abl kinase initially was identified as the cellular homolog of the Abelson murine 
leukemia virus oncogene (v-Abl) [224,225] and later was implicated in the etiology of 
human chronic myelogenous leukemia (CML) as a result of the t(9;22) chromosomal 
translocation that produces the BCR-ABL1 fusion protein, which displays constitutive 
Abl kinase activity [226]. However, a growing body of literature also has demonstrated 
important functions for Abl and the closely-related Arg kinase in normal physiology, as 
these kinases play a role in intracellular signaling pathways activated by diverse 
extracellular stimuli, leading to regulation of cellular responses including cytoskeletal 
remodeling, proliferation, survival, adhesion, and migration [223,227,228]. 
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1.4.1 Structural Properties 
The Abl family kinases contain multiple structural and functional domains 
(Figure 1.4). The N-terminal portions of Abl and Arg are highly conserved, consisting of 
regulatory Src homology-3 (SH3) and SH2 domains, as well as the tyrosine kinase 
domain (SH1 domain) [229]; this domain structure is shared with other non-receptor 
tyrosine kinases, including Src family kinases [230,231]. Each of these domains display at 
least 90% amino acid sequence identity between Abl and Arg [229]. Alternative splicing, 
resulting in the usage of different 5’ exons, leads to the production of two major Abl 
isoforms [232]. Human Abl isoform 1b (isoform IV in mice) contains an N-terminal 
myristoylation site, which is not present in human Abl isoform 1a (murine isoform I) 
[232,233]. Similar myristoylated and non-myristoylated isoforms of Arg also have been 
identified [229]. The SH3 and SH2 domains, along with N-terminal myristoyl group 
attachment, have important roles in the intramolecular regulation of Abl kinase 
activation [234]. Abl also contains a region of approximately 80 amino acids located N-
terminal to the SH3 domain; this “cap” region is thought to contribute to Abl 
intramolecular auto-inhibition [235]. 
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Figure 1.4 Structural Features of the Abl Family Kinases 
Schematic of the major structural and functional domains of the Abl family of non-
receptor tyrosine kinases (Abl and Arg). Alternative splicing leads to the generation of 
two major isoforms of each protein (1a and 1b); the 1b isoforms contain N-terminal 
myristoylation sites. The N-terminal regions of both Abl and Arg include highly-
conserved Src homology-3 (SH3), SH2, and SH1 (tyrosine kinase) domains. Sites of 
regulatory tyrosine phosphorylation (Abl Y245/Arg Y272 in the SH2-SH1 interlinker 
region and Abl Y412/Arg Y439 in the kinase activation loop; numbering indicates 
position of tyrosine residues in Abl/Arg 1b isoforms) are indicated (yellow circles). Both 
Abl and Arg contain proline-rich sequences (PXXP motifs, green rectangles), as well as a 
C-terminal filamentous (F)-actin-binding domain (BD). Abl additionally contains a 
binding domain for monomeric globular (G)-actin, while Arg possesses a second, 
internal F-actin binding domain and a microtubule (MT)-binding domain. The Abl C-
terminus also has three nuclear localization sequences (NLS, black rectangles), a nuclear 
export sequence (NES, yellow rectangle), and a DNA-binding domain, which are not 
found in Arg. Adapted from [236]. 
 
 
The SH3 and SH2 domains mediate interaction of the Abl family kinases with a 
variety of binding partners and substrates, through association with proline-rich regions 
and phosphorylated tyrosine residues on interacting proteins, respectively [223,228]. 
Protein-protein interactions are also mediated through proline-rich sequences (PXXP 
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motifs) found C-terminal to the tyrosine kinase domain in Abl and Arg, which are 
binding sites for interacting proteins containing SH3 domains [228]. The kinase domain 
of the Abl kinases preferentially phosphorylates tyrosine residues in the consensus 
sequence I/V/L-Y-X-X-P (I=isoleucine; V=valine; L=leucine; Y=tyrosine; X=any amino 
acid; P=proline) [237,238]. Numerous proteins have been identified as Abl/Arg binding 
partners and/or substrates, including signaling adaptor proteins and receptor tyrosine 
kinases, as well as regulators of cytoskeletal remodeling, DNA damage response, and 
apoptosis, among other processes [228]. 
In contrast to the highly-conserved N-terminal structural domains, Abl and Arg 
are more divergent in their C-terminal sequences, both from other non-receptor tyrosine 
kinases and from each other [228]. The C-terminal regions of Abl and Arg exhibit only 
29% overall amino acid identity [229]. However, both Abl and Arg exhibit C-terminal 
binding domains enabling direct interaction with the actin cytoskeleton [239,240,241], 
which are not found in other non-receptor tyrosine kinases. Abl and Arg each contain a 
calponin homology (CH) domain at their extreme C-terminus that mediates binding to 
filamentous (F)-actin [239,240,241], while Abl also has a binding domain for monomeric 
globular (G)-actin [240]. Arg additionally possesses a second, internal F-actin binding 
domain (I/LWEQ domain), which is not found in Abl [241]. Both Abl and Arg have 
shown the ability to bundle F-actin in vitro [240,241]. Arg also contains a microtubule 
(MT) binding domain, which enables this kinase to mediate in vitro cross-linking of actin 
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filaments and microtubules [242]. Thus, the structural properties of the Abl family 
kinases enable their function in the regulation of processes involving cytoskeletal 
remodeling. 
While Abl and Arg have a highly similar overall domain structure, the C-
terminal region of Abl contains three nuclear localization sequences (NLS) not found in 
Arg [243,244], as well as a DNA-binding domain, which preferentially binds to A/T-rich 
DNA sequences [245,246]. Abl also possesses a functional nuclear export sequence (NES) 
[247], which enables nuclear-cytoplasmic shuttling of the Abl kinase in response to 
stimuli including integrin-mediated adhesion [247,248]. In contrast, Arg exhibits 
predominantly cytoplasmic localization [249]. Interestingly, a total of eight distinct Arg 
isoforms have been identified, resulting from alternative splicing at both the N- and C-
termini [250]. One of these Arg isoforms localizes to the nucleus upon overexpression in 
COS-7 cells [251]; however, the mechanism underlying its nuclear localization and its 
functional consequences are unknown. 
1.4.2 Regulation of Abl Family Kinase Activity 
1.4.2.1 Intramolecular Regulation 
The tyrosine kinase activity of the Abl kinases is tightly regulated in cells, in part 
through several auto-inhibitory mechanisms. The SH3 domain has a particularly 
important role in intramolecular inhibition of Abl kinase activity, as deletion of this 
region results in increased tyrosine phosphorylation of Abl, indicative of elevated Abl 
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kinase activity [252]. Structural studies have demonstrated that the SH3 and SH2 
domains of Abl form a rigid clamp structure, which folds back onto the tyrosine kinase 
domain (on the side distal to the active site) to hold it in an inactive conformation [253]. 
This autoinhibitory association requires the binding of the SH3 domain to a polyproline 
sequence in the interlinker region connecting the SH2 and kinase domains [253], and 
mutation of interlinker proline residues leads to Abl kinase activation [252]. In this 
conformation, the SH2 domain closely docks with the distal surface of the C-terminal 
lobe (C-lobe) of the kinase domain, mediated by hydrogen bonding interactions [253]. In 
addition, the N-terminal myristoyl group present in some Abl/Arg splice variants binds 
to a hydrophobic pocket within the C-lobe. This binding acts to stabilize the inactive 
conformation of the kinase, by inducing a conformational change in the kinase domain 
to allow docking of the SH2 domain [253]. Mutation of the hydrophobic residues of the 
myristoyl binding pocket leads to increased Abl kinase activity [254]. Disruption of the 
SH3-SH2 clamp inhibitory function likely is mediated by binding of interacting proteins 
to either the SH3 or SH2 domain, resulting in displacement of the “clamp” from the 
kinase domain [227]; in this regard, treatment with phosphopeptides derived from 
known SH2 domain-binding Abl substrates activates Abl kinase activity in vitro [254]. 
1.4.2.2 Intermolecular Regulation 
In addition to these auto-inhibitory interactions, the activity of the Abl kinases is 
regulated by interactions with a variety of cellular proteins, which act either to 
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positively or negatively regulate kinase activity [228]. Proteins which inhibit Abl kinase 
activity include the SH3 domain-binding proteins peroxiredoxin 1 (PRDX, also known 
as PAG) [255] and ABL-associated protein 1 (AAP1) [256], as well as proline-serine-
threonine phosphatase-interacting protein 1 (PSTPIP1), which binds to the Abl kinase 
PXXP motifs and recruits the PEST-type protein tyrosine phosphatase (PTP-PEST, also 
known as PTPN12) to mediate dephosphorylation of Abl [257]. In the nucleus, the 
retinoblastoma protein tumor suppressor (Rb) binds to the ATP-binding lobe of the Abl 
kinase domain to inhibit kinase activity during the G1 phase of the cell cycle [258]; 
hyperphosphorylation of Rb relieves this inhibitory interaction, leading to Abl kinase 
activation upon entry into S phase. Binding to F-actin inhibits Abl kinase activity upon 
detachment of fibroblasts from the ECM, and deletion of the C-terminal actin-binding 
domain relieves this inhibition [259]. The activity of Abl and Arg also is inhibited by the 
phospholipid PIP2
In contrast, association of Abl with distinct binding partners has been reported to 
increase Abl kinase activity. The Ras effector Rin1 (Ras and Rab interactor 1) interacts 
with both the SH3 and SH2 domains of Abl, leading to release of the Abl kinase from 
intramolecular inhibition [261]. The Crk adaptor protein also activates Abl kinase 
activity, through binding of the SH3 domains of Crk to the proline-rich motifs of Abl 
, which binds to the Abl kinases, most likely in the kinase domain 
[260]. 
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[262]. In addition, Abl is activated through binding to the Nck adaptor protein [263] or 
to the docking protein Dok-R [264]. 
Pharmacological inhibition of the Abl kinases with small molecule inhibitors has 
proven useful for the therapeutic treatment of Abl-mediated pathologies as well as 
uncovering cellular processes dependent upon Abl family kinase activity. Imatinib 
(Novartis; also known as Gleevec or STI571) is a potent ATP-competitive inhibitor of the 
Abl kinases, as well as the BCR-ABL1 oncogene and the PDGF, colony-stimulating 
factor-1 (CSF-1), Kit, and discoidin domain (DDR) receptors [265,266,267,268]. Imatinib 
has proven extremely beneficial for the treatment of BCR-ABL1-driven CML [269]. 
However, development of imatinib resistance has led to the development of second-
generation BCR-ABL1 (and Abl/Arg) kinase inhibitors, including nilotinib (Novartis; 
also known as Tasigna), which inhibits the Abl kinases with 10 to 20-fold increased 
potency compared to imatinib [270,271]. The sets of kinases targeted by imatinib and 
nilotinib are similar, as both of these inhibitors function by binding to and stabilizing the 
inactive conformation of the kinase domain [272]. More recently, novel allosteric Abl 
inhibitors have been identified, which inhibit Abl kinase activity through binding to the 
myristoyl binding site on the kinase domain [273,274]. These compounds, known as 
GNF-2 and GNF-5 (a GNF-2 analogue with improved pharmacokinetic properties [275]), 
display greater target specificity than imatinib or nilotinib and are not known to inhibit 
any kinases other than BCR-ABL1, Abl, and Arg [273,274]. 
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1.4.2.3 Regulation by Phosphorylation 
Along with release from intramolecular and intermolecular inhibition, full 
activation of the Abl and Arg kinases requires tyrosine phosphorylation, which 
stabilizes the active kinase conformation. Specifically, phosphorylation of Abl Y245 (in 
the interlinker region between the SH2 and kinase domains) and Y412 (in the activation 
loop of the kinase domain), or the analogous tyrosine residues in Arg, is required for 
maximal kinase activity (Figure 1.4) [276,277]. Mutation of Y412 to phenylalanine (F) 
decreased Abl activation by 90%, while the kinase activity of an Abl Y245F mutant was 
reduced by 50% [276]. Phosphorylation of these tyrosines can result from Abl/Arg 
autophosphorylation (occurring in trans) [276,277,278] or from Src-mediated 
phosphorylation [277,278,279]. Phosphorylation of Abl kinases on additional tyrosines, 
as well as serine or threonine phosphorylation, also can regulate kinase activity [228]. 
Abl kinase trans-autophosphorylation (and kinase activation) is enhanced by kinase 
oligomerization; in the BCR-ABL1 fusion protein, this is mediated by the N-terminal 
coiled-coil oligomerization domain of BCR [280]. 
Mechanisms exist which counterbalance the activating effects of 
phosphorylation-mediated Abl kinase activation. The Abl kinases are dephosphorylated 
by protein tyrosine phosphatases including PTPN12 (PTP-PEST) [257], leading to 
decreased kinase activity, and inhibition of tyrosine phosphatases increases Abl tyrosine 
phosphorylation [257,281] and kinase activity [278]. Abl kinase activity also is 
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downregulated through targeting of activated Abl kinases for ubiquitin-mediated 
proteasomal degradation [281]. 
1.4.2.4 Stimuli Leading to Abl Kinase Activation 
The Abl kinases are activated in response to a wide range of both extracellular 
and intracellular stimuli and regulate an equally diverse set of cellular responses (Figure 
1.5) [223,227,228,236]. The Abl kinases are activated downstream of numerous RTKs, 
including the receptors for PDGF [279], EGF [279], hepatocyte growth factor (HGF) 
[282], insulin-like growth factor 1 (IGF-1) [283], ephrin B4 [284], and agrin [285], leading 
to modulation of responses including receptor signaling, proliferation and survival, 
actin remodeling, motility, and invasion. PDGF-mediated Abl activation in fibroblasts 
requires both Src-mediated phosphorylation of Abl Y412 and PLCγ activation, which 
reduces levels of the Abl inhibitor PIP2 through conversion to IP3
The Abl kinases also are activated following engagement of immunoreceptors, 
including the B-cell receptor [287], T-cell receptor (TCR) [288], and Fcγ receptor (FcγR) 
[289]. Loss of Abl kinase activity impairs TCR-induced signaling, proliferation, and 
cytokine production [288,290], as well as TCR-stimulated integrin affinity maturation 
[291]. Abl kinases additionally are required for maximal FcγR-induced phagocytosis in 
macrophages [289]. Chemokine stimulation can lead to Abl kinase activation, as shown 
in response to stromal cell-derived factor 1α (SDF-1α) stimulation of T cells [292] or 
 and DAG [279,286]. 
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breast cancer cells [293]. Chemokine-mediated Abl kinase activation is required for 
induction of chemotaxis and invasion in T cells and cancer cells, respectively. 
 
Figure 1.5 Abl Kinase Activating Signals and Downstream Responses 
The Abl family kinases (Abl and Arg) are activated in response to a variety of 
extracellular stimuli, including growth factor and chemokine signaling, mediated by 
receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs), respectively. 
The Abl kinases also are activated following engagement of cadherin and integrin 
adhesion receptors. In response to these signals, Abl and Arg regulate numerous 
downstream cellular functions, including proliferation, survival, actin remodeling, 
migration, and adhesion. See text for description of Abl kinase activation mechanisms 
and effects of these kinases on cellular responses.  
 
In addition, Abl kinase activity is modulated by adhesion receptors, including 
cadherins and integrins. In fibroblasts, integrin-mediated adhesion leads to Abl kinase 
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activation, along with shuttling of nuclear-localized Abl to the cytoplasm and 
recruitment of Abl to early focal contacts [248]. Abl kinases also are activated following 
cadherin engagement and are required for downstream Rac1 GTPase activation [294], 
which promotes actin polymerization and lamellipodial extension at nascent cell-cell 
adhesions [295]. 
Along with the extracellular stimuli described above, the Abl kinases are 
activated by intracellular stresses, including DNA damage and oxidative stress [223]. A 
number of DNA damage-inducing agents have been linked to activation of the nuclear 
Abl kinase pool, including ionizing radiation, cisplatin, and mitomycin C [296]. Abl 
activation in response to ionizing radiation is dependent upon activation of the ataxia 
telangiectasia-mutated (ATM) protein kinase, which phosphorylates Abl S465, leading to 
kinase activation [297]. Ionizing radiation-induced Abl kinase activation also may 
involve serine phosphorylation of Abl by the DNA-dependent protein kinase (DNA-PK) 
[298]. Oxidative stress induced by treatment with hydrogen peroxide results in 
activation of the cytoplasmic Abl kinase, which may involve activation of PKCδ 
[299,300]. 
1.4.3 Cellular Functions of the Abl Kinases 
Consistent with the diverse set of stimuli which mediate Abl kinase activation, 
the Abl kinases have roles in the regulation of a variety of cellular processes, including 
cytoskeletal remodeling and modulation of cell-cell and cell-matrix adhesions 
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[223,227,228]. Here, I will briefly detail some of the major cellular roles of the Abl family 
kinases, along with the Abl kinase targets involved in regulating these processes. 
1.4.3.1 Regulation of Actin-Dependent Processes 
As previously described, Abl and Arg kinases possess unique actin-binding 
ability, which enables these kinases to modulate cytoskeletal remodeling in response to a 
variety of cellular stimuli [227]. The Abl kinases have been shown to localize to a variety 
of actin-rich cellular structures, including lamellipodial and filopodial cell protrusions 
[241,242,301,302], invadopodia [293,303], membrane ruffles [304], focal adhesions [248], 
stress fibers [240], and the leading edge of migrating cells [305], as well as at the 
immunological synapse [291] and in macrophage phagocytic cups [289]. Expression of 
the Abl kinases stimulates formation of membrane protrusions including lamellipodia 
and filopodia [241,242,306] and promotes neurite outgrowth and branching [307,308]. 
Conversely, loss of Abl kinase function impairs actin cytoskeletal remodeling processes 
including adhesion-induced lamellipodial protrusion [242] and PDGF-induced 
membrane ruffling [279] in fibroblasts, TCR- and chemokine-induced actin 
polymerization in T cells [292,309], and branching of primary cortical neurons [306,307]. 
The Abl kinases interact with and/or phosphorylate numerous cellular proteins 
involved in the regulation of actin cytoskeletal remodeling [228]. Among these targets 
are members of the Wiskott-Aldrich syndrome protein (WASP) and WASP-family 
verprolin-homologous protein (WAVE) family of actin-regulatory proteins. These 
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proteins associate with and promote the activity of the Arp2/3 (actin-related protein 2/3) 
actin-nucleating complex, which nucleates the formation of new branches from pre-
existing actin filaments [310]. The Abl kinases phosphorylate several WASP/WAVE 
family members, including N-WASP, WAVE2, and WAVE3 [304,311,312]. Abl-mediated 
phosphorylation of WASP/WAVE proteins is required for actin remodeling processes 
including actin polymerization, lamellipodia formation, and Shigella flexneri-induced 
actin comet tail formation. Abl kinases also bind to and phosphorylate the Abl-interactor 
(Abi) adaptor proteins (Abi1 and Abi2) [313,314]. The Abi proteins, along with Nap1 
(Hem2), Sra1 (PIR121), and HSPC300, associate with the WAVE proteins to form a 
complex (known as the WAVE complex) regulating Arp2/3-mediated actin nucleation 
[315]. In addition, the Abl kinases phosphorylate the actin-binding protein cortactin 
[316], which promotes Arp2/3-mediated actin polymerization and stabilization of actin 
filaments [227,310]. Abl kinase-mediated cortactin phosphorylation is required for actin-
dependent formation of dorsal waves following PDGF treatment of fibroblasts [316] and 
EGF-induced invadopodia formation in cancer cells [303]. Loss of Abl kinase function 
also impairs cortactin and MT1-MMP localization to breast cancer cell invadopodia, 
leading to decreased ECM degradation and invasion [293]. 
The actin nucleation-promoting effects of the WASP and WAVE proteins are 
regulated by the small GTPases Cdc42 and Rac1, respectively [315]. Abl has been linked 
to Rac1 activation through phosphorylation of the GEF Sos-1 [317]. The Abl kinases also 
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regulate Rac1 activity through phosphorylation of the Crk/CrkL adaptor proteins; Abl-
mediated Crk phosphorylation is required for Rac1 activation following adherens 
junction formation in mouse embryo fibroblasts (MEFs) [294]. Abl-mediated Crk 
phosphorylation also may negatively regulate Rac1 activity, by disrupting a complex 
containing Crk, p130Cas
In addition to regulating Arp2/3-mediated actin polymerization, the Abl kinases 
regulate contractility of the actin cytoskeleton by modulating RhoA GTPase activity 
through phosphorylation of the RhoA negative regulator p190RhoGAP [321]. Abl/Arg-
mediated phosphorylation stimulates p190RhoGAP inhibitory activity [321], leading to 
reduced levels of active RhoA and decreased acto-myosin contractility, as well as altered 
focal adhesion dynamics and fibroblast cell migration [322,323]. Increased RhoA activity, 
leading to stress fiber formation, acto-myosin contractility, and disrupted adherens 
junctions, also was observed following inhibition of the Abl kinases in epithelial cells 
[294]; however, no change in p190 RhoGAP phosphorylation were observed in this 
study, suggesting that the Abl kinases modulate RhoA activity and acto-myosin 
contractility through additional mechanisms. 
, and the Rac1 GEF DOCK180 [318,319,320]. 
1.4.3.2 Regulation of Cell-Cell and Cell-Matrix Adhesions 
The Abl family kinases, which are activated following cadherin and integrin 
engagement [248,294], have important functions in the regulation of both cadherin-
mediated cell-cell adhesion and integrin-mediated cell-matrix adhesion processes. Abl 
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kinases are required for adherens junction formation in both MEFs (N-cadherin) and 
epithelial cells (E-cadherin), as well as for maintenance of epithelial cell-cell junctions 
[294]. Conversely, expression of constitutively-active Arg was sufficient to promote 
formation of N-cadherin-mediated adherens junctions. This enhancement of cell-cell 
adhesion was dependent upon phosphorylation of the Abl kinase substrate Crk/CrkL, 
which was also required for activation of the Rac GTPase following cadherin 
engagement [294]. The Abl kinases also function downstream of active Rac as part of a 
positive feedback loop to promote adherens junction formation and stabilization [324]. 
In addition, Abl regulates β-catenin localization and dynamics (through 
phosphorylation of β-catenin Y667) and is required for proper remodeling of planar 
polarized junctions in Drosophila embryos [325]. 
The Abl kinases also have been implicated in integrin-mediated cell-matrix 
adhesion, with roles both in outside-in integrin signaling and inside-out modulation of 
integrin affinity. As previously discussed, the Abl kinase is activated and transiently 
recruited to nascent focal adhesions following integrin-mediated adhesion to a variety of 
extracellular matrix proteins [248]. The Abl kinases have demonstrated roles in a variety 
of integrin signaling responses, including promoting actin-based cellular protrusions 
[301], sustained cell-matrix adhesion, and cell spreading [326], as well as regulating focal 
adhesion dynamics [322,323]. Direct binding of the Arg kinase to the cytoplasmic tail of 
β1 integrin has been detected in excitatory neurons [327], and loss of Abl/Arg expression 
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in neurons leads to defects in integrin-mediated dendrite branch maintenance [307]. The 
Abl kinase also has been implicated in inside-out integrin signaling in T cells, as Abl 
expression is required for TCR-induced activation of the GTPase Rap1, which promotes 
integrin affinity maturation and increased extracellular matrix adhesion [291]. In 
contrast, expression of constitutively-active Arg kinase decreases Rap1 activation in 
epithelial cells, leading to impaired collagen-induced upregulation of β1 integrin protein 
[328]. 
1.4.4 In Vivo Roles of the Abl Kinases 
Crucial roles for the Abl kinases have been demonstrated in vivo, through the use 
mouse mutants lacking expression of these kinases [329,330,331]. Abl-null mice, as well 
as mice expressing a mutant Abl allele which lacks the C-terminal one-third of the 
protein, have been generated [330,331]. In both cases, homozygous Abl mutant mice are 
runted and most die within one to two weeks after birth, depending on the genetic 
background. The primary phenotypes associated with global loss of Abl function (on a 
mixed genetic background) are thymic and splenic atrophy, reduced numbers of 
circulating B and T lymphocytes, and an increased susceptibility to infection, which 
were observed with variable penetrance [330,331]. Subsequent studies using conditional 
knockout mice have demonstrated a cell-autonomous role for the Abl kinase in T cell 
development and function [290,332]. 
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Global Arg knockout mice have less severe defects than Abl-null mice; mice 
lacking Arg expression are viable, although somewhat runted at early ages, and display 
no histological abnormalities [329]. However, Arg-null mice demonstrate abnormal 
behavioral phenotypes including some motor skill and reflex defects, suggestive of 
improper neuronal function. Indeed, conditional Abl inactivation in neurons (in 
combination with global Arg inactivation) has revealed a requirement for the Abl 
kinases in the maintenance of dendrite branches in early adulthood, although initial 
dendrite arborization during development is normal in mutant mice [307] . 
Interestingly, double-null mice lacking both Abl and Arg expression in all body 
tissues exhibit more severe phenotypes than mice lacking either kinase alone. Global 
Abl/Arg-null mice die embryonically by E11.0 and display defects in neural tube closure, 
as well as abnormal actin cytoskeletal architecture in neuroepithelial cells [329]. Large 
numbers of apoptotic cells also are observed in Abl/Arg double-null embryos, indicating 
a requirement for the Abl kinases in cell survival. Further, Abl-null; Arg+/-
1.4.5 Potential Vascular Roles for the Abl Kinases 
 embryos, 
which die by E16.0, display peritoneal and pericardial hemorrhage and edema [329], 
suggestive of vascular defects. However, the specific vascular role of the Abl kinases had 
not yet been studied in vivo prior to the work described here. 
As previously described, endothelial development and function require the 
coordination of a variety of cellular processes in response to signals including growth 
 54 
factor-mediated RTK activation and engagement of adhesion receptors. The Abl kinases 
have been implicated in signaling responses to diverse stimuli in various cellular 
contexts, although limited studies have examined the role of these kinases in endothelial 
function. However, several previous investigations have suggested potential vascular 
functions for the Abl kinases; some of these studies will be reviewed in the following 
sections. 
1.4.5.1 Angiogenesis 
Elevated endothelial Abl kinase expression has been detected at sites of active 
angiogenic remodeling, both during development and in tumor blood vessels [333], 
suggesting the possible involvement of Abl in neovascularization. Further, imatinib has 
shown anti-angiogenic activity in several in vivo tumor models [334,335,336]. The anti-
angiogenic activity of imatinib largely has been attributed to the inhibition of PDGF 
receptor activity, as PDGF signaling is necessary for endothelial cell interactions with 
supporting mural cells [335]. However, imatinib also can inhibit angiogenesis in a 
“porous chamber” subcutaneous implant mouse model, in which angiogenesis is driven 
by the pro-angiogenic factors VEGF and bFGF [266], suggesting the involvement of an 
alternative imatinib target in the angiogenic process. Indeed, during the course of the 
work described in this dissertation, a study was published describing a role for Abl in 
growth factor-driven angiogenesis [337]; this work has demonstrated a requirement for 
Abl in angiogenesis mediated by bFGF but not VEGF, attributed to involvement of Abl 
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in a signaling cascade downstream of the FGF receptor and integrin β3 [337]. The Abl 
kinase also has been implicated in VEGF-mediated signaling in human umbilical vein 
endothelial cells (HUVECs) [338], and Abl-knockout mice display reduced retinal 
neovascularization in response to hyperoxia [339]. 
1.4.5.2 Endothelial Barrier Function 
Several studies have suggested a role for the Abl kinases in endothelial barrier 
function. Imatinib treatment has been shown to decrease interstitial fluid pressure in 
lung and colon cancer models, resulting in improved tumor oxygenation and drug 
delivery [340,341,342]. Imatinib treatment also reduces vascular permeability following 
administration of thrombolytic tissue plasminogen activator (tPA) in a murine model of 
ischemic stroke [343], suggesting a beneficial effect of imatinib on vascular barrier 
function. Pre-treatment with imatinib (or the more potent Abl kinase inhibitor nilotinib) 
similarly protects against pulmonary edema following lipopolysaccharide (LPS)-
induced acute lung injury in mice [344], and imatinib treatment reduces vascular 
leakage and edema in a murine sepsis model [345]. While these protective effects have 
largely been attributed to imatinib-mediated inhibition of the PDGF receptor, recent 
studies have implicated the Abl kinases in both the promotion of endothelial barrier 
function by the bioactive lipid sphingosine-1-phosphate (S1P) [346] and the disruption 
of the endothelial barrier by VEGF and inflammatory mediators [345]. 
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1.4.5.3 Cardiovascular Function 
The Abl kinases have been linked to several additional aspects of cardiovascular 
function. Abl-null mice display decreased systolic blood pressure [347], and Abl has 
been implicated in signaling and constriction responses to phenylephrine and 
angiotensin II in arterial vascular smooth muscle [347,348]. The Abl kinase also has an 
important role in normal cardiomyocyte function and development, as Abl-null mice (on 
a C57BL/6J genetic background) exhibit perinatal lethality and heart enlargement, as a 
result of abnormally-increased cardiomyocyte proliferation [349]. However, 
cardiomyocyte-specific restoration of Abl expression largely rescues the observed 
cardiac hyperplasia, but does not restore viability, suggesting a critical role for the Abl 
kinase in additional cell types. 
Notably, it has been reported that long-term treatment with imatinib causes 
severe congestive heart failure in a subset of CML patients, which has been attributed to 
the inhibition of the Abl kinase in cardiomyocytes, leading to endoplasmic reticulum 
(ER) stress and cell death [350]. Additional studies have reported left ventricular 
dysfunction and heart failure or increased levels of brain natriuretic peptide (BNP) in a 
subset of imatinib-treated cancer patients [351,352], as well as instances of interstitial 
lung disease of unknown origin [353]. Further, several case reports of cancer patients 
treated with the Abl kinase inhibitor nilotinib have detailed the occurrence of vascular 
occlusive events (infarction; peripheral arterial occlusive disease) in a subset of patients 
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[354,355,356], suggesting potential vascular dysfunction following Abl kinase inhibition. 
Similarly, adverse vascular events, including blood clots and narrowing of blood vessels, 
have been observed in over 10% of CML patients treated with the Abl kinase inhibitor 
ponatinib [357]. However, the role of the Abl kinases in the endothelium has not yet 
been examined in vivo using genetic models. 
1.5 Objectives 
The goal of the studies detailed in this dissertation was to evaluate the 
involvement of the Abl kinases in endothelial cell function in vitro and in vivo, using 
conditional genetic depletion of the Abl kinase in the endothelium, as well as specific 
Abl kinase pharmacological inhibition. Chapter 3 describes the generation and 
characterization of vascular phenotypes of endothelial Abl knockout mice. This work 
also examines the involvement of the Abl kinases in signaling cascades and endothelial 
cell responses downstream of a diverse set of cell surface receptors, including 
angiopoietin/Tie signaling and angiopoietin-1-mediated endothelial cell survival. 
Chapter 4 evaluates the involvement of the Abl kinases in endothelial permeability 
responses to mediators including VEGF, thrombin, and histamine. In all, these studies 
suggest both potential beneficial uses of Abl kinase pharmacological inhibitors, as well 
as deleterious vascular effects of targeting the Abl kinases; a discussion of these 
contrasting effects of Abl kinase inhibition and their possible implications for the clinical 
use of Abl kinase pharmacological inhibitors is included in Chapter 5. 
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2. Materials & Methods 
2.1 Mice 
Both Ablflox/flox mice and Tie2-Cre transgenic mice have been described previously 
(26, 34). Ablflox/flox mice were crossed into an Arg-/- background (13) and backcrossed six 
generations onto the C57BL/6 genetic background. AblECKO; Arg-/- (mutant) embryos were 
obtained from timed matings of Ablflox/flox; Arg+/-; Tie2-Cre+/- males to Ablflox/flox; Arg+/-; Tie2-
Cre-/-
2.2 Cell Culture 
 females. The presence of a vaginal plug was considered to be embryonic day (E)0.5. 
All animal procedures used in this study were reviewed and approved by the Duke 
University Institutional Animal Care and Use Committee (protocols #A183-07-07, A152-
10-06, and A137-13-05) and were carried out in accordance with the Guide for the Care 
and Use of Laboratory Animals (National Research Council). 
Primary human umbilical vein endothelial cells (HUVECs) were obtained from 
Lonza/Clonetics and used between passages 2 and 6. Human microvascular endothelial 
cells (HMVECs) immortalized with telomerase reverse transcriptase (hTERT) were 
provided by Xiao-Fan Wang (Duke University Medical Center) [358]. Endothelial cells 
routinely were cultured in microvascular endothelial growth medium-2 (EGM-2MV; 
Lonza). For experiments examining signaling responses to permeability-inducing 
factors, confluent HMVECs were serum-starved approximately 16 hours in endothelial 
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basal medium-2 (EBM-2) supplemented with 0.2% (wt/vol) bovine serum albumin 
(BSA). Cells were pre-treated with the Abl kinase inhibitors imatinib (10µM) or GNF-2 
(15µM) or the Src kinase inhibitor su6656 (1µM) for one hour prior to treatment with 
VEGF (100ng/mL), thrombin (1U/mL), or histamine (100µM). 
2.3 Inhibitors and Reagents 
Imatinib (Gleevec/STI571) was a generous gift from Novartis and purchased 
from LGM Pharma. Nilotinib was purchased from Cayman Chemical. Recombinant 
human vascular endothelial growth factor (VEGF-A-165), recombinant human 
angiopoietin-1 (C-terminal 6-His tag), and anti-polyHistidine cross-linking antibody 
were purchased from R&D Systems. Recombinant bFGF was purchased from 
Invitrogen. GNF-2 and su6656 were purchased from Sigma. Thrombin from human 
plasma, histamine, thapsigargin, and PMA were purchased from Sigma. 
2.4 Antibodies 
Antibodies used for Western blotting included cleaved caspase-3, phospho-CrkL 
(Y207), phospho-Akt(S473), Akt, phospho-Erk(T202/Y204), phospho-PLCγ1 (Y783), 
phospho-VEGFR2 (Y1175), VEGFR2 (anti-human), phospho-MLC2 (S19), MLC2, and 
Rap1 from Cell Signaling; β-tubulin from Sigma-Aldrich; CrkL (C-20), Arg (9H5), 
Angpt2, VEGFR2 (anti-mouse, Flk-1), Erk, Lamin B, PLCγ1 (530), and Rap1GAP (H-93) 
from Santa Cruz; Abl (8E9) and Rac1 from BD Biosciences; Rho and Rac1 from Pierce 
(Thermo Scientific); phospho-Tie2(Y992) from R&D Systems; and mouse anti-α-catenin 
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from Zymed (Life Technologies). Mouse monoclonal antibody (Ab33) against Tie2 was a 
gift of Christopher Kontos (Duke University) (2). Antibodies used for both Western 
blotting and immunoprecipitation included VE-cadherin (C-19) from Santa Cruz and β-
catenin from BD Biosciences. Antibodies used for immunohistochemistry included: 
CD31 (BD Biosciences), vWF and fibrin/fibrinogen (Dako), CD41 (eBioscience), alpha-
smooth muscle actin (Sigma), and cleaved caspase-3 (Cell Signaling). VE-cadherin 
antibody (anti-Cadherin-5) from BD Biosciences was used for immunofluorescence. 
2.5 Endothelial Cell Viability/Apoptosis Assays 
Primary HUVECs (5x103 cells/well in 96-well plates) were cultured in serum-free 
medium (EBM-2 basal medium with 0.2% BSA) for 24 to 48 hours. Some cells were 
supplemented with either VEGF (100ng/mL) or bFGF (10ng/mL). Abl kinases were 
inhibited by treatment with imatinib (10µM). Cell viability in triplicate samples was 
assessed using CellTiter assay (Promega). In separate experiments, cells were lysed after 
24 hours serum-starvation and cleaved caspase-3 levels examined by Western blotting. 
HUVECs expressing control miRNA or Abl/Arg miRNAs were serum-starved for 24 
hours (96 hours post-miRNA infection). Caspase activity was assessed in triplicate 
samples using the Caspase-3/7-Glo assay (Promega) and normalized to total cell 
number. For Angpt1-mediated survival experiments, 200ng/mL Angpt1 (C-terminal 6-
His tag) was pre-incubated with 20µg/mL anti-polyHistidine cross-linking antibody for 
1 hour at 37°C in serum-free medium prior to treatment of HUVECs. 
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2.6 Mouse Endothelial Cell Isolation, Flow Cytometric Analysis, 
and Characterization of Abl Inactivation 
 E13.5 embryos (wild-type or AblECKO; Arg-/-) were disrupted by trituration and 
digested in 1mg/mL collagenase A solution (in low-glucose DMEM, supplemented with 
1% penicillin-streptomycin, gentamicin, and 25µg/mL DNase I) for 45 minutes at 37°C. 
The cell suspension was then disrupted by passage (20X) through a syringe with 
attached 14Ga cannula and filtered through a 70µm cell strainer, followed by red blood 
cell lysis. Cells were incubated first for 15min on ice with anti-CD16/CD32 mouse Fc 
block (BD Biosciences), followed by staining for 30min with antibodies against CD105, 
CD45, and CD31 (all from eBioscience) or appropriate isotype control antibodies. After 
washing twice, cells were subjected to FACS, and CD105+/CD45-/CD31+ endothelial cells 
collected. Retrovirus expressing Polyoma middle T antigen (PyMT) was used for 
endothelial cell immortalization (3). For flow cytometric analysis of endothelial cells, 
livers from E18.5 embryos (wild-type or AblECKO; Arg-/-) were similarly digested to a 
single-cell suspension, then labeled with antibodies against CD31, CD45, and Tie2 
(CD202b, eBioscience) or appropriate isotype controls. Expression of each marker was 
evaluated by flow cytometry and Tie2 receptor levels examined in CD31+/CD45- 
endothelial cells using FlowJo software (Tree Star Inc.). Endothelial cells were similarly 
isolated from hearts and livers from adult control and AblECKO; Arg+/- mice, along with 
CD105-/CD45-/CD31- non-endothelial/non-hematopoietic cells. Cells were used directly 
for RNA isolation without culturing. Oligo(dT)12-18-primed cDNAs were used for PCR 
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with the following primers: Abl Flox/∆ (forward) - 5’-GCC CTG GCC AGA GAT CCA 
TC-3’, (reverse) – 5’-TCC CTC AGG TAG TCC AGC AGG-3’; Abl exon 5 (forward) – 5’-
GTA CGT GTC CTC CGA GAG CC-3’, (reverse) – 5’-CCT TCA GGA ACT CCT CCA 
CC-3’; Cre (forward) – 5’-CGA TGC AAC GAG TGA TGA GG-3’, (reverse) – 5’-CGC 
ATA ACC AGT GAA ACA GC-3’; β2M (forward) – 5’-ACC GGC CTG TAT GCT ATC 
CAG AAA-3’, (reverse) – 5’-GGT GAA TTC AGT GTG AGC CAG GAT-3’. The Abl 
Flox/∆ primers bind to sites within abl exons 4 and 6, respectively; the unrecombined 
ablflox allele yields a 500 bp PCR product, while a recombined abl∆
2.7 Flow Cytometry Analysis of Fetal Liver Cells 
 allele (lacking exon 5) 
yields a PCR product of approximately 200bp (4). 
Livers were isolated from E15.5 wild-type and AblECKO; Arg-/- embryos. Livers 
were maintained in Hank’s Balanced Salt Solution without calcium or magnesium, 
supplemented with 10% (vol/vol) heat-inactivated FBS and 2mM EDTA, and were 
dissociated by gentle trituration. The resulting cell suspension was filtered through 
70µm and 40µm cell strainers. Approximately 106 cells were used for surface staining of 
hematopoietic markers. Cells were first incubated with anti-CD16/CD32 mouse Fc block 
(BD Biosciences), followed by staining with antibodies against Kit and hematopoietic 
lineage markers (TER-119, GR1, B220, CD3, CD4, and CD8a) or erythroid markers (CD71 
and TER-119) or appropriate isotype controls (all from eBioscience). After washing, cells 
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were analyzed by flow cytometry and expression of cell surface markers evaluated using 
FlowJo software (Tree Star Inc.).  
2.8 Histological Analysis and Immunohistochemistry 
Freshly-dissected mouse organs were imaged using a Zeiss Lumar.V12 
stereoscope. For routine histology, mouse tissue samples were fixed in 4% (wt/vol) 
paraformaldehyde and embedded in paraffin; 5-µm sections were used for hematoxylin-
eosin, Masson Trichrome, and Prussian blue staining, following standard protocols. 
Images were acquired using a Zeiss Axio Imager and Metamorph software. For FITC-
wheat germ agglutinin (WGA) staining, sections were de-waxed and rehydrated, 
followed by proteinase K treatment (100µg/mL, 10 minutes at room temperature). Slides 
were washed with phosphate-buffered saline (PBS), then incubated with FITC-WGA 
(Sigma; 10µg/mL, 2 hours at room temperature). For immunohistochemical analysis, 
tissue samples were infiltrated with 30% (wt/vol) sucrose (in PBS), then fresh-frozen in 
tissue freezing medium (Tissue-Tek O.C.T.; Sakura Finetek); 10-µm sections were 
fixed/permeabilized in ice-cold acetone, blocked in 5% (vol/vol) normal goat serum, and 
stained overnight at 4°C with the indicated antibodies. Sections were then stained with 
Alexa Fluor-conjugated secondary antibodies (Invitrogen) and counterstained with 
Hoechst 33342 (0.5µg/mL). Images were acquired using a Zeiss Axiovert 200M 
fluorescence microscope and AxioVision software. 
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2.9 Viral Transduction 
2.9.1 Retroviral Transduction 
pLNCX vector and pLNCX/hTie2 retroviral constructs were kindly provided by 
Christopher Kontos, Duke University. Control (non-specific) and human Rac1 shRNA 
oligos were cloned in pSuper-Retro-puro (pSR-puro) retroviral vector (OligoEngine). 
shRNA sequences (antisense) were as follows: control shRNA – AAA TGT ACT GCG 
CGT GGA G; Rac1 shRNA – TTT TAC AGC ACC AAT CTC C. Retroviral constructs 
were transfected into 293T cells, along with pCL10A1 packaging vector, using FuGENE6 
reagent (Promega). Retroviral supernatants were collected and filtered 48 hours post-
transfection. HUVECs or HMVECs were incubated 16-24 hours with retroviral medium 
in the presence of 6µg/mL Polybrene. Transduction with pBabe-puro retroviral 
constructs (pBabe-puro vector; pBabe-puro/mAbl-WT; pBabe-puro/hRap1GAP) was 
performed similarly. HUVECs infected with hTie2-expressing retrovirus (or vector 
control) were cultured at least two days in 400µg/mL geneticin selection medium or 
sorted for Tie2 over-expression by FACS (mouse anti-hTie2 antibody; BioLegend) prior 
to microRNA (miRNA) lentiviral infection. HMVECs infected with control or Rac1 
shRNA retroviruses or with pBabe-puro vector-derived retroviruses were selected in 
1µg/mL puromycin for at least two days.   
 65 
2.9.2 Lentiviral Transduction 
Lentiviral miRNA-mediated knockdown of Abl/Arg in HUVECs or HMVECs was 
conducted as previously described (5, 6). miRNA targeting sequences were as follows: 
control miRNA (GGTGTATGGGCTACTATAGAA); Abl miRNA 
(GGTGTATGAGCTGCTAGAGAA); Arg miRNA #1 (CCTTATCTCACCCACTCTGAA); 
Arg miRNA #2 (AGGTACTAAAGTGGCTCTGAG). Abl single knockdown in HMVECs 
was performed using a single lentiviral miRNA vector expressing 3 Abl miRNAs in 
tandem (miRNA Abl 6/2/1; generously provided by Owen Witte, University of 
California, Los Angeles, [359]). HUVECs were lysed for Western blotting or used for 
RNA isolation 96 hours post-miRNA infection. HMVECs were plated for signaling 
experiments and Transwell permeability assays 48 hours after miRNA viral 
transduction. 
2.9.3 Cre Recombinase Adenoviral Transduction 
In vitro Cre-mediated Abl deletion was performed using adenovirus expressing 
Cre recombinase (Ad5CMVCre-eGFP and Ad5CMV-eGFP control, obtained from the 
University of Iowa Gene Transfer Vector Core). Primary liver endothelial cells from 
Ablflox/flox; Arg+/+; Tie2-Cre-/- mice were incubated with adenovirus for 8 hours at a 
multiplicity of infection of 200. Lentiviral shRNA transduction was used for Arg 
knockdown in primary mouse endothelial cells.  Lentiviral shRNA plasmid (pLKO.1 
vector, The RNAi Consortium, (7)) targeting murine Arg was obtained from Open 
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Biosystems (Thermo Scientific), and control (non-specific) shRNA oligos were cloned 
into pLKO.1 vector. shRNA sequences (anti-sense) were as follows: control shRNA 
(TCGTAAGCCAGATAGTCATGC); Arg shRNA (TTGAGATAGGTCAATACCTGG). 
Transduced cells were selected in 1µg/mL puromycin for at least two days. 
2.10  Lysis and Western Blotting 
Cells were washed once with ice-cold phosphate-buffered saline (PBS), then 
lysed in radioimmunoprecipitation assay (RIPA) buffer [50mM Tris-HCl, pH 7.5; 150mM 
NaCl; 1% Triton X-100; 0.1% sodium dodecyl sulfate (SDS); 1% sodium deoxycholate; 
0.05% NP-40; 5mM ethylenediaminetetraacetic acid (EDTA)] with protease/phosphatase 
inhibitors [0.1mM phenylmethane sulfonyl fluoride (PMSF); 1µg/mL aprotinin; 1µg/mL 
leupeptin; 10µg/mL pepstatin; 10mM β-glycerophosphate; 1mM sodium fluoride; 0.1mM 
sodium orthovanadate]. Alternatively, freshly-dissected mouse tissues were flash-frozen 
in liquid nitrogen, then homogenized in RIPA buffer containing protease/phosphatase 
inhibitors. Cell debris was removed by microcentrifugation, and protein concentrations 
were quantified using Bio-Rad DC protein assay reagents. Equal amounts of protein 
were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred 
to nitrocellulose membranes. Membranes were incubated with primary antibodies in 
blocking solution containing either 5% (wt/vol) non-fat dry milk or 3% (wt/vol) BSA in 
Tris-buffered saline-Tween 20 (TBS-T), overnight at 4°C. Blots were washed three times 
with TBS-T, then incubated with horseradish peroxidase-coupled secondary antibodies 
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(Jackson ImmunoResearch or Santa Cruz) in blocking solution for one hour at room 
temperature. Blots were washed with TBS-T and developed using enhanced 
chemiluminescence (ECL) Western blotting detection reagent (Amersham/GE 
Healthcare). Western blots were quantified using ImageJ analysis software (NIH). 
2.11  Real-time RT-PCR Array 
RNA was isolated from control or Abl/Arg-knockdown HUVECs 120 hours post-
miRNA infection, using a Qiagen RNeasy kit. 1µg each RNA was used for cDNA 
synthesis, using an RT2
2.12  Real-time RT-PCR Analysis 
 First Strand cDNA kit (SABiosciences). Gene expression was 
evaluated using the SABiosciences Human Endothelial Cell Biology Real-time RT-PCR 
Array, according to the manufacturer’s protocol. 
RNA was isolated from HUVECs using an illustra RNAspin Mini RNA isolation 
kit (GE Healthcare) and cDNA synthesized using Oligo(dT)12-18 primer and M-MLV 
reverse transcriptase (Invitrogen). Real-time PCR was performed using iQ SYBR Green 
Supermix (Bio-Rad). Primers used were as follows:  Tie2/Tek (forward) – 5’-GGG CTA 
CAG ACT GGA GAA GC-3’, (reverse) – 5’-TGT CAA GGG TCT CCC ATG CC-3’; Tie1 
(forward) – 5’- ACC CTG GTG TGC ATC CGC AG-3’, (reverse) – 5’-GTG ATG TCC TCC 
CAC TCT AGC-3’; Angpt1 (forward) – 5’-ACT GGG AAG GGA ACC GAG CC-3’, 
(reverse) – 5’-TGG AGG GGC CAC AAG CAT CAA-3’; Angpt2 (forward) – 5’-GAC ACA 
CCA CGA ATG GCA TC-3’, (reverse) – 5’-CTG AAG GGT TAC CAA ATC CC-3’; RPLP0 
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(forward) – 5’-GGA CAT GTT GCT GGC CAA TAA-3’, (reverse) – 5’-GGG CCC GAG 
ACC AGT GTT-3’. Analysis was performed using a Bio-Rad CFX384 real-time machine 
and CFX Manager software.  PCR reactions were performed in triplicate. Expression 
levels of each gene were normalized to the expression of the RPLP0 ribosomal protein 
housekeeping control gene. 
2.13  Biotinylation of Cell Surface Protein 
Confluent HMVECs were serum-starved overnight (EBM-2 with 0.2% BSA), pre-
treated for 1 hour with imatinib (10µM), then stimulated for 15 or 30 minutes with VEGF 
(100ng/mL) at 37°C. Cells were immediately moved to 4°C for the remainder of the 
procedure. Cell surface proteins were biotinylated with EZ-link Sulfo-NHS-SS-biotin 
(Thermo Scientific; 0.4mg/mL in PBS, with calcium and magnesium) for 30 min, 
followed by PBS washes and quenching of unreacted biotin in 50mM ammonium 
chloride in PBS with calcium and magnesium (2x5 minute washes). Following PBS 
washes, cells were lysed in RIPA Buffer (with protease/phosphatase inhibitors). For 
isolation of biotinylated cell surface proteins, equal amounts of each lysate (250µg) were 
incubated with high-capacity NeutrAvidin Agarose resin (Thermo Scientific) for 1 hour 
at 4°C with constant mixing. Beads were washed four times with PBS with 1% NP-40 
and protease/phosphatase inhibitors, then boiled in 2X reducing SDS-PAGE sample 
buffer for analysis by western blotting. 
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2.14  Immunoprecipitation 
Confluent HMVECs were serum-starved overnight (EBM-2 with 0.2% BSA), pre-
treated for 1 hour with imatinib (10µM), then stimulated for 5 or 15 minutes with VEGF 
(100ng/mL). Cells were washed once with ice-cold PBS, then lysed in NP-40 lysis buffer 
(50mM Tris-HCl, pH 8.0, with 150mM sodium chloride and 1% NP-40) with 
protease/phosphatase inhibitors. Equal amounts of each lysate (300µg, pre-cleared) were 
incubated with either VE-cadherin (0.6µg) or β-catenin (0.5µg) antibodies overnight at 
4°C with constant mixing, followed by incubation with Protein G Sepharose 4 Fast Flow 
beads (GE Healthcare Life Sciences) for 6 hours at 4°C. Beads were washed four times 
with NP40 buffer with protease/phosphatase inhibitors, then boiled in 2X reducing SDS-
PAGE sample buffer for analysis by western blotting. 
2.15  GTPase Activation Assays 
Confluent HMVECs were serum-starved overnight (EBM-2 with 0.2% BSA), pre-
treated with 10µM imatinib for 1 hour, then stimulated for 2 minutes with VEGF 
(100ng/mL) or thrombin (1U/mL). Activity of Rac1, Rap1, and Rho GTPases was 
examined using Active GTPase Pull-down and Detection kits (Pierce/Thermo Scientific), 
following the manufacturer’s protocol. 
2.16  Immunofluorescence 
HMVECs were cultured to confluence on glass coverslips, then serum-starved 
approximately 16 hours in EBM-2 basal medium with 0.2% BSA. Cells were pre-treated 
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with either imatinib (10µM) or GNF-2 (15µM) one hour prior to treatment with VEGF 
(100ng/mL, 30 minutes) or thrombin (1U/mL, 5 minutes). Cells were washed with ice-
cold PBS, then fixed 15 minutes in 4% paraformaldehyde (in PBS) and permeabilized 15 
minutes in 3% BSA in PBS with 0.05% sodium azide and 0.05% Triton X-100. VE-
cadherin primary antibody (anti-Cadherin-5; BD Biosciences) was added to coverslips at 
1:200 dilution in blocking buffer (3% BSA in PBS with 0.05% sodium azide) for one hour 
at room temperature. Following PBS washes, Alexa 568- or Alexa 488-coupled goat anti-
mouse IgG was added at 1:250 dilution in blocking buffer for one hour at room 
temperature, followed by DNA counterstaining with Hoechst 33342 (0.5µg/mL, 5 
minutes). Images were acquired using a Zeiss Axiovert 200M fluorescence microscope 
and AxioVision software (Rel. 4.8). 
2.17  Transwell Permeability Assay 
Transwell supports (6.5mm diameter, 0.4µm pore size, polyester membranes; 
Corning) in 24-well tissue-culture plates were pre-coated with 0.02mg/mL bovine 
fibronectin (Sigma) for one hour at 37°C, prior to seeding of HMVECs at 2.7x104 cells per 
Transwell. HMVECs were cultured in Transwells for three days at 37°C to allow 
formation of a confluent monolayer. Cells were then pre-treated with Abl kinase 
inhibitors in serum-free medium (EBM-2 with 0.2% BSA) for one hour prior to 
permeability assay. Fluorescein-labeled dextran (anionic, molecular weight 40kDa; 
Invitrogen/Life Technologies) was added to the top chamber of each Transwell at 
 71 
1mg/mL, followed by treatment with permeability-inducing factors. Each treatment was 
performed in triplicate wells. At the indicated times, 50µL samples were removed from 
the bottom chamber of each Transwell and replaced with 50µL fresh culture medium. 
The collected samples were diluted 20-fold with PBS and fluorescence measured 
(excitation 485nm/emission 535nm) using a VICTOR3
2.18  In Vivo Permeability Assays (Modified Miles Assay) 
 plate reader (PerkinElmer) and 
Wallac 1420 Workstation software. 
2.18.1 Abl Kinase Inhibition 
In vivo vascular permeability was examined using a modified Miles assay [360], 
examining leakage of Evans blue dye as an indicator of albumin extravasation.  
Approximately 12-week-old female athymic nude mice were anesthetized with 
100mg/kg ketamine and 10mg/kg xylazine. Evans blue dye (Sigma; 30mg/kg in 100µL 
sterile saline) was administered by tail vein injection, followed by intradermal injections 
of PBS and VEGF (100ng in 30µL PBS) into the back skin, co-injected with either vehicle 
or either of two Abl kinase inhibitors (imatinib or GNF-2, 15 µM). Fifteen minutes after 
intradermal injections, mice were humanely euthanized by CO2 inhalation and the back 
skin surrounding each injection site dissected, blotted dry, and weighed. Evans blue dye 
was extracted from skin tissue samples in formamide (Sigma) overnight at 56°C, and 
absorbance measured at 620nm. Amounts of extracted Evans blue dye were calculated 
 72 
based on a standard curve of Evans blue dye in formamide and normalized to skin 
tissue sample weight. 
2.18.2 Endothelial Abl Knockout Mice 
The modified Miles assay described above was also performed using 
approximately 16-week-old endothelial Abl knockout mice (Ablflox/flox; Arg+/-; Tie2-Cre+/-, 
referred to as AblECKO; Arg+/-) and age- and sex-matched Arg+/- controls (Ablflox/flox; Arg+/-; 
Tie2-Cre-/-
2.19  Analysis of Intracellular Ca
). Mice were anesthetized with 100mg/kg ketamine and 10mg/kg xylazine, 
followed by intravenous administration of 30mg/kg Evans blue dye. Back hair was 
shaved using mouse clippers prior to intradermal injections of PBS and VEGF (100ng in 
30µL PBS). Mice were euthanized 15 minutes after VEGF administration, and Evans blue 
dye was extracted and quantified as described above. 
2+
HMVECs were cultured to confluence on 35mm glass bottom microwell dishes 
(MatTek Corporation; Ashland, MA, USA), then serum-starved overnight in EBM-2 
basal medium with 0.2% BSA. Cells were loaded with 3µM cell-permeant Calcium 
Green-1, AM fluorescent Ca
 Levels 
2+ indicator (Molecular Probes/Life Technologies) in the 
presence of 0.1% Pluronic F-127 in serum-free medium for 45 minutes at room 
temperature. Cells were washed three times with Hank’s Balanced Salt Solution (HBSS; 
with calcium and magnesium, without phenol red), then pre-treated with imatinib 
(10µM) or GNF-2 (15µM) in HBSS for 1 hour. Intracellular Ca2+ levels, as assessed by 
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Calcium Green-1 fluorescence, were measured by live cell imaging using a Zeiss Axio 
Observer Z1 fluorescence microscope (GFP filtercube: BP 470/40, FT 495, BP 525/50) and 
MetaMorph software.  Images were acquired using four microscope fields per treatment. 
Three images were acquired prior to addition of permeability-inducing factors, for 
assessment of baseline intracellular Ca2+
2.20  Statistical Analysis 
 levels. Images were acquired for 10 minutes (at 
20 second intervals) following addition of VEGF (100ng/mL), thrombin (1U/mL), or 
histamine (100µM) in HBSS. Average fluorescence intensity (with baseline subtracted) 
was measured on a single-cell basis for 35 cells per treatment, using Metamorph 
software. 
All statistical analyses were performed using GraphPad Prism 5 or 6 software. 
Comparisons of two groups were performed using Student’s t tests (two-tailed). 
Comparisons involving multiple groups were evaluated using one-way ANOVA, 
followed by Bonferroni post-tests. Two-way ANOVA, followed by Bonferroni post-tests, 
was used to evaluate differences in HUVEC survival between drug treatments over 
time, changes in mRNA expression in control vs. Abl/Arg knockdown cells, and changes 
in HMVEC permeability in multiple treatment groups over time. Survival of embryos of 
various genotypes was evaluated by log-rank (Mantel-Cox) test. For all tests, P<0.05 was 
considered statistically significant. 
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3. Abl Kinases Are Required for Vascular Function, Tie2 
Expression, and Angiopoietin-1-Mediated Survival 
This chapter originally was published in modified form in Proc Natl Acad Sci USA 
2013 Jul 23; 110(30):12432-12437 and is discussed further in Cell Cycle 2013; 12(24) 
<http://dx.doi.org/10.4161/cc.26877>. 
3.1 Introduction 
Disruption of vascular homeostasis plays a key role in pathological conditions 
including atherosclerosis, cancer, diabetes mellitus, and inflammatory arthritis [2,3]. 
Endothelial function is regulated, in part, by a variety of vascular growth factors, 
including VEGF and the angiopoietins (Angpt) [64]. These factors signal through 
receptor tyrosine kinases to support endothelial cell proliferation, survival, migration, 
and vascular stability. The angiopoietins, of which Angpt1 and Angpt2 are most well-
characterized, signal through the Tie2 receptor. Angpt1 is the primary Tie2 stimulatory 
ligand, while Angpt2 functions as a context-dependent Tie2 antagonist or agonist 
[361,362]. While VEGF signaling is necessary for initial vasculogenesis, angiopoietin 
signaling is important for subsequent vascular remodeling as well as for interaction of 
the endothelium with supporting mural cells [70,130]. Vascular growth factor signaling 
also functions to maintain homeostasis in the quiescent vasculature [71,129]. Thus, 
delineating the intracellular signaling mechanisms that mediate endothelial responses to 
these factors has important implications for understanding vascular homeostasis as well 
as cardiovascular diseases. 
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The Abl family of non-receptor tyrosine kinases, which includes the Abl (Abl1) 
and Arg (Abl2) kinases, has roles in diverse cellular processes including proliferation, 
survival, adhesion, and migration [223]. These kinases are transiently activated and 
mediate cytoskeletal remodeling downstream of several growth factor receptors and 
following cadherin and integrin engagement [223,294]. Abl is activated constitutively as 
a result of the t(9;22) chromosomal translocation that produces the BCR-ABL1 fusion 
protein, the causal agent in CML [226]. Global Abl/Arg-null mice die by E10.5, exhibiting 
hemorrhage and pericardial edema, suggesting a role for these kinases in vascular 
development [329]. It was reported that long-term treatment with imatinib 
(Gleevec/STI571), a pharmacological inhibitor of the Abl kinases (as well as Kit and the 
platelet-derived growth factor receptor) caused severe congestive heart failure in a 
subset of CML patients [350]. This cardiotoxicity was attributed to Abl inhibition in 
cardiomyocytes, leading to endoplasmic reticulum stress and cell death. Similarly, 
global Abl deletion (C57BL/6J genetic background) led to cardiomyocyte dysfunction, 
heart enlargement, and perinatal lethality [349]. However, cardiomyocyte-specific 
restoration of Abl expression did not rescue viability [349], suggesting a critical role for 
the Abl kinase in additional cell types. Notably, several case reports of patients treated 
with the second-generation BCR-ABL1 kinase inhibitor nilotinib have detailed the 
occurrence of vascular occlusive events [354,355], suggesting potential vascular 
dysfunction following Abl kinase inhibition. In vitro studies have demonstrated a 
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requirement for the Abl kinases in mediating both endothelial barrier-promoting effects 
of sphingosine-1-phosphate and barrier-disrupting effects of VEGF and inflammatory 
mediators [345,346]. However, the role of the Abl kinases in the endothelium has not yet 
been examined using genetic models. 
Here, we demonstrate a crucial role for the Abl kinases in the vasculature using 
endothelial Abl knockout mice. Loss of endothelial Abl kinases resulted in lethality at 
late embryonic and perinatal stages of development, with focal regions of vascular loss 
and tissue necrosis/apoptosis. Further, we demonstrate increased endothelial cell 
apoptosis in these embryos, as well as in Abl/Arg-knockdown endothelial cells in vitro. 
Notably, our studies reveal an unexpected link to angiopoietin/Tie2 signaling, with loss 
of endothelial Abl kinases leading to decreased Tie2 expression, diminished Tie2 
receptor signaling, and loss of Angpt1-mediated survival. Further, we find that Abl 
kinases are activated by Angpt1/Tie2 signaling. Together, these findings reveal bi-
directional signaling linking Abl kinases and Tie2, which is critical for endothelial cell 
survival and function. 
3.2 Results 
3.2.1 Embryonic Lethality of AblECKO; Arg-/-
To evaluate the vascular function of the Abl kinases, we generated mice with 
endothelial inactivation of the Abl kinase by crossing mice carrying a floxed Abl allele 
(Abl
 Mice 
flox/flox mice) on an Arg-/- background to Tie2-Cre mice. In these mice, Cre-mediated 
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recombination results in excision of a 2.2kb genomic fragment containing abl exon 5, 
yielding minimal levels of a truncated, kinase-inactive Abl protein [290,307]. A near-
complete loss of both Abl mRNA and protein was observed in endothelial cells of both 
embryos and adult mice (Figure 3.1A-D). No Cre-mediated recombination or Abl 
depletion was observed in non-endothelial/non-hematopoietic cells (Figure 3.1B-D).  
 
Figure 3.1 Analysis of Abl mRNA and Protein Levels in AblECKO
(A) Assessment of Abl knockdown levels in Abl
 Mouse Endothelial 
Cells 
ECKO; Arg-/- embryos. Endothelial cells 
(CD105+/CD45-/CD31+) were isolated from E13.5 Ablflox/flox; Arg+/+; Tie2-Cre-/- (wild-type, 
WT) and AblECKO; Arg-/- (mutant) embryos. Abl mRNA expression was assessed by real-
time RT-PCR. Data are shown as means +/- SD, n=5-6 embryos/genotype. (B) 
Endothelial-specific Abl inactivation in livers from AblECKO; Arg+/- adult mice. RNA was 
isolated from endothelial (EC; CD105+/CD45-/CD31+) and non-hematopoietic/non-
endothelial (non-EC; CD105-/CD45-/CD31-) liver cell populations from AblECKO; Arg+/- (+ 
Tie2-Cre) and Arg+/- control (- Tie2-Cre) mice, and Cre-mediated recombination of abl 
exon 5 was assessed by RT-PCR. Deletion of abl exon 5 was only observed in endothelial 
cells (200bp band in top panel vs. 500bp band in non-recombined allele). (C) Analysis of 
Abl and Arg protein depletion in PyMT-immortalized cells from WT and AblECKO; Arg-/- 
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embryos, either prior to (unsorted) or after sorting for CD31+ endothelial cells (EC). (D) 
Abl protein depletion specifically in endothelial (EC; CD105+/CD45-/CD31+) cells, rather 
than non-hematopoietic/non-endothelial (non-EC; CD105-/CD45-/CD31-) cells, from 
E18.5 Ablflox/flox; Tie2-Cre-/- and Ablflox/flox; Tie2-Cre+/-
 
 embryos, quantified in right panel 
(means +/- SD, n=3). (*P<0.05; ***P<0.001). 
 
Strikingly, loss of the endothelial Abl kinases resulted in significant lethality. The 
majority of endothelial Abl/Arg-null pups (Ablflox/flox; Arg-/-; Tie2-Cre+/-, hereafter referred to 
as AblECKO; Arg-/- or mutant) died at birth, with 90% mortality by the end of postnatal day 
1 (Figure 3.2A). Further, the total number of AblECKO; Arg-/- mice born was reduced (6.5%) 
compared to the expected Mendelian ratio (12.5%), suggesting that approximately 50% 
died during embryonic development. While mutant embryo viability largely was 
unaffected at earlier stages of cardiovascular development, a decreased number of 
AblECKO; Arg-/- embryos was observed at later stages (E17.5-E18.5), and mutant embryo 
viability was decreased (Figure 3.2B). In contrast, no decrease in viability of Arg-/- 
embryos (Ablflox/flox; Arg-/-; Tie2-Cre-/-) was observed at E18.5; however, approximately 40% 
of Arg-/- mice died within a week of birth (data not shown). Thus, loss of endothelial 
expression of both Abl and Arg kinases resulted in more frequent and earlier lethality 
than did loss of Arg alone. 
 79 
 
Figure 3.2 Embryonic and Perinatal Lethality of AblECKO; Arg-/-
(A) Survival of Abl
 Mice 
ECKO; Arg-/- mice compared to Ablflox/flox; Arg+/+; Tie2-Cre-/- (wild-type, WT) 
and Ablflox/flox; Arg+/-; Tie2-Cre+/- (AblECKO; Arg+/-) littermates (P0 = postnatal day 0, birth; 
n=462 total pups examined). (B) Survival of AblECKO; Arg-/-
 
 (mutant) embryos at various 
stages of gestation, relative to expected Mendelian frequency (12.5%, indicated by 
dashed line). 
Surviving late-stage AblECKO; Arg-/- embryos were indistinguishable from wild-
type (Ablflox/flox; Arg+/+; Tie2-Cre-/-) littermates, with no defects in gross vascular 
morphology (Figure 3.3A). In addition, no changes in overall vascular patterning were 
observed in the heart or lungs (Figure 3.3B,C), nor was smooth muscle cell coverage of 
vessels affected (Figure 3.3D). However, over 50% (42 of 77) of AblECKO; Arg-/- embryos 
displayed focal areas of hepatic necrosis of varying severity, typically localized to the 
periphery of the lobes (Figure 3.4A,B). Co-staining of liver sections for the endothelial 
marker CD31 (also known as PECAM-1) and apoptosis marker cleaved caspase-3 
showed dramatic reduction in vascular density and extensive apoptosis in the 
peripheral necrotic areas (Figure 3.4C), suggesting a loss of vascular perfusion in these 
regions. 
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Figure 3.3 Normal Overall Vascular Morphology and Patterning in AblECKO; Arg-/- 
(A) Image of E18.5 WT and Abl
Embryos 
ECKO; Arg-/- embryos. Scale bar = 1mm. (B) CD31 staining of 
heart sections from E18.5 WT and AblECKO; Arg-/- embryos. Scale bar = 100µm. (C) CD31 
staining (red) of lung sections from E18.5 WT and AblECKO; Arg-/- embryos. Scale bars = 
100µm (top panels); 50µm (bottom panels). (D) Co-staining of lung sections from E18.5 
WT and AblECKO; Arg-/-
 
 embryos for CD31 (red) and α-smooth muscle actin (αSMA, 
green). Scale bar = 20µm.  
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Figure 3.4 Localized Loss of Vasculature and Necrosis/Apoptosis in Livers of AblECKO; 
Arg-/-
(A) E18.5 mutant liver, displaying peripheral necrosis (arrow). (B) Hematoxylin/eosin 
(H&E)-stained sections of E18.5 WT and mutant livers, demonstrating necrotic areas in 
mutant liver (arrows). Scale bar = 100µm. (C) E18.5 mutant liver section co-stained for 
CD31/PECAM-1 (endothelial cell marker, red) and cleaved caspase-3 (apoptosis marker, 
green). Scale bar = 50µm. 
 Embryos 
 
As Tie2-Cre also drives Abl inactivation in hematopoietic cells [363], we 
additionally examined hematopoietic progenitor cells in mutant fetal livers. No 
differences in percentages of lineage-negative (Lin-)/Kit+
 
 hematopoietic progenitors or 
erythroid marker TER-119/CD71 double-positive progenitors were observed in mutant 
embryos compared to wild-type littermates (Table 3.1). Thus, together our data suggest 
that loss of Abl kinases in endothelial cells results in lethality linked to loss of vascular 
function late in development. 
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Table 3.1 No Differences in Hematopoietic Progenitors in AblECKO; Arg-/- Embryos 
 
Fetal liver cells were isolated from E15.5 wild-type (WT) and AblECKO; Arg-/- embryos and 
their expression of various hematopoietic markers assessed by flow cytometry.  No 
differences in the percentages of lineage-negative (Lin-)/Kit+ hematopoietic progenitors 
or TER-119+/CD71+ erythroid progenitors were observed.  Data are presented as means 
(%) +/- SD (WT, n=5 embryos; AblECKO; Arg-/-
 
, n=3 embryos). 
3.2.2 Cardiac Enlargement and Scarring in AblECKO; Arg+/-
To examine the role of endothelial Abl kinases in vascular structure and function 
in adult mice, we employed endothelial Abl-deficient mice on an Arg
 Mice 
+/- background 
(Ablflox/flox; Arg+/-; Tie2-Cre+/-, hereafter referred to as AblECKO; Arg+/-), which survive to 
adulthood. The majority of adult AblECKO; Arg+/-
 
 mice did not display any obvious 
cardiovascular pathology, although a slight decrease in left ventricular function (% 
fractional shortening) was observed (Table 3.2).  
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Table 3.2 Echocardiographic Evaluation of Left Ventricular Function in Adult AblECKO; 
Arg+/- Mice 
 
Left ventricular function of 4- to 5-month-old female AblECKO; Arg+/- mice and age/sex-
matched Arg+/- control mice (Ablflox/flox; Arg+/-; Tie2-Cre-/-
 
) was evaluated by 
echocardiography (unanesthetized mice). These studies were performed by Lan Mao in 
Howard Rockman’s laboratory (Departments of Medicine, Cell Biology, and Molecular 
Genetics; Duke University School of Medicine). Data are shown as means +/- SD. 
(*P<0.05). Abbreviations: FS, fractional shortening; LVDd, left ventricular end-diastolic 
dimension; LVDs, left ventricular end-systolic dimension; IVSW, interventricular 
septum width (thickness); PW, posterior wall width (thickness); LVm, left ventricular 
mass; ET, ejection time; HR, heart rate; bpm, beats per minute; mVcf, mean velocity of 
circumferential fiber shortening; circ/s, circumferential shortening per second; mVcfc, 
heart rate-corrected mVcf.  
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However, approximately 15% (17 of 118) of the AblECKO; Arg+/- mice were severely 
runted (body weights less than 75% of Ablflox/flox; Arg+/-; Tie2-Cre-/- littermate controls) and 
displayed dramatic cardiovascular phenotypes by 2-3 months of age. The hearts of these 
mice were enlarged, typically with prominent dilation of the left atrium (Figure 3.5A,B). 
Histological analysis of cardiac tissue sections demonstrated localized regions of 
collagen deposition and scarring in the left ventricle (Figure 3.5C).  
 
Figure 3.5 Cardiac Enlargement and Scarring in AblECKO; Arg+/-
(A) Stereoscopic image of hearts from 8-week-old Arg
 Mice 
+/- control (Ablflox/flox; Arg+/-; Tie2-Cre-/-
) and AblECKO; Arg+/- mice, demonstrating overall heart enlargement and dilated left 
atrium in AblECKO; Arg+/- mouse. Scale bar = 1mm. (B) Quantification of weights of hearts 
from Arg+/- control and AblECKO; Arg+/- mice (lines indicate mean values, n=8 
mice/genotype; *P<0.05). (C) Trichrome staining of AblECKO; Arg+/- heart, displaying 
scarring in the left ventricle (magnified in inset, arrow). Scale bar = 50µm. (D) CD31 
staining (green) of AblECKO; Arg+/-
 
 left ventricle. A complete loss of capillaries was 
observed in the scarred region (above red dotted line, arrow). Scale bar = 20µm.  
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While overall capillary density in the heart and skeletal muscle of AblECKO; Arg+/- 
mice was not significantly different from Arg+/- controls (Figure 3.6A,B), a near-complete 
loss of blood vessels was observed in the scarred regions (Figure 3.5D). These findings 
are consistent with the localized loss of vasculature observed in the livers of AblECKO; Arg-
/- embryos (Figure 3.4C) and suggest a critical role for the Abl kinases in vascular 
maintenance and function. Interestingly, these AblECKO; Arg+/- mice also displayed 
thickening of the right ventricular wall, which correlated with cardiomyocyte 
hypertrophy (Figure 3.7A,B). 
 
Figure 3.6 Normal Capillary Density in Heart and Skeletal Muscle of AblECKO; Arg+/-
(A) CD31 staining of heart cross-sections from 8-week-old Arg
 
Adult Mice 
+/- control (Ablflox/flox; Arg+/-; 
Tie2-Cre-/-) and AblECKO; Arg+/- mice, revealing comparable capillary density, quantified in 
right panel (means +/- SD, relative to capillary density in Arg+/- control hearts, n=3 
mice/genotype). (B) CD31 staining of tibialis anterior muscle cross-sections from 8-week-
old Arg+/- control and AblECKO; Arg+/- mice. No significant difference was observed, 
although a trend toward decreased capillary density was noted in AblECKO; Arg+/- mice 
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(right panel; means +/- SD, relative to capillary density in Arg+/-
 
 control muscle, n=3 
mice/genotype). Scale bars in (A) and (B) = 20µm. 
 
 
Figure 3.7 Right Ventricular Hypertrophy in AblECKO; Arg+/- 
(A) Trichrome-stained heart sections from 8-week-old Arg
Mice 
+/- control (Ablflox/flox; Arg+/-; Tie2-
Cre-/-) and AblECKO; Arg+/- mice, displaying increased right ventricle wall thickness in 
AblECKO; Arg+/- heart (brackets). Scale bar = 1mm. (B) FITC-wheat germ agglutinin staining 
of right ventricle cross-sections, demonstrating increased cardiomyocyte cross-sectional 
area in AblECKO; Arg+/-
 
 right ventricle, quantified in bottom panel (means +/- SD, n=3 
mice/genotype; *P<0.05). Scale bar = 20µm. 
3.2.3 Lung Fibrosis and Thrombosis in AblECKO; Arg+/-
As right ventricular hypertrophy may occur as a consequence of altered 
pulmonary circulation and hypertension [364], we examined the lungs of Abl
 Mice 
ECKO; Arg+/- 
mice. The lungs of these mice were enlarged and dense, with prominent white, fibrous 
areas (Figure 3.8A,B). Histological analysis of pulmonary structure showed extensive 
interstitial fibrosis (Figure 3.8C), along with fibrin deposition in the airways (Figure 3.8 
D,E), indicative of prior hemorrhage and defective pulmonary vascular integrity. We 
also observed a dramatic loss of vascular density, as assessed by staining for the 
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endothelial marker von Willebrand factor (vWF) (Figure 3.8E). An abundance of 
hemosiderin-laden macrophages was detected in the lungs of AblECKO; Arg+/- mice (Figure 
3.8F); the presence of these cells has been associated with heart failure [365]. Thus, 
defective left ventricular function may contribute to the observed lung abnormalities, by 
producing congestion of the lung vasculature, with resulting leakage of red blood cells.  
 
Figure 3.8 Pulmonary Fibrosis in AblECKO; Arg+/-
(A) Stereoscope image of lungs from 8-week-old Arg
 Mice 
+/- control and AblECKO; Arg+/- mice. 
AblECKO; Arg+/- lungs displayed regions of apparent fibrosis (arrow). Scale bar = 1mm. (B) 
Quantification of weights of lungs from Arg+/- control and AblECKO; Arg+/- mice (lines 
indicate mean values, n=8 mice/genotype; ***P<0.001). (C) Trichrome staining, 
displaying collagen deposition in AblECKO; Arg+/- lung (blue staining; arrows). Scale bar = 
100µm. (D) H&E staining of lung sections, demonstrating fibrin deposition in airways of 
AblECKO; Arg+/- lung (arrows). Scale bar = 100µm. (E) Co-staining of lung sections for vWF 
(endothelial cell marker, red) and fibrin/fibrinogen (green). Loss of vessel density, as 
well as fibrin deposition (arrow), was observed in AblECKO; Arg+/- lung. Scale bars = 20µm. 
(F) Prussian blue (iron) staining, showing accumulation of hemosiderin-laden 
macrophages (blue staining; arrows) in AblECKO; Arg+/-
 
 lung. Scale bar = 100µm. 
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Interestingly, no overt cardiac and pulmonary phenotypes were observed in 
E18.5 AblECKO; Arg-/- embryos (Figure 3.9A,B), suggesting that these defects develop later 
in adult AblECKO; Arg+/- mice, potentially as a result of cumulative injury or stress in the 
adult vasculature. Importantly, Arg protein levels were comparable in Arg+/- control and 
AblECKO; Arg+/- mice (Figure 3.10 A,B), and no cardiac hypertrophy or pulmonary fibrosis 
was observed in adult Arg-/- mice (Figure 3.11A-E), suggesting that the observed 
cardiovascular phenotypes result from endothelial Abl, rather than Arg, depletion in 
AblECKO; Arg+/- adult mice. 
 
Figure 3.9 Lack of Cardiac Abnormalities and Pulmonary Fibrosis in AblECKO; Arg-/-
(A) H&E-stained heart sections from E18.5 Abl
 
Embryos 
flox/flox; Arg+/+; Tie2-Cre-/- (wild-type, WT) and 
AblECKO; Arg-/- embryos. Scale bar = 1mm. (B) H&E-stained lung sections from E18.5 wild-
type (WT) and AblECKO; Arg-/- embryos. Scale bar = 100µm. 
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Figure 3.10 Characterization of Abl and Arg Protein Levels in AblECKO; Arg+/-
(A) Analysis of Abl and Arg protein levels in endothelial (EC; CD105
 Adult 
Mice 
+/CD45-/CD31+) and 
non-hematopoietic/non-endothelial (non-EC; CD105-/CD45-/CD31-) liver cell populations 
from Arg+/- control (Ablflox/flox; Arg+/-; Tie2-Cre-/-) and AblECKO; Arg+/- adult mice, 
demonstrating endothelial cell-specific Abl depletion in AblECKO; Arg+/- mice, quantified in 
right panel (means +/- SD, n=3). (B) Analysis of Abl and Arg protein levels in whole 
tissue homogenates from lungs of two pairs of Arg+/- control and AblECKO; Arg+/- adult 
mice, quantified in right panel (means +/- SD, n=3). While Arg protein levels were 
comparable in whole tissue homogenates from lungs of Arg+/- control and AblECKO; Arg+/- 
mice, reduced Abl levels were observed in AblECKO; Arg+/- 
 
lungs, likely as a result of the 
high vascular content of this tissue. (*P<0.05; **P<0.01). 
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Figure 3.11 Lack of Cardiac Hypertrophy and Pulmonary Fibrosis in Arg-/-
(A) H&E-stained heart sections from 8-week-old Arg
 Adult Mice 
+/+ (Ablflox/flox; Arg+/+; Tie2-Cre-/-), Arg+/- 
(Ablflox/flox; Arg+/-; Tie2-Cre-/-), and Arg-/- (Ablflox/flox; Arg-/-; Tie2-Cre-/-) mice. Scale bar = 1mm. 
(B) Quantification of weights of hearts from Arg+/+, Arg+/-, and Arg-/- adult mice (means +/- 
SD, n=3 mice/genotype). (C) H&E-stained lung sections from 8-week old Arg+/+, Arg+/-, 
and Arg-/- mice. Scale bar = 100µm. (D) Quantification of weights of lungs from Arg+/+, 
Arg+/-, and Arg-/- adult mice (means +/- SD, n=3 mice/genotype). A mild reduction in 
average lung weight was noted in Arg-/- mice, likely resulting from the slightly lower 
body weights of these animals (body weights approximately 85-90% of wild-type 
littermates). (E) Assessment of Arg protein levels in lung homogenates from Arg+/+, Arg+/-
, and Arg-/-
 
 adult mice, quantified in right panel (means +/- SD, n=3 mice/genotype). 
(*P<0.05; ***P<0.01). 
The occurrence of liver necrosis in AblECKO; Arg-/- embryos and left ventricular 
scarring in adult AblECKO; Arg+/- mice suggests that loss of endothelial Abl kinases results 
in localized defects in tissue perfusion, with infarctions leading to tissue death and 
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scarring. In this regard, we observed sporadic thrombi in lung and liver microvessels of 
AblECKO; Arg+/- adult mice, which were not seen in vessels of Arg+/- 
3.2.4 Increased Apoptosis Following Loss of Endothelial Abl Kinases 
control mice. These 
thrombi stained positively for vWF, fibrin (Figure 3.12A), and the platelet fibrinogen 
receptor integrin αIIb (CD41) (Figure 3.12B). Importantly, these thrombi were observed 
in mice without any outward cardiac pathology, suggesting that their occurrence is not a 
secondary effect of compromised cardiac function. Histological analysis revealed 
abnormally swollen endothelial cells adjacent to a lung thrombus (Figure 3.12C, right 
panel), consistent with endothelial injury contributing to thrombosis. These findings 
suggest that loss of Abl kinases perturbs vascular function as a result of endothelial cell 
damage or death. 
Global Abl/Arg knockout mice displayed increased apoptosis in all tissues [329], 
suggesting that the Abl kinases may have an important pro-survival function. Thus, we 
examined whether loss of Abl kinases affected endothelial cell viability in vivo. Indeed, a 
significant increase in cleaved caspase-3-positive cells, as well as numerous 
CD31/cleaved caspase-3 double-positive endothelial cells, were observed in AblECKO; Arg-
/- embryo lungs (Figure 3.13A-C), demonstrating that loss of endothelial Abl kinases led 
to increased apoptosis. This finding is consistent with the extensive apoptosis detected 
in AblECKO; Arg-/- 
 
embryo livers (Figure 3.4C).  
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Figure 3.12 Vascular Occlusions in AblECKO; Arg+/-
(A) Co-staining of Abl
 Mice 
ECKO; Arg+/- liver sections for vWF (red) and fibrin/fibrinogen 
(green). (B) Co-staining of AblECKO; Arg+/- lung sections for CD41 (platelet marker, red) 
and vWF (green). Scale bars in (A) and (B) = 20µm. (C) Left panel: Co-staining of AblECKO; 
Arg+/- lung section for vWF (red) and α-smooth muscle actin (αSMA, green). Scale bar = 
20µm. Right panel: H&E staining of AblECKO; Arg+/-
 
 lung section, demonstrating abnormal 
endothelial morphology at site of lung thrombus (arrow). Scale bar = 100µm. 
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Figure 3.13 Increased Apoptosis Following Loss of Endothelial Abl Kinases In Vivo 
(A and B) Staining of lung sections from E18.5 Ablflox/flox; Arg+/+; Tie2-Cre-/- (wild-type, WT) 
and AblECKO; Arg-/-
 
 (mutant) embryos for cleaved caspase-3 (green), revealing an increased 
number of apoptotic cells in mutant lungs, quantified in (B) (lines indicate mean values, 
n=6 embryos/genotype; *P<0.05). Scale bar = 100µm. (C) Co-staining of E18.5 mutant 
lungs for CD31 (red) and cleaved caspase-3 (green), demonstrating double-positive 
apoptotic endothelial cells (arrows). Scale bar = 20µm. 
To confirm that the observed endothelial cell apoptosis represented a cell-
autonomous phenotype, we examined the role of the Abl kinases in endothelial cell 
survival in vitro. Treatment of primary human umbilical vein endothelial cells 
(HUVECs) with the Abl pharmacological inhibitor imatinib decreased cell viability and 
increased levels of apoptosis following serum-starvation (Figure 3.14A,B). The pro-
survival effects of both VEGF and basic fibroblast growth factor (bFGF) also were 
decreased in the presence of the Abl inhibitor. Treatment with either VEGF or bFGF led 
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to increased Abl kinase activation, as assessed by the phosphorylation of CrkL at Y207, 
an Abl-specific phosphorylation site [366] (Figure 3.14C,D), suggesting that the Abl 
kinases might modulate pro-survival signaling downstream of the VEGF and bFGF 
receptors. Interestingly, imatinib treatment did not increase apoptosis in HUVECs 
maintained in serum-containing medium (Figure 3.14 B), suggesting that the Abl 
kinases may support survival specifically under stress conditions such as nutrient 
deprivation, as well as downstream of pro-angiogenic factors. Similarly, microRNA 
(miRNA)-mediated Abl/Arg knockdown in HUVECs led to increased apoptosis in 
response to serum-starvation stress (Figure 3.14 E,F). These findings demonstrate an 
important pro-survival role for the Abl kinases in endothelial cells. 
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Figure 3.14 Increased Apoptosis Following Loss of Endothelial Abl Kinases In Vitro 
(A) Viability of primary HUVECs serum-starved (UT) or supplemented with bFGF 
(10ng/mL) in serum-free medium, +/- imatinib (10µM), as assessed by MTS assay. Values 
are expressed relative to viability of bFGF-treated cells 24 hours after serum-starvation. 
Data are presented as means +/- SD (n=3; ***P<0.001). (B) Analysis of cleaved caspase-3 
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levels (apoptosis) in HUVECs serum-starved and either left untreated (UT) or 
supplemented with VEGF (100ng/mL) or bFGF (10ng/mL), or maintained in serum-
containing medium (serum), +/- imatinib. (C and D) Assessment of Abl kinase 
activation, as determined by phospho-CrkL(Y207) levels, following stimulation of 
serum-starved HUVECs with either (C) VEGF or (D) bFGF (each 10ng/mL, 5 or 15 
minutes) +/- imatinib. Results are quantified in the bottom panels; data are presented as 
means +/- SD (n=3; *P<0.05; **P<0.01; ***P<0.001). (E) Analysis of caspase-3/7 activity in 
HUVECs expressing control or Abl/Arg miRNAs either maintained in serum-containing 
medium (+serum) or serum-starved (-serum) 24 hours. Data are presented as means +/- 
SD (n=3; ***P<0.001). (F) Assessment of Abl/Arg knockdown upon miRNA expression in 
HUVECs.  
 
3.2.5 Abl Kinases Regulate Tie2 Expression 
To determine the pathways whereby Abl kinases impact endothelial cell 
survival, we examined gene expression differences in HUVECs following Abl/Arg 
knockdown, using a real-time RT-PCR array. While mRNA expression of most of the 
endothelial receptors analyzed was unchanged, Abl/Arg knockdown led to a greater 
than 2-fold reduction in Tie2 (also known as Tek) mRNA levels (Figure 3.15A). Given the 
important role of Angpt1/Tie2 signaling in mediating endothelial cell survival and 
vascular integrity [160,172], we examined the effects of Abl/Arg loss of function on this 
pathway. Using two Abl/Arg knockdown constructs, we confirmed by real-time RT-PCR 
(Figure 3.16A) and Western blot analyses (Figure 3.15B,C) that both Tie2 mRNA and 
protein levels were markedly decreased following Abl/Arg knockdown. Interestingly, 
levels of Angpt2 were increased following loss of Abl/Arg (Figures 3.15 B,C and 3.16C), 
while Angpt1 mRNA levels were decreased (Figure 3.16D). No consistent difference in 
Tie1 receptor expression was observed in cells lacking Abl kinases (Figure 3.16B).  
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Figure 3.15 Decreased Tie2 Expression Following Abl/Arg Knockdown 
(A) Real-time RT-PCR array analysis of gene expression in HUVECs expressing control 
or Abl/Arg miRNAs. mRNA expression levels in Abl/Arg-knockdown HUVECs are 
shown, relative to levels in cells expressing control miRNA. (AGTR1 = angiotensin II 
receptor, type 1; EDNRA = endothelin receptor type A; FLT1 = VEGF receptor 1; KDR = 
VEGF receptor 2; NPR1 = natriuretic peptide receptor 1). (B and C) Analysis of Tie2 and 
angiopoietin-2 (Angpt2) protein levels in HUVECs expressing control miRNA or either 
of two Abl/Arg miRNAs, quantified in (C) (means +/- SD, n=9; *P<0.05; **P<0.01; 
***P<0.001). 
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Figure 3.16 Altered Angiopoietin/Tie2 mRNA Levels Following Abl/Arg Knockdown 
Real-time RT-PCR analysis of expression of (A) Tie2 (Tek), (B) Tie1, (C) angiopoietin-1 
(Angpt1), and (D) angiopoietin-2 (Angpt2) in HUVECs 24 to 96 hours following infection 
with either control or Abl/Arg miRNA lentiviruses. Fold-changes in gene expression are 
shown relative to levels in cells expressing control miRNA. Data are presented as means 
+/- SD (n=3). (*P<0.05; ***P<0.001). 
 
Importantly, decreased levels of Tie2 protein were also observed in AblECKO; Arg-/- 
embryo liver tissue (Figure 3.17A), as well as in liver endothelial cells from E18.5 AblECKO; 
Arg-/- embryos (Figure 3.17B), while VEGFR2 levels were unchanged (Figure 3.17A). 
Moreover, a similar decrease in Tie2 expression was observed in primary endothelial 
cells isolated from Ablflox/flox; Arg+/+; Tie2-Cre-/- mice following Arg knockdown and in vitro 
Abl depletion by adenoviral Cre transduction (Figure 3.17C). 
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Figure 3.17 Decreased Tie2 Levels Following Loss of Abl/Arg Kinases in Mouse 
Endothelial Cells 
(A) Analysis of levels of Tie2 protein in livers from three pairs of Ablflox/flox; Arg+/+; Tie2-
Cre-/- (wild-type, WT) and AblECKO; Arg-/- (mutant) littermate embryos, quantified in right 
panel (means +/- SD, normalized to Lamin B levels, n=3 mice/genotype; **P<0.01). (B) 
Flow cytometric analysis of Tie2 levels in CD31+/CD45- endothelial cells from E18.5 WT 
and AblECKO; Arg-/- embryo livers, quantified in right panel (means +/- SD, normalized to 
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CD31 levels, n=3 mice/genotype; *P<0.05). (C) Analysis of levels of Tie2 protein in 
primary endothelial cells (EC) isolated from livers of Ablflox/flox; Arg+/+; Tie2-Cre-/-
 
 adult 
mice, following in vitro Abl/Arg depletion. Primary liver endothelial cells were infected 
with either GFP or Cre-GFP-expressing adenoviruses (AdV), followed by lentiviral 
transduction of either control or Arg shRNAs. Abl, Arg, and Tie2 protein levels 
(normalized to β-tubulin) are quantified in the panel at right, relative to levels in control 
knockdown cells (means +/- SD, n=3; *P<0.05; **P<0.01; ***P<0.001). 
3.2.6 Abl Kinases Regulate Tie2 Signaling 
To evaluate the physiological consequences of Tie2 downregulation in 
endothelial cells lacking Abl kinases, we examined the activation of downstream cellular 
signaling pathways. As expected, treatment of control HUVECs with angiopoietin-1 led 
to tyrosine phosphorylation of the Tie2 receptor, along with activation of Akt and Erk 
pathways (Figure 3.18 A,B); activation of the PI3K/Akt pathway is required for Angpt1-
mediated survival [173]. Notably, the Abl kinases were also activated following Angpt1 
treatment, as evidenced by increased phospho-CrkL (Y207) levels (Figure 3.18A, lanes 1 
and 7). Abl kinase activation similarly was observed following Angpt1 stimulation of 
both immortalized human microvascular endothelial cells (HMVECs; Figure 3.18C, lanes 
1 and 4) and PyMT-immortalized mouse embryo endothelial cells (Figure 3.19, lanes 1-6). 
These findings suggest a potential role for the Abl/Arg kinases in mediating 
downstream Tie2 signaling. In this regard, activation of Akt by Angpt1 was dramatically 
reduced in Abl/Arg-knockdown cells (Figure 3.18A, lanes 7-9). Erk activation also was 
decreased to a lesser extent by Abl/Arg depletion. Similarly, Abl/Arg knockdown 
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diminished Angpt1-mediated Akt activation in HMVECs, while Erk activation was 
unchanged (Figure 3.18C, lanes 4-6).  
 
Figure 3.18 Abl Kinases Modulate Angpt1 Signaling 
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(A and B) Assessment of Angpt1-mediated activation of intracellular signaling 
pathways in HUVECs infected with control or Abl/Arg miRNA lentiviruses, with or 
without exogenous hTie2 expression, quantified in (B). Cells were serum-starved for 6 
hours, then left unstimulated (UT) or treated with Angpt1 (200ng/mL, 15 minutes). (B) 
pAkt and pErk levels (normalized to total Akt and Erk protein) are shown as means +/- 
SD, relative to levels in Angpt1-stimulated control miRNA-expressing cells (n=4; 
**P<0.01; ***P<0.001). (C) Assessment of angiopoietin-1 (Angpt1)-mediated activation of 
intracellular signaling pathways in immortalized human microvascular endothelial cells 
(HMVECs) infected with control or Abl/Arg miRNA lentiviruses, quantified in bottom 
panels. Cells were serum-starved for 6 hours, then left unstimulated (UT) or treated with 
Angpt1 (200ng/mL, 15 minutes). pAkt and pErk levels (normalized to total Akt and Erk 
protein) are shown as means +/- SD, relative to levels in Angpt1-stimulated control 
miRNA-expressing cells (n=3; *P<0.05). 
 
 
Figure 3.19 Abl Kinases Are Activated Following Angpt1 Stimulation 
Assessment of timecourse of Angpt1-mediated activation of Abl kinases, as determined 
by phospho-CrkL (Y207) levels, in PyMT-immortalized endothelial cell lines from 
Ablflox/flox; Arg+/+; Tie2-Cre-/- (wild-type, WT) and AblECKO; Arg-/- embryos. Fold-changes in 
pCrkL levels (normalized to total CrkL protein) are quantified in the right panel (means 
+/- SD, n=3). Angpt1 treatment increased pCrkL levels in WT, but not AblECKO; Arg-/-
 
, 
endothelial cells. (*P<0.05; **P<0.01). 
Importantly, while Angpt1 inhibited apoptosis following serum-starvation in 
control HUVECs, the pro-survival effects of Angpt1 were decreased in Abl/Arg 
knockdown cells (Figure 3.20A). Thus, downregulation of Tie2 receptor levels following 
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Abl/Arg-knockdown decreased both Angpt1-mediated signaling and downstream anti-
apoptotic responses. Single Abl and Arg knockdowns demonstrated that loss of either 
kinase was sufficient to impair both Angpt1-mediated signaling (Figure 3.20B) and 
survival (Figure 3.20C). Interestingly, expression of exogenous Tie2 in Abl/Arg-
knockdown cells largely restored Angpt1-mediated signaling (Figure 3.18A, lanes 10-12) 
and partially rescued the anti-apoptotic effects of Angpt1 (Figure 3.20A). These findings 
suggest that the increased apoptosis observed upon loss of Abl kinase expression may 
be due in part to downregulation of Tie2 signaling. 
 
Figure 3.20 Abl and Arg Kinases Are Required for Angpt1-Mediated Survival 
(A) Analysis of levels of apoptosis in HUVECs infected with Tie2 retrovirus and Abl/Arg 
miRNAs following 24 hours serum-starvation in the presence of Angpt1 (200ng/mL). 
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Values are expressed as percent inhibition of apoptosis by Angpt1 relative to serum-
starved (non-supplemented) control cells. Data are presented as means +/- SEM (n=3; 
*P<0.05). (B) Assessment of Angpt1-mediated activation of intracellular signaling 
pathways in HUVECs expressing control miRNA, individual Abl or Arg miRNAs, or 
dual Abl/Arg miRNA. Fold-changes in pathway activation (normalized to total protein 
levels) are shown, expressed relative to unstimulated (UT) control miRNA-expressing 
cells. (C) Analysis of levels of apoptosis in HUVECs after 24 hours serum-starvation in 
the presence of Angpt1 (200ng/mL) following either Abl or Arg individual knockdown 
or dual knockdown of both Abl/Arg kinases. Values are expressed as percent inhibition 
of apoptosis by Angpt1 relative to serum-starved (non-supplemented) cells. Data are 
presented as means +/- SEM (n=3; *P<0.05; **P<0.01). 
 
3.3 Discussion 
Our findings have uncovered a crucial role for the endothelial Abl kinases in the 
vasculature, as loss of endothelial Abl/Arg kinase expression resulted in embryonic and 
perinatal lethality. Loss of endothelial Abl kinases adversely impacted vascular function, 
leading to localized loss of vascular density and resultant cell death in affected tissues 
(necrosis/apoptosis). Interestingly, even partial loss of endothelial Abl kinase expression 
produced focal loss of cardiac vasculature and myocardial injury. The localized nature 
of the observed vascular loss and tissue damage, along with the normal overall vascular 
density, branching, and patterning observed in AblECKO; Arg-/- mice, suggest that loss of 
endothelial Abl/Arg kinases likely adversely affects vascular maintenance and stability, 
rather than vessel formation. Given that Tie2-Cre-mediated recombination occurs in 
most endothelial cells by E9.5 [367], it is possible that subtle structural defects during 
vessel formation could contribute to the phenotypes observed later in development in 
mutant embryos. However, our finding that loss of the Abl kinases sensitizes endothelial 
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cells to stress-induced apoptosis in vitro suggests that the sporadic and focal nature of 
the observed phenotypes may result from vascular damage due to localized endothelial 
cell apoptosis in response to cumulative vascular stresses in the absence of the Abl 
kinases.  
Our demonstration of a critical requirement for the Abl kinases in the 
vasculature is particularly notable considering the cardiotoxicity previously observed in 
a subset of patients upon chronic Abl kinase inhibition using imatinib [350,351,352]. 
Additional case reports detail instances of interstitial lung disease of unknown origin in 
some imatinib-treated cancer patients [353]. Although the incidence of these events 
appears to be low, and imatinib is generally well tolerated [368], our findings 
demonstrate a crucial role for the Abl kinases in normal vascular development and 
function, which may have implications for the clinical use of Abl kinase inhibitors such 
as imatinib and nilotinib. 
Using both pharmacological inhibition and knockdown studies, we found a 
requirement for Abl kinases in promoting endothelial cell survival, both under stress 
conditions and in the presence of specific angiogenic factors. Consistent with a previous 
report, Abl kinase activity was required for maximal bFGF-mediated endothelial 
survival [337]. However, we also observed a requirement for Abl family kinases during 
VEGF-mediated endothelial cell survival. Imatinib has shown anti-angiogenic activity in 
several in vivo models [334,335,336]. While these anti-angiogenic actions have been 
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attributed largely to the inhibition of PDGFR activity, which is necessary for endothelial 
cell interactions with supporting mural cells, our findings that the Abl kinases modulate 
endothelial survival in response to pro-angiogenic growth factors (angiopoietin-1, 
VEGF, and bFGF) suggest that the endothelial Abl kinases may be additional anti-
angiogenic targets of imatinib.  
Previous studies have established both anti- and pro-apoptotic roles for the Abl 
kinases in various cell types. Global Abl/Arg knockout embryos exhibited increased 
apoptosis in all tissues [329]. Enhanced apoptosis susceptibility similarly was observed 
in Abl-null thymocytes [332], as well as following serum-deprivation in Abl-deficient B 
cell lines [369]. However, while Abl kinases are activated upon growth factor 
stimulation in various cell types [279,337], Abl also is activated following exposure to 
ionizing radiation or chemotherapeutic agents and is required for apoptosis induced by 
these stresses [370], suggesting a pro-apoptotic role for the Abl kinases. Our findings, 
however, suggest a physiological anti-apoptotic role for the Abl kinases in the 
endothelium, which may be important clinically, as endothelial cell apoptosis has been 
reported in a number of vascular pathologies [371]. 
Unexpectedly, the current study also reveals bi-directional links between the Abl 
kinases and pro-survival angiopoietin/Tie2 signaling in the endothelium. Loss of 
endothelial Abl/Arg kinase expression decreased Tie2 receptor levels and led to a shift in 
angiopoietin levels, with enhanced Angpt2 levels and decreased Angpt1 levels. 
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Consequently, loss of Abl kinases decreased Angpt1/Tie2 signaling and diminished the 
pro-survival effects of Angpt1. Our finding that Abl kinases are activated following 
Angpt1 stimulation supports a dual role for Abl kinases in the regulation of 
angiopoietin/Tie2 signaling, through the control of receptor/ligand expression, as well as 
the modulation of downstream pro-survival signaling pathways (Figure 3.21). Loss of 
Tie2 impairs endothelial cell survival in vivo [160]. Angpt1/Tie2 signaling also supports 
vascular stability and inhibits inflammatory endothelial barrier dysfunction and 
adhesion molecule expression [372]. It will be of interest to determine whether, in 
addition to the observed effects on Angpt1-mediated survival, the Abl kinases also may 
modulate other endothelial cell responses to Angpt1, including anti-permeability and 
anti-inflammatory effects.  
Taken together, our findings support an important role for the Abl kinases in 
Angpt1/Tie2-mediated vascular homeostasis. Alterations in the angiopoietin/Tie2 
pathway, including a shift in angiopoietin balance with Angpt2 levels exceeding Angpt1 
levels, have been implicated in diverse vascular pathologies [373]. Thus, future studies 
are required to evaluate the role of the Abl kinases in the modulation of Angpt/Tie2 
signaling during the progression of these disorders, in order to fully understand the role 
of these kinases in both vascular development and adult vascular maintenance.  
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Figure 3.21 Model for the Dual Role of the Abl Kinases in Angiopoietin/Tie2 
Signaling 
The Abl kinases positively regulate Tie2 (Tek) mRNA expression and are required for 
maximal Angpt1-mediated pro-survival signaling primarily through the PI3K/Akt and, 
to a lesser extent, Erk signaling pathways. The Abl kinases are also activated 
downstream of the Tie2 receptor. 
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4. Abl Family Kinases Regulate Endothelial Barrier 
Function In Vitro and in Mice 
4.1 Introduction 
The endothelium forms a critical semi-permeable barrier between tissues and the 
bloodstream, regulating the transport of solutes and immune cells into and out of the 
circulation. The maintenance of this barrier is a dynamic and tightly-controlled process. 
Loosening of the endothelial barrier is induced by a variety of soluble factors, including 
cytokines and other inflammatory mediators, as well as VEGF, and is an important 
aspect of both normal angiogenic remodeling and inflammatory responses [5,30]. 
However, abnormally elevated vascular permeability is a key feature of a variety of 
pathological conditions, including cancer, sepsis, and ischemia-reperfusion injury 
[31,32]. This uncontrolled vascular leakage can lead to edema, increased interstitial fluid 
pressure, and tissue damage [32].  
Vascular permeability can occur through both transcellular and paracellular 
mechanisms. In the transcellular pathway, solutes or cells pass through individual 
endothelial cells via vesicular transport mechanisms [374]. In contrast, paracellular 
permeability requires the dynamic opening and closure of inter-endothelial cell-cell 
adherens and tight junctions, enabling the passage of plasma molecules or cells between 
neighboring endothelial cells [41]. The transmembrane protein VE-cadherin is the major 
structural component of endothelial adherens junctions and is a critical regulator of 
vascular integrity and endothelial barrier function [44]. Dimerization and clustering of 
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VE-cadherin at sites of endothelial cell-cell contact leads to homotypic, Ca2+
The endothelial adherens junction complex is targeted by a variety of vascular 
permeability-inducing factors, including VEGF, thrombin, and histamine. Stimulation of 
endothelial cells with these barrier-disruptive factors leads to dissolution of cell-cell 
junctions through mechanisms including VE-cadherin internalization, destabilization of 
adherens junction protein complexes, or reduced association of VE-cadherin complexes 
with the actin cytoskeleton [106,122,375,376,377]. In addition to direct effects on cell-cell 
junctions, endothelial barrier-disrupting factors increase acto-myosin contractility and 
centripetal tension, which weakens intercellular adhesion and can lead to cell retraction 
and formation of intercellular gaps [378,379]. Tyrosine phosphorylation has been 
implicated in the destabilization of the endothelial barrier by a variety of permeability-
inducing factors. Increased tyrosine phosphorylation of adherens junction proteins 
including VE-cadherin and β-catenin has been observed following VEGF, histamine, and 
thrombin stimulation [105,375,380]; this phosphorylation has been linked to 
destabilization of cell-cell adhesion. Additionally, treatment with tyrosine kinase 
inhibitors decreased endothelial permeability induced by each of these agonists 
-dependent 
interaction of the extracellular domains of VE-cadherin proteins on neighboring cells, 
which are then linked indirectly to the actin cytoskeleton through the binding of the VE-
cadherin intracellular domain to β-catenin and α-catenin proteins [45].  
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[92,375,378,381], demonstrating an important role for tyrosine kinases in the induction of 
endothelial barrier dysfunction. 
Our previous work has demonstrated a role for the Abl family kinases (Abl and 
Arg) both in formation and maintenance of epithelial adherens junctions [294], 
suggesting a potential role for these kinases in the regulation of barrier function. 
Interestingly, treatment with the Abl kinase pharmacological inhibitor imatinib 
(Gleevec) decreased interstitial fluid pressure in lung and colon cancer models, resulting 
in improved tumor oxygenation and drug delivery [340,341,342]. Imatinib treatment also 
reduced permeability following administration of thrombolytic tissue plasminogen 
activator in a murine model of ischemic stroke [343], suggesting a beneficial effect of 
imatinib on vascular barrier function. Pre-treatment with imatinib (or the more potent 
Abl kinase inhibitor nilotinib) similarly protected against pulmonary edema following 
lipopolysaccharide-induced acute lung injury in mice [344]. These protective effects have 
been attributed to the inhibition of the PDGF receptor (PDGFR), which is also targeted 
by imatinib [265]. However, recent studies have implicated the Abl kinases in the 
regulation of endothelial barrier function [345,346]. Expression of the Abl kinase is 
required for the endothelial barrier-promoting effects of sphingosine-1-phosphate in 
vitro [346]. Imatinib treatment protected against vascular leakage and edema in a murine 
sepsis model, which was attributed to the inhibition of the endothelial Arg kinase [345]. 
However, the in vivo protective effects of imatinib may result from inhibition of multiple 
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tyrosine kinases and targeting of cell types other than endothelial cells, including 
immune cells. 
In the current study, we demonstrate a requirement for activation of the Abl 
kinases in endothelial permeability induced by VEGF and the inflammatory mediators 
thrombin and histamine. Use of Abl/Arg-specific pharmacological inhibitors or Abl 
knockdown impaired induction of endothelial permeability in response to these agonists 
in vitro. VEGF-induced permeability similarly was decreased following Abl kinase 
inhibition in vivo. Importantly, impaired VEGF-induced permeability was also observed 
in conditional knockout mice lacking endothelial Abl expression. Mechanistically, we 
demonstrate that Abl kinase inhibition both increased activation of the endothelial 
barrier-supporting GTPases Rac1 and Rap1 and decreased the activation of pathways 
regulating induction of acto-myosin contractility in response to permeability-inducing 
factors. Taken together, these findings demonstrate an important role for the Abl kinases 
in mediating endothelial barrier dysfunction induced by a variety of agonists and 
support the potential use of Abl kinase inhibitors in the treatment of disorders 
characterized by pathological vascular permeability. 
4.2 Results 
4.2.1 Abl Kinases Are Activated Following Treatment with Endothelial 
Permeability-Inducing Factors 
Endothelial barrier dysfunction can be induced in response to a variety of soluble 
mediators [30]. To assess a potential role for the Abl kinases in the regulation of 
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endothelial barrier function, we initially evaluated Abl kinase activity following 
treatment of human microvascular endothelial cells (HMVECs) with the permeability-
inducing factors VEGF, thrombin, and histamine. In agreement with previous findings 
in human umbilical vein endothelial cells (HUVECs) [338,345,382], stimulation of 
HMVECs with VEGF resulted in Abl kinase activation, as assessed by the 
phosphorylation of CrkL at tyrosine (Y) 207, an Abl-specific phosphorylation site [366] 
(Figure 4.1A), which was prevented by pre-treatment with the ATP-competitive Abl 
kinase inhibitor imatinib. Interestingly, pre-treatment with the Src kinase inhibitor 
su6656 partially blocked Abl kinase activation in response to VEGF stimulation (Figure 
4.1B), suggesting that the Abl kinases may act downstream of Src family kinases in 
VEGF-mediated signaling. Notably, Abl kinases were markedly activated by treatment 
of HMVECs with thrombin (Figure 4.1C) or histamine (Figure 4.1D). Thus, these 
findings demonstrate that the Abl kinases are activated in response to several distinct 
endothelial permeability-inducing mediators, suggesting a potential function for these 
kinases in mediating downstream permeability responses. 
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Figure 4.1 Abl kinases Are Activated Following Treatment with Endothelial 
Permeability-Inducing Factors 
(A) Assessment of Abl kinase activation, as determined by phospho-CrkL tyrosine (Y) 
207 levels, following stimulation of serum-starved HMVECs with 100ng/mL VEGF for 5 
minutes, with or without imatinib pre-treatment (10µM). pCrkL (Y207) levels 
(normalized to total CrkL) are quantified in the right panel, relative to levels in 
untreated (UT) cells. Data are presented as means +/- SD (n=7). (B) Evaluation of pCrkL 
(Y207) levels in HMVECs treated with VEGF, with or without su6656 pre-treatment 
(1µM). pCrkL levels (normalized to total CrkL) are quantified in the right panel, relative 
to levels in untreated (UT) cells. Data are presented as means +/- SD (n=2). *P<0.05; 
**P<0.01; ***P<0.001. (C) Evaluation of Abl kinase activation (pCrkL Y207) following 
treatment of HMVECs with thrombin (1U/mL, 5 minutes), with or without imatinib pre-
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treatment. pCrkL levels (normalized to total CrkL) are quantified in the right panel, 
relative to levels in untreated (UT) cells. Data are presented as means +/- SD (n=5). (D) 
Assessment of Abl kinase activation (pCrkL Y207) following stimulation of HMVECs 
with histamine (100µM, 5 minutes), with or without imatinib pre-treatment. pCrkL 
levels (normalized to total CrkL) are quantified in the right panel, relative to levels in 
untreated (UT) cells. Data are presented as means +/- SD (n=3).  
 
4.2.2 Loss of Abl Kinase Function Decreased Endothelial 
Permeability In Vitro 
We examined whether the Abl kinases may play a role in the induction of 
endothelial permeability in vitro, by assessing the passage of fluorescein-labeled dextran 
through HMVEC monolayers following pharmacological inhibition of the Abl kinases. 
Consistent with previous reports [99,345], Abl kinase inhibition with imatinib greatly 
decreased endothelial barrier dysfunction induced by VEGF (Figure 4.2A,B). Imatinib 
similarly inhibited permeability induced by thrombin and histamine (Figure 4.2B). As 
imatinib also inhibits kinases other than Abl and Arg, including the receptors c-Fms, 
PDGFR, Kit, and the discoidin domain receptors [265,267,268], we examined the effects 
of the allosteric Abl kinase inhibitor GNF-2 on endothelial permeability. GNF-2, which 
binds to the myristate-binding pocket in the kinase domain of Abl and Arg, displays 
greater target specificity than imatinib and is not known to inhibit any additional 
kinases [274,275].  Importantly, the Abl/Arg-specific inhibitor GNF-2 also decreased 
endothelial permeability induced by VEGF, thrombin, or histamine (Figure 4.2B), 
suggesting that the preservation of endothelial barrier function upon imatinib treatment 
likely results from inhibition of the Abl family kinases.  
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Figure 4.2 Abl Kinase Inhibition Decreased Endothelial Permeability In Vitro 
(A) Evaluation of endothelial monolayer permeability, as assessed by passage of 
fluorescein-labeled dextran (molecular weight 40kDa) through HMVEC monolayers 
grown on Transwells, following treatment with VEGF (100ng/mL) with or without 
imatinib pre-treatment (10µM). Data shown are mean fluorescence of samples collected 
from bottom Transwell chambers at the indicated times post-VEGF treatment, +/- SD of 
three replicates per treatment. Data are representative of three independent 
experiments. (B) Quantification of inhibition of endothelial monolayer permeability to 
fluorescein-labeled dextran by imatinib (10µM) or GNF-2 (15µM). Endothelial barrier 
dysfunction was induced by treatment of HMVECs with VEGF (100ng/mL, 120 
minutes), thrombin (1U/mL, 30 minutes) or histamine (100µM, 60 minutes). Values are 
expressed relative to permeability induction in vehicle-treated cells (UT). Data are 
presented as means +/- SEM (n=3). (*P<0.05; **P<0.01; ***P<0.001). 
 
To directly evaluate whether Abl is implicated in the regulation of endothelial 
permeability, we depleted Abl expression in HMVECs. VEGF-induced endothelial 
permeability was inhibited by micro-RNA (miRNA)-mediated Abl knockdown (Figure 
4.3A,C,E), and permeability induction was restored by re-expression of miRNA-resistant 
Abl (Figure 4.3A,B). A similar reduction of thrombin-induced endothelial barrier 
dysfunction was observed upon Abl knockdown (Figure 4.3D,E). Interestingly, Abl 
kinase inhibition using either imatinib or GNF-2 more potently inhibited endothelial 
permeability responses than did Abl knockdown alone (Figure 4.2B vs. Figure 4.3E), 
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suggesting that Arg may also contribute to VEGF- and thrombin-induced endothelial 
permeability.  
 
Figure 4.3 Abl Knockdown Impaired VEGF- and Thrombin-Induced Endothelial 
Permeability 
(A) Quantification of VEGF-induced endothelial permeability of HMVECs expressing 
either control or Abl miRNAs, with or without re-expression of miRNA-resistant, wild-
type murine Abl (mAbl-WT). Values are expressed relative to VEGF-induced 
permeability in control miRNA-expressing cells. Data are presented as means +/- SEM 
(n=3). (B) Assessment of Abl protein levels following miRNA expression in HMVECs, 
with or without re-expression of miRNA-resistant Abl. (C and D) Assessment of 
permeability of HMVEC monolayers expressing either control or Abl miRNAs to 
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fluorescein-labeled dextran (molecular weight 40kDa), following (C) VEGF (100ng/mL) 
or (D) thrombin (1U/mL) treatment. Data shown are mean fluorescence of samples 
collected from bottom Transwell chambers at the indicated times following VEGF or 
thrombin treatment, +/- SD of three replicates per treatment. Data are representative of 
4-5 independent experiments. (E) Quantification of inhibition of VEGF- and thrombin-
induced endothelial permeability following Abl knockdown. Values are expressed 
relative to permeability of HMVECs expressing control miRNA. Data are presented as 
means +/- SEM (VEGF, n=5; thrombin, n=4). (*P<0.05; **P<0.01; ***P<0.001). 
 
However, dual knockdown of both Abl and Arg kinases led to a nearly twofold 
increase in baseline permeability of unstimulated HMVEC monolayers (Figure 4.4A,B), 
which precluded the analysis of VEGF- and thrombin-induced permeability. These data 
are consistent with our finding that depletion of both Abl and Arg proteins induces 
dissolution of adherens junctions in epithelial cells [294]. In all, these results 
demonstrate a requirement for Abl kinase activity, as well as Abl expression, in 
endothelial barrier dysfunction induced by several permeability-inducing factors.  
 
Figure 4.4 Increased Baseline Endothelial Permeability Following Abl/Arg 
Knockdown 
(A) Evaluation of baseline permeability to fluorescein-labeled dextran of unstimulated 
HMVEC monolayers expressing control, Abl, or Abl/Arg miRNAs. Data are presented as 
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means +/- SEM (n=4). (B) Assessment of Abl and Arg protein levels in HMVECs 
following Abl or Abl/Arg knockdown. (*P<0.05; **P<0.01). 
 
4.2.3 Abl Kinase Activity Is Required for VEGF-Induced Permeability 
In Vivo 
To evaluate whether Abl kinases are involved in VEGF-induced vascular 
permeability in vivo, we employed both pharmacological inhibition and genetic 
inactivation of endothelial Abl kinase in mice. Consistent with our in vitro findings, 
inhibition of the Abl kinases with either imatinib or GNF-2 decreased VEGF-induced 
vascular leakage of albumin (by approximately 30% and 50%, respectively), as assessed 
by extravasation of intravenously-administered Evans blue dye following intradermal 
administration of VEGF (Figure 4.5A).  
To directly assess the role of the Abl kinases in VEGF-induced permeability in 
vivo, we generated conditional knockout mice lacking Abl kinase expression in the 
endothelium, by crossing mice carrying a floxed Abl allele (Ablflox/flox) on an Arg-/- 
background to Tie2-Cre mice [382]. As loss of both endothelial Abl and Arg expression 
(Ablflox/flox; Arg-/-; Tie2-Cre+/-) resulted in late-stage embryonic and perinatal lethality [382], 
we instead examined permeability responses using endothelial Abl knockout mice on an 
Arg+/- background (Ablflox/flox; Arg+/-; Tie2-Cre+/-, referred to as AblECKO; Arg+/-), which survive 
to adulthood. Notably, VEGF-induced vascular permeability was reduced in AblECKO; 
Arg+/- mice (Figure 4.5B). While VEGF induced a two-fold increase in Evans blue dye 
extravasation in Arg+/- control mice (Ablflox/flox; Arg+/-; Tie2-Cre-/-), no significant increase in 
 120 
vascular leakage was observed following VEGF treatment in AblECKO; Arg+/- mice. A 
previous report suggested that Arg, rather than Abl, mediates the in vitro endothelial 
barrier-enhancing effects of imatinib [345]. However, our genetic results show that Abl is 
a critical player in the regulation of endothelial barrier function in vivo. Taken together, 
these findings demonstrate a requirement for the Abl family kinases in VEGF-induced 
vascular permeability in vivo. 
 
Figure 4.5 Abl Kinases Are Required for VEGF-Induced Vascular Permeability In 
Vivo 
(A) Evaluation of vascular leakage of Evans blue dye in mice following intradermal 
injection of VEGF (100ng, 15 minutes) with or without concomitant treatment with 
imatinib or GNF-2 (15µM). Results are expressed as fold-change in permeability relative 
to phosphate-buffered saline (PBS) control (UT). Data are presented as means +/- SD 
(n=12). (B) Quantification of VEGF-induced dermal vascular leakage of Evans blue dye 
in AblECKO; Arg+/- (Ablflox/flox; Arg+/-; Tie2-Cre+/-) and age/sex-matched Arg+/- control mice 
(Ablflox/flox; Arg+/-; Tie2-Cre-/-). Dye extravasation was normalized to tissue weight. Values 
are presented as means +/- SD (Arg+/- controls, n=8; AblECKO; Arg+/-
 
, n=6). (*P<0.05; 
**P<0.01). 
4.2.4 Abl Kinase Activity Is Required for VEGF- and Thrombin-
Induced Remodeling of Endothelial Adherens Junctions 
Induction of endothelial barrier dysfunction has previously been linked to 
disruption of endothelial cell-cell adhesion, through the phosphorylation and disruption 
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of endothelial adherens junction complexes, as well as VE-cadherin mislocalization and 
internalization [106,122,375,376,377]. As the Abl kinases are required for adherens 
junction formation and mediate signaling downstream of cadherin engagement in 
epithelial cells [294], we examined whether the Abl kinases might regulate VE-cadherin 
dynamics in endothelial cells following stimulation with permeability-inducing factors. 
While a continuous pattern of VE-cadherin staining was observed at endothelial cell-cell 
junctions in unstimulated cells, both VEGF and thrombin treatment disrupted VE-
cadherin localization, leading to destabilization of endothelial adherens junctions (“zig-
zag” VE-cadherin staining pattern, arrowheads) and formation of inter-endothelial cell 
gaps (arrows) (Figure 4.6A-C). Consistent with their anti-permeability effects, pre-
treatment with the Abl kinase inhibitors imatinib (Figure 4.6A,B) or GNF-2 (Figure 4.6C) 
reduced the VEGF- and thrombin-induced disruption of VE-cadherin localization.  
However, imatinib treatment did not alter VE-cadherin cell-surface levels (Figure 
4.7A) or association with catenin proteins (Figure 4.7B-E). VEGF-induced endothelial 
permeability previously has been linked to tyrosine phosphorylation of adherens 
junction proteins including VE-cadherin and β-catenin, which is thought to destabilize 
cellular adherens junctions [41,105,376]. However, we did not observe changes in VE-
cadherin or β-catenin tyrosine phosphorylation in response to VEGF stimulation, either 
in the presence or absence of imatinib treatment (data not shown). Taken together, these 
findings suggest that Abl kinase inhibition prevents VEGF- and thrombin-induced 
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disruption of endothelial adherens junctions independently of direct effects on VE-
cadherin and other adherens junction components. 
 
Figure 4.6 Abl Kinase Activity Is Required for VEGF- and Thrombin-Induced 
Remodeling of Endothelial Adherens Junctions 
(A) Staining of HMVEC monolayers for the adherens junction marker VE-cadherin 
(green) following treatment with VEGF (100ng/mL, 30 minutes), with or without 
imatinib pre-treatment (10µM). (B) VE-cadherin staining (red) of HMVEC monolayers 
treated with thrombin (1U/mL, 5 minutes), +/- imatinib. (C) VE-cadherin staining (red) 
of VEGF or thrombin-treated HMVECs, with or without GNF-2 pre-treatment (15µM). 
VEGF and thrombin treatment induced formation of inter-endothelial cell gaps (arrows) 
and destabilization of endothelial cell-cell junctions (“zig-zag” VE-cadherin staining 
pattern, arrowheads), which were reduced by pre-treatment with Abl kinase inhibitors. 
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Figure 4.7 Abl Kinase Inhibition Did Not Alter VE-cadherin Cell Surface Levels or 
Adherens Junction Complex Association 
(A) Evaluation of total and cell surface VE-cadherin protein levels in HMVECs treated 
with VEGF (100ng/mL) with or without imatinib pre-treatment (10µM), as assessed by 
biotinylation of cell surface proteins. Cell surface VE-cadherin levels are quantified in 
the right panel, relative to levels in untreated cells (UT). Data are presented as means +/- 
SD (n=3). (B) Assessment of VE-cadherin association with β-catenin in HMVECs treated 
with VEGF +/- imatinib, following VE-cadherin immunoprecipitation. Data are 
quantified in the right panel as means +/- SD (n=5), relative to co-immunoprecipitated β-
catenin levels in vehicle-treated cells (UT) at each time point. (C-E) Assessment of β-
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catenin association with VE-cadherin and α-catenin in HMVECs treated with VEGF +/- 
imatinib, following β-catenin immunoprecipitation. (D and E) Quantification of levels of 
co-immunoprecipitated (D) VE-cadherin and (E) α-catenin, relative to levels in vehicle-
treated cells (UT) at each time point. Data are presented as means +/- SD (VE-cadherin, 
n=5; α-catenin, n=2). 
 
4.2.5 Activation of Rac1 and Rap1 GTPases Following Abl Kinase 
Inhibition 
Endothelial permeability and adherens junction stability are modulated by the 
activity of a variety of small GTPase proteins, which regulate cytoskeletal remodeling 
and act either to stabilize or disrupt barrier function [383]. Of these, the Rho family 
GTPase Rac1 and Ras family GTPase Rap1 have been identified as important mediators 
in the maintenance of endothelial barrier function. Rac1 activation opposes the induction 
of endothelial permeability, in part by remodeling of cortical actin and stabilizing 
adherens junctions [190,191,192]. Consistent with previously-reported findings [345], 
Abl kinase inhibition with imatinib increased the levels of active, GTP-bound Rac1 both 
in unstimulated and VEGF-treated HMVECs (Figure 4.8A,B). To examine the 
contribution of this increased Rac1 activation to the anti-permeability effects of imatinib, 
we examined endothelial monolayer permeability in HMVECs expressing Rac1 shRNA 
(Figure 4.8D). As expected, and in line with the barrier-stabilizing effects of Rac1 
activation, Rac1 knockdown increased baseline permeability in unstimulated cells 
(Figure 4.8C). However, imatinib inhibited VEGF-induced permeability in HMVECs 
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after Rac1 knockdown (Figure 4.8C), suggesting that Rac1-independent pathways 
mediate the endothelial barrier-stabilizing effects of Abl kinase inhibition. 
 
Figure 4.8 Increased Rac1 GTPase Activity Following Abl Kinase Inhibition 
(A and B) Assessment of levels of GTP-bound (active) Rac1 GTPase in HMVECs treated 
with imatinib (10µM), then treated with VEGF (100ng/mL, 2 minutes) or left 
unstimulated (UT). Rac1-GTP levels, normalized to total Rac1, are quantified in (B), 
relative to levels in vehicle-treated cells (UT). Data are presented as means +/- SD (n=2). 
(C) Evaluation of permeability of HMVECs expressing either control or Rac1 shRNAs to 
fluorescein-labeled dextran, following 60 minutes VEGF stimulation with or without 
imatinib pre-treatment. Data shown are mean fluorescence of samples collected from 
bottom Transwell chambers, +/- SD of three replicates per treatment. Data are 
representative of three independent experiments. (D) Assessment of Rac1 protein levels 
following Rac1 shRNA expression. (*P<0.05; **P<0.01; ***P<0.001). 
 
Similar to Rac1, the Rap1 GTPase has been implicated in the regulation of 
endothelial barrier integrity by promoting cortical actin deposition and VE-cadherin 
junctional stabilization [384]. Rap1 activation induces maturation of adherens junctions 
in unstimulated endothelial cells and inhibits thrombin-induced barrier dysfunction 
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[385]. The Abl kinases previously have been demonstrated to regulate Rap1 activation in 
both T cells and epithelial cells, thereby modulating integrin function [291,328]. 
Interestingly, Abl kinase inhibition led to increased levels of active Rap1 in unstimulated 
cells, as well as following VEGF treatment (Figure 4.9A,B). However, imatinib 
effectively inhibited VEGF-induced endothelial permeability in cells expressing the 
negative regulator Rap1 GTPase activating protein (Rap1GAP), which prevented both 
basal and imatinib-induced Rap1 activation (Figure 4.9C,D). Thus, neither Rac1 nor 
Rap1 GTPase activation alone account for the anti-permeability effects of imatinib in 
endothelial cells. 
 
Figure 4.9 Increased Rap1 GTPase Activity Following Abl Kinase Inhibition 
(A and B) Assessment of levels of GTP-bound (active) Rap1 GTPase in HMVECs treated 
with imatinib (10µM), either treated with VEGF (100ng/mL, 2 minutes) or left 
unstimulated (UT). Rap1-GTP levels, normalized to total Rap1, are quantified in (B), 
relative to levels in vehicle-treated cells (UT). Data are presented as means +/- SD (n=5). 
(C) Evaluation of permeability of HMVECs expressing either Rap1GAP or vector control 
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to fluorescein-labeled dextran, following 60 minutes VEGF treatment with or without 
imatinib pre-treatment. Data shown are mean fluorescence of samples collected from 
bottom Transwell chambers, +/- SD of three replicates per treatment. Data are 
representative of two independent experiments. (D) Assessment of levels of active, GTP-
bound Rap1 in vehicle (UT)- or imatinib-treated cells expressing either Rap1GAP or 
vector control. (*P<0.05; **P<0.01; ***P<0.001). 
 
4.2.6 Loss of Abl Kinase Activity Impaired Induction of Acto-Myosin 
Contractility by Endothelial Permeability-Inducing Factors 
In addition to the adhesive forces of cell-cell and cell-matrix interactions, the 
function of the endothelial barrier is modulated by the generation of contractile forces 
regulated in part by actin-myosin tension [378,379]. A key determinant of acto-myosin 
contractility is the phosphorylation of the myosin regulatory light chain (MLC2) at 
serine (S) 19 or diphosphorylation at threonine 18 and S19, which promotes contractility 
by increasing myosin ATPase activity [98]. Interestingly, while stimulation of HMVECs 
with VEGF or thrombin increased levels of phospho-MLC2 (S19), the induction of MLC2 
phosphorylation by these permeability-inducing factors was decreased by inhibition of 
Abl kinase activity (Figure 4.10A,C) or Abl knockdown (Figure 4.10B). Thus, Abl kinase 
activity is required for signaling leading to the induction of acto-myosin contractility 
downstream of endothelial permeability factors. 
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Figure 4.10 Loss of Abl Kinase Activity Impaired MLC2 Phosphorylation in Response 
to Endothelial Permeability-Inducing Factors 
(A) Assessment of phospho-MLC2 serine (S) 19 levels in HMVECs following VEGF 
stimulation (100ng/mL, 5 minutes) with or without imatinib pre-treatment (10µM). 
pMLC2(S19) levels, normalized to total MLC2, are quantified in the right panel, relative 
to levels in untreated cells (UT). Data are presented as means +/- SD (n=7). (B) 
Evaluation of pMLC2(S19) levels in HMVECs expressing either control or Abl miRNAs 
following VEGF treatment. pMLC2(S19) levels, normalized to total MLC2, are quantified 
in the right panel, relative to levels in untreated control miRNA-expressing cells (UT). 
Data are presented as means +/- SD (n=3). (C) Assessment of pMLC2(S19) levels in 
thrombin-treated HMVECs (1U/mL, 2 minutes), with or without imatinib pre-treatment. 
pMLC2(S19) levels, normalized to total MLC2, are quantified in the right panel, relative 
to levels in untreated cells (UT). Data are presented as means +/- SD (n=4). (*P<0.05; 
**P<0.01). 
 
 129 
The phosphorylation status of MLC2 (S19) is regulated by a balance of 
phosphorylation and dephosphorylation. Phosphorylation of MLC2 in endothelial cells 
is mediated primarily by the activity of Ca2+/calmodulin-dependent myosin light chain 
kinase (MLCK), as well as the Rho GTPase effector Rho kinase (ROCK), while 
dephosphorylation is mediated by myosin light chain (MLC) phosphatase [30]. ROCK 
activity additionally increases levels of MLC2 phosphorylation by phosphorylating and 
inactivating MLC phosphatase [193]. As loss of Abl kinase activity decreased MLC2 
(S19) phosphorylation (Figure 4.10), we examined whether Abl kinase activity was 
required for Rho GTPase activation. We did not detect Rho activation following VEGF 
or histamine treatment (data not shown). However, thrombin stimulation induced 
potent activation of Rho GTPase, which was not inhibited in imatinib-treated cells 
(Figure 4.11), indicating that the decreased MLC2 phosphorylation observed in imatinib-
treated cells was not a result of impaired Rho pathway activation. 
 
Figure 4.11 Abl Kinase Inhibition Did Not Affect Thrombin-Induced Activation of 
Rho GTPase 
Assessment of levels of GTP-bound (active) Rho GTPase in HMVECs either left 
unstimulated (UT) or treated with thrombin (1U/mL, 2 minutes), +/- imatinib (10µM). 
Rho-GTP levels, normalized to total Rho, are quantified in the right panel, relative to 
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levels in thrombin-stimulated cells. Data are presented as means +/- SD (n=5). 
(***P<0.001). 
 
4.2.7 Abl Kinase Inhibition Impaired Ca2+
The lack of inhibition of thrombin-induced Rho GTPase activation by imatinib 
suggested that Abl kinases regulate acto-myosin contractility through an alternative 
pathway. Stimulation of endothelial cells with permeability-inducing agonists is known 
to increase levels of intracellular calcium, mediated both by release of Ca
 Mobilization by Endothelial 
Permeability-Inducing Factors 
2+ from 
intracellular stores and by extracellular Ca2+ entry through plasma membrane channels, 
contributing to the activation of Ca2+/calmodulin-regulated enzymes including MLCK 
[97,386]. Notably, we observed decreased VEGF-induced Ca2+ mobilization in the 
presence of the Abl kinase inhibitors imatinib or GNF-2 (Figure 4.12A,B). Increases in 
intracellular Ca2+ levels induced by VEGF, thrombin, or histamine were decreased by 30-
50% following Abl kinase inhibition (Figure 4.12C).  
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Figure 4.12 Abl Kinase Inhibition Impaired Ca2+
(A and B) Quantification of intracellular Ca
 Mobilization by Endothelial 
Permeability-Inducing Factors 
2+ levels in HMVECs stimulated with VEGF 
(100ng/mL) with or without (A) imatinib (10µM) or (B) GNF-2 (15µM) pre-treatment. 
Values are expressed as increases in intracellular Ca2+ levels, relative to levels in 
unstimulated cells. Arrows indicate timing of addition of permeability-inducing factors. 
Data are presented as means +/- SD of 35 cells per treatment and are representative of 3 
independent experiments. (C) Quantification of inhibition of Ca2+ mobilization by 
imatinib or GNF-2. Values shown are maximum intracellular Ca2+
 
 levels in HMVECs 
treated with VEGF, thrombin (1U/mL), or histamine (100µM) in the presence of Abl 
kinase inhibitors, relative to levels in vehicle-treated cells (UT). Data are presented as 
means +/- SEM (n=3). (*P<0.05; **P<0.01; ***P<0.001). 
The release of Ca2+ from intracellular stores is triggered by the binding of 
inositol-1,4,5-trisphosphate (IP3) to its cognate receptor on the endoplasmic reticulum 
(ER) membrane. Cellular IP3 levels are, in turn, regulated by the activity of 
phosphoinositide-specific phospholipase C (PLC) family enzymes. In endothelial cells, 
VEGF-mediated IP3 generation is regulated by PLCγ activation downstream of VEGF 
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receptor 2 (VEGFR2) [387]. We observed delayed PLCγ1 activation following VEGF 
stimulation in HMVECs treated with the Abl kinase inhibitor GNF-2, as assessed by 
levels of activating phosphorylation of PLCγ1 (Y783) [388] (Figure 4.13A,B). The levels of 
phosphorylated PLCγ1 (Y783) induced by VEGF stimulation were reduced by 50% in 
GNF-2-treated cells 1 minute after VEGF treatment (Figure 4.13B). The effect of GNF-2 
was transient, as comparable levels of phospho-PLCγ1 (Y783) were detected in vehicle- 
and GNF-2-treated cells by 5 minutes post-VEGF stimulation. Similar findings were 
observed upon VEGF stimulation in the presence of imatinib (data not shown). VEGF-
mediated PLCγ1 activation requires phosphorylation of VEGFR2 on Y1175 [82]. 
Interestingly, Abl kinase inhibition also impaired VEGF-induced phosphorylation of 
VEGFR2 (Y1175) at earlier time points (1 to 2 minutes) (Figure 4.13A,C). Taken together, 
these findings suggest that Abl kinase inhibition impairs the VEGF-induced 
mobilization of intracellular Ca2+ in part through decreased VEGF receptor 
phosphorylation and resulting inhibition of PLCγ activation.  
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Figure 4.13 Abl Kinase Inhibition Delayed VEGF-Mediated PLCγ Activation 
(A) Assessment of VEGF-mediated phosphorylation of PLCγ1 and VEGFR2 in HMVECs, 
with or without GNF-2 pre-treatment. (B and C) Quantification of levels of (B) phospho-
PLCγ1 tyrosine (Y) 783 and (C) phospho-VEGFR2 Y1175 in HMVECs treated with VEGF 
+/- GNF-2, relative to levels in vehicle-treated cells (UT) at each time point. Data are 
presented as means +/- SD (n=3). (*P<0.05; **P<0.01; ***P<0.001). 
 
4.3 Discussion 
Excessive vascular leakage is a feature of a wide range of pathological conditions, 
leading to complications including edema and increased tissue damage following 
ischemic stroke and myocardial infarction, increased interstitial fluid pressure in 
cancers, and pulmonary dysfunction in acute respiratory distress syndrome [31,32]. 
Efforts to prevent this increased vascular permeability are complicated, in part, by the 
multiple permeability-inducing factors involved in these disorders [389]. In the current 
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study, we have identified the Abl family kinases, Abl and Arg, as mediators of 
endothelial barrier dysfunction induced by several disparate permeability factors, 
including agonists signaling through both receptor tyrosine kinases (VEGF) and G 
protein-coupled receptors (thrombin and histamine). Importantly, Abl kinase inhibition, 
using either imatinib or the Abl/Arg-specific allosteric inhibitor GNF-2, impaired VEGF-
induced vascular permeability both in cultured endothelial cells and in mice. We 
showed for the first time a direct requirement for Abl in VEGF-induced dermal vascular 
leakage in mice lacking endothelial Abl expression. Loss of Abl kinase activity protects 
against endothelial barrier dysfunction; this effect is accompanied by activation of the 
barrier-stabilizing GTPases Rac1 and Rap1, as well as inhibition of both agonist-induced 
Ca2+ mobilization and generation of acto-myosin contractility. A model for the proposed 
role of the Abl kinases in signaling pathways regulating endothelial permeability is 
shown in Figure 4.14. 
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Figure 4.14 Model for the Role of the Abl Kinases in Signaling Pathways Regulating 
Endothelial Permeability 
The Abl and Arg kinases are activated in endothelial cells downstream of receptors for 
the permeability-inducing factors VEGF, thrombin, and histamine. VEGF-mediated Abl 
kinase activation requires Src family kinase activity. The Abl kinases positively regulate 
phosphorylation of MLC2 (S19) in response to these permeability-inducing agonists, 
likely through regulating the activity of Ca2+/calmodulin-dependent targets such as 
MLCK. Abl kinase activity is required for maximal Ca2+ mobilization in response to 
stimulation with permeability-inducing factors. The Abl kinases additionally modulate 
VEGF-induced phosphorylation of VEGFR2 at Y1175, which regulates downstream 
PLCγ activation, IP3 generation, and ER Ca2+ release. Abl kinases promote Ca2+ 
mobilization by thrombin and histamine by mechanisms yet to be characterized. Abl 
kinases negatively regulate basal activity levels of the Rac1 and Rap1 GTPases, which 
have been shown to support endothelial barrier function by promoting cortical actin 
deposition and adherens junction stability. Abbreviations: EC, endothelial cell; VEGF, 
vascular endothelial growth factor; VEGFR2, VEGF receptor 2; Y, tyrosine; PAR-1, 
protease-activated receptor 1 (thrombin); H1, histamine H1 receptor; MLC2, myosin 
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regulatory light chain; S, serine; MLCK, myosin light chain kinase; PLC, phospholipase 
C; IP3, inositol-1,4,5-trisphosphate; IP3R, IP3
 
 receptor; ER, endoplasmic reticulum. 
The endothelial barrier is regulated by a dynamic balance of adhesive and 
contractile forces [30]. We found that inhibition of the Abl kinases led to increased 
activation of the endothelial barrier-promoting GTPases Rac1 and Rap1, which promote 
cortical actin remodeling and adherens junction stability [190,191,192,384,385]. The Abl 
kinases previously have been linked either to positive or negative regulation of GTPase 
activation, depending upon the cellular context. The Abl kinases are required for Rac1 
activation downstream of cadherin engagement in epithelial cells [294], as well as Rap1 
activation following T cell receptor engagement or chemokine stimulation in T cells 
[291,292]. In contrast, expression of constitutively-active Abl kinases reduced levels of 
active Rap1 in epithelial and HEK293 cells, as a result of Abl-mediated tyrosine 
phosphorylation of the CrkII adaptor and disruption of the association between CrkII 
and the Rap1 guanine nucleotide exchange factor (GEF) C3G [328,390]. It remains to be 
determined whether the enhanced Rap1 activation we observed upon Abl kinase 
inhibition in endothelial cells results from increased CrkII/C3G interaction and C3G GEF 
activity. However, our findings that reduced Rac1 expression or Rap1 activity did not 
prevent imatinib-mediated endothelial barrier stabilization suggest that Rac1- and Rap1-
independent pathways mediate the anti-permeability effects of Abl/Arg kinase 
inhibition. 
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Notably, inhibition of Abl kinase activity impaired VEGF- and thrombin-induced 
phosphorylation of the myosin regulatory light chain (MLC2), which regulates myosin 
ATPase activity and induction of barrier-destabilizing acto-myosin contractility [98]. 
However, Abl kinase inhibition in endothelial cells did not affect activation of the 
Rho/ROCK pathway, which increases MLC2 phosphorylation through inhibitory 
phosphorylation of myosin light chain phosphatase [193]. In contrast, in fibroblasts, the 
Arg kinase previously has been linked to inhibition of acto-myosin contractility during 
integrin-mediated adhesion and migration, through phosphorylation and activation of 
the RhoA inhibitor p190RhoGAP [323]. Similarly, Abl kinase inhibition in epithelial cells 
leads to increased baseline Rho activation, formation of actin stress fibers, and weakened 
intercellular adhesion [294]. These disparate findings may be explained by differential 
roles for Abl kinases in the regulation of signaling pathways mediating basal versus 
agonist-induced Rho activation and acto-myosin contractility in various cell types. 
Phosphorylation of the myosin regulatory light chain can be regulated by the 
Ca2+/calmodulin-dependent myosin light chain kinase (MLCK) [97]. Interestingly, 
treatment with the endothelial barrier-promoting bioactive lipid sphingosine-1-
phosphate was shown to increase Abl-mediated MLCK (Y464) phosphorylation [346], 
raising the possibility that Abl kinase activation by endothelial permeability-inducing 
mediators similarly may contribute to MLCK phosphorylation and activation. Tyrosine 
phosphorylation of MLCK has been linked to enhanced enzymatic activity at lower Ca2+ 
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concentrations [391]. Notably, we found that increases in intracellular Ca2+ levels 
induced by endothelial barrier-disrupting factors were attenuated by Abl kinase 
inhibition. Thus, we postulate that decreased intracellular Ca2+ mobilization in cells with 
reduced Abl kinase activity might contribute to impaired agonist-stimulated MLCK 
activity, leading to the observed reduction in MLC2 phosphorylation. Further 
investigation is needed to characterize fully the effects of Abl kinase inhibition on MLCK 
activity, as well as to determine whether the impaired Ca2+ mobilization inhibits 
activation of other Ca2+
Consistent with the observed impairment of agonist-mediated Ca
-regulated enzymes involved in endothelial barrier dysfunction, 
such as PKCα [387].  
2+ mobilization, 
we found that VEGF-induced PLCγ activation was delayed in the absence of Abl kinase 
activity. Interestingly, phosphorylation of VEGFR2 (Y1175), which is required for PLCγ 
activation [82], similarly was delayed in endothelial cells treated with Abl kinase 
inhibitors. Previous work has demonstrated Abl kinase-mediated phosphorylation of 
the PDGF and epidermal growth factor receptors [260,392]; however, it remains to be 
determined whether VEGFR2 is an Abl kinase target. In addition, we have previously 
identified a bi-directional link between PLCγ and Abl in PDGF-stimulated fibroblasts, 
whereby PLCγ is required for Abl kinase activation, and in turn, Abl modulates PLCγ 
enzymatic activity [286]. Further investigation will be required to determine if a similar 
PLCγ-Abl connection exists in VEGF-stimulated endothelial cells. In all, these findings 
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suggest that impaired VEGF-induced Ca2+ mobilization upon Abl kinase inhibition may 
result, at least in part, from decreased PLCγ-mediated IP3 generation, resulting in 
impaired release of endoplasmic reticulum (ER) Ca2+ stores. However, distinct 
mechanisms are likely to be involved in the inhibition of thrombin- and histamine-
induced Ca2+ mobilization, which is regulated by G protein-mediated activation of PLCβ 
[387]. In this regard, previous studies have suggested a role for tyrosine kinases in 
regulating extracellular calcium entry through plasma membrane channels following 
depletion of intracellular Ca2+ stores (store-operated Ca2+
In summary, we have demonstrated a requirement for the Abl kinases in 
induction of endothelial permeability by VEGF and the inflammatory mediators 
thrombin and histamine. Our findings and recent reports suggest that the endothelial 
barrier-protective effects of Abl kinase inhibition result from several distinct 
mechanisms, including promoting cell-cell and cell-matrix adhesion [345], as well as 
impairing induction of acto-myosin contractility. While the precise Abl kinase targets 
involved in the regulation of these pathways remain to be characterized, the existence of 
multiple pathways mediating the anti-permeability effects of Abl kinase inhibition 
suggests that pharmacological targeting of the Abl kinases may be capable of inhibiting 
endothelial permeability induced by a broad range of agonists. However, further studies 
will be needed to evaluate the involvement of the Abl kinases in endothelial barrier 
dysfunction mediated by additional permeability-inducing factors, as well as to 
 influx) [387]. 
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determine whether in vivo pharmacological or genetic inactivation of the Abl kinases 
may have protective effects in disorders involving pathological vascular leakage. 
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5. Discussion and Future Directions 
Proper endothelial cell function is required for maintenance of normal 
cardiovascular physiology, ensuring appropriate regulation of vascular barrier function 
and tissue perfusion [2]. These functions are regulated in part by a variety of soluble 
mediators, which signal through endothelial cell surface receptors to influence processes 
including proliferation, survival, migration, and vascular stability [64,65]. The work 
described in the preceding chapters supports an important role for the Abl family of 
non-receptor tyrosine kinases (Abl and Arg) in endothelial cell responses to several pro-
angiogenic and permeability-inducing factors, including the pro-survival effects of 
VEGF, bFGF, and Angpt1 (Chapter 3) and the destabilization of the endothelial barrier 
in response to VEGF, thrombin, and histamine (Chapter 4). Most notably, these studies 
have shown that the Abl family kinases play a crucial role in vascular function in vivo, as 
mice lacking endothelial expression of the Abl/Arg kinases died at late embryonic and 
perinatal stages of development (Chapter 3).  
5.1 Role of the Abl Kinases in Vascular Function 
Previous studies have reported cardiotoxic effects (left ventricular dysfunction; 
heart failure) [2,350,351,352] as well as vaso-occlusive events [354,355,356] in a subset of 
cancer patients following long-term treatment with Abl kinase inhibitors. The work 
detailed in Chapter 3 has demonstrated, using a mouse genetic model of endothelial Abl 
inactivation, that expression of Abl/Arg kinases is required for proper vascular function 
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during embryonic development. AblECKO; Arg-/-
5.1.1 Variability of Cardiovascular Phenotypes of Abl
 mice died at late embryonic stages of 
development or shortly after birth and displayed localized hepatic vascular loss and 
tissue damage (Chapter 3). These vascular defects may result from impaired endothelial 
cell survival, as we have demonstrated that loss of Abl kinase function leads to increased 
susceptibility to endothelial cell apoptosis both in vitro and in vivo.  
ECKO; Arg+/-
In contrast to the late-stage embryonic and perinatal lethality of Abl
 Mice 
– Effects of Genetic Background? 
ECKO; Arg-/- 
mice, endothelial Abl-knockout mice on an Arg+/- background (AblECKO; Arg+/-) were 
viable, indicating that the remaining Arg allele largely compensates for the loss of 
endothelial Abl expression. Interestingly, a subset (approximately 15%) of these AblECKO; 
Arg+/- mice displayed dramatic cardiovascular phenotypes, including left ventricular 
scarring, lung fibrosis, and right ventricular hypertrophy. This phenotypic heterogeneity 
did not result from differing degrees of Abl inactivation, as a significant decrease in 
endothelial Abl expression was observed even in AblECKO; Arg+/- mice that did not exhibit 
overt cardiovascular pathology (Figure 5.1A,B). This finding suggests that loss of 
endothelial Abl expression predisposes these mice to vascular complications, but that 
additional factors are required for overt pathological cardiovascular phenotypes. 
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Figure 5.1 Decreased Abl mRNA Expression in AblECKO; Arg+/-
Assessment of Abl knockdown levels in Abl
 Mice, Regardless of 
Cardiovascular Phenotype 
ECKO; Arg+/- mice. (A) Endothelial cells 
(CD105+/CD45-/CD31+) were isolated from the livers of adult Arg+/- control mice and 2 
subsets of AblECKO; Arg+/- mice: (1) phenotypically normal AblECKO; Arg+/- mice and (2) 
AblECKO; Arg+/- mice which exhibited cardiovascular pathology. Real-time RT-PCR 
analysis of Abl mRNA expression demonstrated decreased Abl levels in AblECKO; Arg+/- 
mice, regardless of cardiovascular phenotype. Data are shown as means +/- SD, 
normalized to Abl expression in Arg+/- control mice (n=2 mice per genotype). (B) Abl 
mRNA expression was assessed in endothelial cells isolated from the lungs of adult 
Arg+/- control mice and phenotypically normal AblECKO; Arg+/- mice (n=3 mice per 
genotype, pooled). Data are presented as means +/- SD of 3 replicates, normalized to Abl 
expression in Arg+/-
 
 control mice. (*P<0.05). 
The variability of the phenotype of AblECKO; Arg+/- mice is similar to the 
incomplete penetrance of the immunological phenotypes observed in global Abl 
knockout mice [330,331]. It is possible that genetic modifiers on a mixed (129/SvJ x 
C57BL/6) genetic background may underlie the different degrees of cardiovascular 
phenotype observed; indeed, global Abl deletion leads to different cardiac phenotypes, 
depending upon the mouse genetic background [349]. Notably, Koleske and colleagues 
independently generated Ablflox/flox; Arg-/-; Tie2-Cre+ mice to examine the role of the Abl 
kinases in macrophage function during parasitic infection [393]. In contrast to the 
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embryonic and perinatal lethality of our AblECKO; Arg-/- mice, the mice generated in that 
study apparently were viable, although their vascular phenotype was not analyzed. It is 
possible that differences in genetic background may contribute to these contrasting 
phenotypes, as the Koleske group’s mice were in a mixed genetic background (129Sv/J x 
C57BL/6), whereas our AblECKO; Arg-/-
5.1.2 Localized, Sporadic Vascular Loss in Abl
 mice were backcrossed six generations into the 
C57BL/6 background [393]. 
ECKO
Loss of endothelial expression of the Abl kinases did not affect overall vascular 
density, branching, and patterning, indicating that the Abl kinases are not required for 
angiogenic remodeling after E9.5 (the stage at which Tie2-Cre-mediated recombination 
has occurred in the majority of endothelial cells, [367]). Rather, loss of endothelial 
Abl/Arg kinases likely adversely affects vascular maintenance and stability, rather than 
vessel formation. However, it remains possible that subtle structural defects during 
vessel formation could contribute to the phenotypes observed later in development in 
mutant embryos. Electron microscopy analysis of mid-gestation Abl
 Mice 
ECKO; Arg-/- embryos 
would be required for the detailed examination of endothelial structure in these mice. It 
similarly would be of interest to examine the effects of inducible endothelial Abl 
inactivation (i.e., by crossing to VE-cadherin-CreERT2, Tie2-CreERT2, or Pdgfb-iCreER mice 
[394,395,396,397]) on vascular structure and function at later stages of embryonic and 
postnatal development.  
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The primary phenotype observed in mice lacking endothelial Abl kinase 
expression was a localized loss of blood vessels, which led to subsequent tissue 
infarction and organ damage. The focal and sporadic nature of this vascular loss was 
striking and, in combination with our observation that loss of the Abl kinases sensitizes 
endothelial cells to stress-induced apoptosis in vitro, leads us to speculate that the 
vascular damage observed in these mice may result from localized endothelial cell 
apoptosis in response to cumulative vascular stresses in the absence of the Abl kinases. 
The sporadic vascular occlusions observed in some adult AblECKO; Arg+/- mice may result 
from endothelial cell apoptosis and vascular damage, which may contribute to 
thrombosis and defective tissue perfusion. Interestingly, while adult AblECKO; Arg+/- mice 
exhibited leukocyte and red blood cell counts comparable to Arg+/-
 
 control mice, these 
mice showed a 10% reduction in the number of circulating platelets (Table 5.1), 
suggesting that thrombosis in these mice may contribute to a slight depletion of 
circulating platelets. However, as Tie2-Cre-mediated recombination also inactivates Abl 
in hematopoietic cells (including megakaryocytes) [363], we cannot exclude the 
possibility that Abl kinase activity in megakaryocytes or platelets may regulate platelet 
generation or function. In this regard, treatment of mice with the ATP-competitive dual 
Src/Abl kinase inhibitor dasatinib leads to mild thrombocytopenia as a result of 
inhibition of platelet formation [398]. 
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Table 5.1 Complete Blood Counts (CBC) Analysis of AblECKO; Arg+/- Adult Mice 
 
Blood samples were collected from 3- to 4-month-old female AblECKO; Arg+/- mice 
(phenotypically normal) and age/sex-matched Arg+/- control mice via cardiac puncture. 
EDTA-treated blood samples were used for analysis of complete blood counts (CBC). 
CBC analysis was performed by the Duke University School of Medicine Division of 
Laboratory Animal Resources (DLAR) Veterinary Diagnostic Lab (VDL), using an Abbot 
Cell Dyn 3700 analyzer. Data are presented as means +/- SD. (*P<0.05). Abbreviations: 
WBC, white blood cells; RBC, red blood cells; K, x103; M, x106
 
. 
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Endothelial cell death or damage has been reported in numerous vascular 
pathologies [371], and a resulting loss of endothelial integrity can trigger coagulation by 
exposing thrombogenic ECM components to the circulation [399,400]. Endothelial cells 
also typically synthesize a variety of both soluble and membrane-bound factors (nitric 
oxide, prostacyclin, tissue factor pathway inhibitor, thrombomodulin, etc.) which 
function to maintain the vasculature in an anti-thrombotic state [401]; thus, endothelial 
cell damage or dysfunction can contribute to thrombosis through altered production of 
these regulatory factors. It is possible that the sporadic thrombosis observed in mice 
lacking endothelial Abl kinase expression may result from a specific defect in 
endothelial regulation of coagulation and hemostasis, in addition to increased 
susceptibility to endothelial cell apoptosis. Interestingly, Abl kinase activity is required 
for LPS-induced nitric oxide (NO) production in macrophages (Greuber and Pendergast, 
unpublished, and [402]); however, it is not known whether the Abl kinases may play a 
similar role in the regulation of endothelial cell NO production. Thus, it may be of 
interest to examine whether endothelial Abl inactivation affects thrombus formation or 
resolution in murine thrombosis models [403], particularly in light of vascular occlusive 
events observed in some nilotinib-treated cancer patients [354,355]. 
5.2 Role of the Abl Kinases in Angpt/Tie2 Signaling 
Endothelial Abl inactivation in mice resulted in sporadic thrombosis, endothelial 
cell apoptosis, and vascular loss. Notably, localized thrombosis and endothelial cell 
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apoptosis similarly were observed upon endothelial Vegf deletion, which was attributed 
to a requirement for intracrine VEGF signaling for endothelial cell survival and 
maintenance of vascular homeostasis [71]. Similarly, a role for Tie2 signaling in 
maintaining quiescence and homeostasis in the adult vasculature has been proposed, 
which correlates with the detection of Tie2 phosphorylation/activation in the vasculature 
of all adult tissues examined [162]. Our current studies have uncovered a novel role for 
the Abl kinases in Angpt1/Tie2 signaling, as loss of Abl/Arg kinase expression resulted 
in decreased Tie2 receptor expression, as well as diminished Angpt1-mediated signaling 
responses and pro-survival effects. The Abl kinases appear to play a dual role in 
Angpt1/Tie2 signaling through the regulation of Tie2 expression and modulation of 
signaling networks required for Angpt1-mediated endothelial cell survival. 
5.2.1 Altered Expression of Tie2 and Angiopoietins Following Abl/Arg 
Knockdown 
Interestingly, in addition to Tie2 receptor downregulation, Abl/Arg knockdown 
led to altered expression of its angiopoietin ligands. While mRNA and protein levels of 
the antagonistic Angpt2 ligand were increased following Abl/Arg depletion, expression 
of the Tie2 agonist Angpt1 was decreased. However, changes in Angpt1 and Angpt2 
expression occurred 72 to 96 hours after Abl/Arg knockdown, while Tie2 expression was 
decreased at earlier time points (within 24 to 48 hours), suggesting that altered 
angiopoietin levels may be secondary effects of Abl/Arg depletion, induced by Tie2 
downregulation. The mechanisms by which loss of Abl kinase expression contributes to 
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changes in Tie2 and angiopoietin expression remain to be determined. Reporter assays 
(i.e., Tie2 promoter-driven luciferase expression, [404]) will shed light on whether the 
observed changes in gene expression result from altered transcription, rather than effects 
on mRNA stability or miRNA-mediated regulation, and may identify promoter regions 
important for this regulation. Tie2 expression is promoted by transcription factors 
including the Ets family member NERF2 (new Ets-related factor 2) [404], as well as 
Kruppel-like factor 2 (KLF2) [405], and Tie2 levels are increased in response to the 
proinflammatory cytokines TNFα and interleukin-1β (IL-1β) [406]. In contrast, decreased 
Tie2 mRNA levels have been observed in response to a variety of cellular stresses, 
including endoplasmic reticulum (ER) stress [407] and exposure to high glucose levels 
[408]. Tie2 expression also may be reduced in response to hypoxia [138], although other 
studies have shown hypoxia-induced Tie2 upregulation [406].  Thus, the decrease in Tie2 
expression observed following loss of the Abl kinases may result either from direct 
effects on transcription factor activity or indirectly through induction of cellular stress. 
Notably, imatinib treatment of cardiomyocytes has been linked to induction of ER stress 
[350], although it remains to be determined if loss of Abl kinase function has similar 
effects in endothelial cells. 
In contrast to Tie2, which is broadly expressed in endothelial cells in the adult 
vasculature [162], Angpt2 expression is not readily detectable in quiescent vessels in 
adult tissues [134]. However, increased Angpt2 levels are observed at sites of 
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inflammation or angiogenic remodeling [135], and Angpt2 mRNA expression is 
upregulated in response to hypoxia or stimulation with cytokines or growth factors 
including VEGF [138,139]. Angpt2 expression is promoted by Ets family transcription 
factors [409], as well as the forkhead transcription factor FOXO1 (also known as FKHR) 
[176]. Interestingly, Angpt1-mediated Akt activation leads to phosphorylation and 
inactivation of FOXO1, which results in suppression of Angpt2 expression [176], 
suggesting the presence of a regulatory loop controlling angiopoietin expression and 
Angpt/Tie2 pathway activity. PI3K/Akt pathway activation by Angpt1 regulates both 
Tie2 and Angpt2 expression through induction of KLF2 expression [179,410]. In addition 
to promoting Tie2 expression, KLF2 suppresses expression of Angpt2 [405]. Thus, it is 
possible that the increased Angpt2 levels observed following Abl/Arg depletion may be a 
consequence of diminished Angpt1/Tie2-mediated signaling. It would be of interest to 
determine whether Tie2 knockdown would result in similar changes in angiopoietin 
expression to those detected after knockdown of Abl/Arg. It also is unclear whether the 
observed increase in endothelial cell Angpt2 levels may affect Tie2 signaling or 
downstream responses, as Angpt2 expression has been linked to both protective and 
destabilizing effects in different cellular contexts [151,196]. 
5.2.2 Role of the Abl Kinases in Angiopoietin-1/Tie2 Signaling 
Importantly, in addition to reducing Tie2 levels, Abl/Arg knockdown resulted in 
decreased Angpt1/Tie2 signaling responses (particularly Akt phosphorylation), as well 
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as diminished Angpt1-mediated pro-survival effects. However, re-expression of 
exogenous Tie2 did not fully restore the anti-apoptotic effects of Angpt1, suggesting that 
the Abl kinases also modulate Angpt1-mediated endothelial cell survival through 
mechanisms other than regulation of Tie2 expression. Interestingly, we found that 
Angpt1 stimulation of endothelial cells leads to activation of the Abl kinases. Thus, the 
Abl kinases additionally may play a role in signaling responses downstream of the Tie2 
receptor. As Angpt1 can bind to integrins as well as the Tie2 receptor, it is possible that 
Abl kinase activation may also occur downstream of Angpt1/integrin binding [154]. 
Analysis of Angpt1-mediated Abl kinase activation in Tie2-knockdown endothelial cells 
will be necessary to examine this possibility.  
Further studies will be required to determine how the Abl kinases are activated 
following Angpt1/Tie2 binding, as well as to investigate the involvement of these 
kinases in mediating Angpt1/Tie2 downstream cellular responses. It is possible that the 
Abl kinases are recruited to the Tie2 receptor following Angpt1 stimulation either 
directly (as has been observed following activation of the PDGF receptor [260]) or 
indirectly through interaction with adaptor or docking proteins including Grb2 or Dok-
R [264,411]. While the data presented here suggest that the Abl kinases may function 
downstream of Tie2 to mediate endothelial cell survival, it will be of interest to 
determine whether Abl/Arg may modulate other endothelial cell responses to Angpt1, 
including migration, as well as anti-permeability and anti-inflammatory effects. In this 
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regard, several signaling proteins required for Angpt1/Tie2-dependent endothelial cell 
migration, including Dok-R, Nck and PAK [183,184], are binding partners and/or 
substrates of the Abl kinases [264,411,412]. 
Interestingly, Abl/Arg depletion led to a more pronounced inhibition of Angpt1-
mediated Akt phosphorylation than of Erk activation. The activation of distinct Tie2 
complexes either at cell-cell or cell-matrix contacts has been linked to preferential 
activation of the Akt or Erk pathways, respectively [179,180]. Thus, an intriguing 
possibility is that the Abl kinases may modulate Tie2 signaling responses particularly at 
cell-cell contacts. Alternatively, the Abl kinases may have a role in receptor trafficking, 
including Angpt1-induced translocation of Tie2 to cell-cell contacts in confluent 
endothelial cells. In this regard, the Abl kinase has been shown to regulate EGF receptor 
endocytosis [392] and is required for proper Notch receptor endocytic trafficking [413]. 
In addition, single knockdown of either Abl or Arg demonstrated that loss of either 
kinase was sufficient to inhibit Angpt1-mediated signaling. However, in contrast to dual 
Abl/Arg knockdown, Abl depletion alone did not decrease total Tie2 receptor levels, 
although Angpt1-induced Tie2 phosphorylation was diminished (Figure 3.20B). It will 
be of interest to determine whether Tie2 localization is altered upon Abl knockdown, as 
well as to examine whether the Abl and Arg kinases may differentially regulate 
Angpt1/Tie2-mediated signaling through effects on Tie2 activation and expression, 
respectively. 
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5.2.3 Effects of Abl Kinase Inhibition on the Angiopoietin/Tie2 
Pathway 
Our studies evaluating the effects of loss of Abl/Arg kinase expression on 
angiopoietin/Tie2 expression and signaling have suggested that the observed decreases 
in Tie2 expression and Angpt1-mediated endothelial cell survival may result from loss 
of the tyrosine kinase activity and/or scaffolding function of the Abl family kinases. To 
evaluate the contribution of Abl kinase activity to regulation of the angiopoietin/Tie2 
pathway, we examined the effects of pharmacological inhibition of the Abl kinases on 
angiopoietin/Tie2 expression and Angpt1-mediated endothelial cell survival. Treatment 
with the Abl family kinase inhibitor imatinib (10µM) resulted in substantial inhibition of 
Angpt1-mediated HUVEC survival following serum-starvation (Figure 5.2A). A slight 
reduction in Tie2 protein levels was observed after 24 hours imatinib treatment, along 
with a more pronounced increase in Angpt2 levels (Figure 5.2B). A similar increase in 
Angpt2 protein expression occurred after Abl kinase inhibition with nilotinib (Figure 
5.2C), as well as treatment with a lower concentration of imatinib (5µM). However, no 
change in Tie2 expression was observed after nilotinib or 5µM imatinib treatment 
(Figure 5.2C). Thus, it is possible that the reduced Tie2 levels observed following 
treatment with 10µM imatinib may be due to inhibition of multiple kinases that are 
targeted by higher imatinib levels. Importantly, the increase in Angpt2 levels observed 
following imatinib treatment was reduced by expression of imatinib-resistant Abl and 
Arg mutants (Abl-T315I, [414]) (Figure 5.2D), demonstrating that imatinib-mediated 
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Angpt2 upregulation likely results from inhibition of Abl/Arg. It remains to be 
determined whether Abl kinase inhibition similarly increases Angpt2 levels in vivo, as 
well as the physiological effects of this increase in Angpt2 expression in cells lacking 
active Abl kinases. 
Interestingly, an increased ratio of Angpt2 to Angpt1 expression has been 
reported in a number of disorders involving vascular dysfunction, including diabetes, 
hyperoxic lung injury, and sepsis [202,203,204,205]. Further, elevated circulating Angpt2 
levels have been correlated with disease progression in sepsis [135]. If Abl kinase 
inhibition also leads to increased Angpt2 expression in vivo, it is possible that use of Abl 
kinase inhibitors could have deleterious effects on progression of these disorders. On the 
other hand, increased Angpt2 expression has been proposed to serve a protective 
function in stressed endothelial cells (following inhibition of pro-survival PI3K/Akt 
signaling) [151]. Thus, an alternative interpretation of our findings is that the increase in 
Angpt2 levels is a component of an endothelial cell stress response following Abl kinase 
inhibition. Further study will be needed to investigate these possibilities. 
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Figure 5.2 Inhibition of Angpt1-Mediated Endothelial Cell Survival and Altered 
Angiopoietin/Tie2 Expression Following Pharmacological Inhibition of the Abl 
Kinases 
(A) Analysis of levels of apoptosis in HUVECs following 24 hours serum-starvation in 
the presence of Angpt1 (200ng/mL) +/- imatinib (10µM). Values are expressed as percent 
inhibition of apoptosis by Angpt1 relative to serum-starved (non-supplemented) cells. 
Data are presented as means +/- SEM (n=3; **P<0.01). (B) Assessment of Angpt2 and Tie2 
protein levels in HUVECs treated with 10µM imatinib for 24 hours. (C) Analysis of 
Angpt2 and Tie2 protein expression in HUVECs after treatment with Abl family kinase 
inhibitors (5µM imatinib or 1µM nilotinib) for 24, 48, or 72 hours (culture medium with 
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inhibitors was changed daily). (D) Assessment of Angpt2 and Tie2 protein levels in 
HUVECs infected with retroviruses expressing wild-type murine Abl and Arg proteins 
or imatinib-resistant Abl and Arg proteins (mAbl-T315I and analogous mArg mutation; 
numbering indicates position of mutated threonine residue in mAbl 1a isoform) after 
imatinib treatment (5µM, 24 hours). All results are representative of at least 2 
independent experiments. 
 
5.3 Role of the Abl Kinases in Angiogenesis 
Our studies have demonstrated that the Abl family kinases are activated 
following treatment with a variety of pro-angiogenic growth factors, including Angpt1, 
VEGF, and bFGF. These factors promote neovascularization by stimulating endothelial 
cell proliferation, survival, migration, and/or vascular stability [64,65] and thus 
represent potential therapeutic targets for the treatment of disorders involving aberrant, 
excessive angiogenesis. Interestingly, we observed that inhibition of Abl kinase activity 
impaired the ability of each of these growth factors to support endothelial cell survival. 
This finding raises the possibility that pharmacological targeting of the Abl kinases may 
have anti-angiogenic effects. Imatinib has shown anti-angiogenic activity in several 
tumor models [334,335,336], as well as inhibiting VEGF- and bFGF-driven angiogenesis 
in vivo [266]. While these anti-angiogenic effects have been attributed to imatinib-
mediated inhibition of the PDGF receptor, an additional study demonstrated that 
expression of a dominant-negative Abl protein in endothelial cells results in reduced 
bFGF-driven angiogenesis in vitro and in vivo, as well as decreased tumor size and 
vascularization in an endothelial cell/breast cancer co-implantation xenograft tumor 
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model [337]. These findings suggest an in vivo pro-angiogenic function for the Abl 
family kinases.  
In order to evaluate the potential angiogenic role of the endothelial Abl kinases, 
we examined subcutaneous xenograft tumor growth in endothelial Abl knockout mice, 
using both Lewis Lung Carcinoma (LLC) and B16-F10 melanoma syngeneic tumor 
models. Since AblECKO; Arg-/- mice are embryonic lethal, these tumors were implanted into 
adult AblECKO; Arg+/- mice, as well as Arg+/- control mice. However, no differences in LLC 
tumor growth (Figure 5.3A) or vascularization (Figure 5.3B) were observed in mice 
lacking endothelial Abl expression, although a trend toward decreased tumor growth 
was observed in the B16-F10 model (Figure 5.3C,D). It is likely that Arg can compensate 
for the effects of loss of endothelial Abl inactivation in these tumor models. Therefore, it 
may be useful to examine tumor vascularization using inducible endothelial Abl 
knockout mice (on an Arg-/- background), in order to bypass the lethality of constitutive 
loss of endothelial Abl/Arg expression. However, the normal overall vascular 
patterning, branching, and vessel density observed in AblECKO; Arg-/- embryos suggest 
that the Abl kinases are not required for developmental angiogenesis. It remains to be 
determined whether endothelial Abl/Arg expression similarly is dispensable for 
pathological angiogenesis. Notably, treatment with the Abl/Arg-specific 
pharmacological inhibitor GNF-5 decreased growth of lung cancer xenograft tumors 
(Greuber, Ring, and Pendergast, unpublished data). While no obvious differences in 
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vascularization were observed in tumors from mice treated with GNF-5, these tumors 
displayed increased hypoxic area, suggesting that Abl kinase inhibition leads to 
defective function of the tumor vasculature. Further studies will be required to 
characterize the mechanisms by which GNF-5 exerts its anti-tumor effects. 
 
Figure 5.3 Xenograft Tumor Growth and Vascularization in AblECKO; Arg+/-
Lewis lung carcinoma (LLC) or B16-F10 melanoma cells were implanted subcutaneously 
into separate cohorts of approximately 3-month-old Abl
 Mice 
ECKO; Arg+/- mice and Arg+/- 
controls (5x105 LLC cells; 1.5x105 B16-F10 cells). Upon detection of palpable tumors, 
tumor dimensions were measured every 1-2 days using calipers and tumor volume 
calculated as volume = ½ * width2 * length. (A) Assessment of growth of LLC tumors in 
AblECKO; Arg+/- mice and Arg+/- controls. Data are presented as means +/- SD (n=8-11 mice 
per genotype). (B) CD31 immunostaining of LLC tumor cryosections from AblECKO; Arg+/- 
and Arg+/- control mice, demonstrating no obvious differences in tumor vascularization. 
Scale bar = 100µm. (C) Assessment of growth of B16-F10 tumors in AblECKO; Arg+/- mice 
and Arg+/- controls. Data are presented as means +/- SD (n=6-8 mice per genotype). (D) 
Image of B16-F10 tumors excised (15 days post- implantation) from the AblECKO; Arg+/- 
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and Arg+/- control mice in (C), showing a trend toward decreased tumor size in AblECKO; 
Arg+/-
 
 mice. (*P<0.05). 
5.4 Role of the Abl Kinases in Endothelial Permeability 
5.4.1 Possible Implications for the Treatment of Pathological 
Vascular Permeability 
In addition to its pro-angiogenic function, VEGF is a potent inducer of 
endothelial permeability [81], resulting in disruption of endothelial barrier function. 
While loosening of the endothelial barrier by VEGF and other soluble mediators is an 
important aspect of both normal angiogenic remodeling and inflammatory responses 
[5,30], abnormally elevated vascular permeability contributes to edema, elevated 
interstitial fluid pressure, and tissue damage in pathological conditions including 
cancer, sepsis, and ischemia-reperfusion injury [31,32]. Our studies have demonstrated 
that inhibition of the Abl family kinases using either imatinib or GNF-2 potently inhibits 
the induction of endothelial permeability by VEGF treatment both in vitro and in vivo. 
Importantly, reduced VEGF-induced vascular leakage also was observed in AblECKO; 
Arg+/- mice. Abl kinase inhibition similarly decreased endothelial permeability in 
response to the inflammatory mediators thrombin and histamine. Together, these 
findings suggest that the Abl kinases play an important role in regulating endothelial 
barrier function and that pharmacological targeting of Abl/Arg thus may represent a 
potential treatment for disorders involving excessive vascular leakage. 
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Indeed, within the past year, two published studies documented beneficial 
effects of the Abl family kinase inhibitors imatinib or nilotinib in murine models of 
sepsis and LPS-induced acute lung injury (ALI) [344,345]. In these studies, imatinib or 
nilotinib treatment reduced vascular leakage and pulmonary edema. However, as both 
of these inhibitors target multiple kinases in addition to Abl/Arg [415], it remains 
unclear whether their protective effects are a result of inhibition of the Abl kinases or 
other targets. Imatinib and nilotinib also target multiple cell types in these in vivo disease 
models, raising the possibility that cell types other than endothelial cells may mediate 
the anti-permeability effects of these drugs. In this regard, imatinib and nilotinib 
treatment were found to decrease levels of pro-inflammatory cells (i.e., macrophages 
and neutrophils) and cytokines (TNFα, IL-6, IL-1β) in bronchoalveolar lavage fluid 
during LPS-induced ALI in mice [344]. As we observed decreased VEGF-induced 
permeability in mice lacking endothelial Abl expression (AblECKO; Arg+/- mice), it may be 
of interest to determine whether vascular leakage induced by additional factors 
(histamine, thrombin, etc.) is similarly attenuated in these mice, as well as whether loss 
of the endothelial Abl kinase impacts vascular permeability and disease progression in 
mouse models of disorders involving excessive vascular leakage (including sepsis/ALI). 
A recent study suggested an important contribution of the Arg kinase to endothelial 
permeability responses in vitro [345]. Thus, endothelial Abl knockout alone may not be 
sufficient to impair permeability in disease models in vivo. An examination of the 
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specific endothelial role of the Arg kinase will require generation of conditional Arg 
knockout mice. 
Seemingly in contrast to the endothelial barrier-enhancing effects of Abl kinase 
inhibition observed in these studies, peripheral edema is one of the most commonly 
reported side effects of imatinib treatment in chronic myelogenous leukemia patients 
[416]. However, use of the more potent Abl kinase inhibitor nilotinib has not been 
associated with similar clinical development of edema [270]. We typically did not 
observe altered baseline endothelial permeability upon Abl kinase inhibition, although 
an improvement in basal barrier function was observed in some experiments. However, 
the Abl kinases also have roles in signaling downstream of the endothelial barrier-
promoting mediators S1P and Angpt1 [346,382]. Thus, further investigation will be 
needed to evaluate the effects of chronic Abl kinase inhibition on endothelial barrier 
function in vivo. 
5.4.2 Anti-Permeability Mechanisms of Abl Kinase Inhibition 
5.4.2.1 Adhesion and Contractility 
Endothelial barrier function is governed in part by two opposing forces: the pro-
adhesive effects of cell-cell junctions and cell-matrix adhesions and the barrier-
destabilizing effects of acto-myosin contractility. Permeability-inducing factors upset 
this balance by disrupting endothelial cell-cell junctions [106,122,375,376,377], as well as 
generating increased cellular contractility [378,379]. We found that Abl kinase inhibition 
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in endothelial cells altered pro-adhesive signaling through activation of the Rac1 and 
Rap1 GTPases, which act to promote cortical actin remodeling and stabilize cell-cell 
junctions [190,191,192,384,385]. However, loss of Rac1 or Rap1 expression or function 
did not rescue the imatinib-mediated inhibition of VEGF-induced permeability, 
suggesting that the Abl kinases regulate endothelial barrier function through additional 
mechanisms. Interestingly, our studies demonstrated that loss of Abl kinase activity also 
decreases VEGF- and thrombin-induced generation of acto-myosin contractility, as 
assessed by phosphorylation of the myosin regulatory light chain (phospho-MLC2 S19). 
Thus, pharmacological targeting of the Abl kinases may impair endothelial permeability 
through multiple pathways, including strengthening cellular adhesions and inhibiting 
the barrier-disruptive force of acto-myosin contractility. 
Previous work from our laboratory has shown a requirement for the Abl kinases 
in both formation and maintenance of epithelial adherens junctions [294]. Our current 
work suggests that Abl kinase activity is similarly required for the dissolution of 
endothelial cell-cell junctions in response to VEGF and inflammatory mediators. We 
observed that VEGF-induced activation of the Abl kinases is dependent in part upon the 
activity of Src family kinases, consistent with previous findings in PDGF-stimulated 
fibroblasts [279,286]. Src kinase activation plays an important role in VEGF-induced 
vascular permeability [102], through phosphorylation of the adherens junction protein 
VE-cadherin [103,104] , as well as regulation of VE-cadherin endocytosis and resulting 
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dissolution of endothelial cell-cell junctions [106]. However, we were unable to detect 
any changes in VE-cadherin phosphorylation upon VEGF stimulation, either in the 
absence or presence of Abl kinase inhibitors (data not shown). Intracellular association 
of VE-cadherin with β-catenin and α-catenin was also unchanged. While our inability to 
detect VEGF-induced VE-cadherin tyrosine phosphorylation may reflect technical 
limitations, due to the close association of the VE-cadherin complex with multiple 
protein tyrosine phosphatases, including vascular endothelial cell-specific 
phosphotyrosine phosphatase (VE-PTP) [417] and DEP-1 [50], this finding also suggests 
that additional mechanisms underlie the induction of endothelial permeability, 
independent of direct effects on the VE-cadherin protein complex. 
In this regard, endothelial barrier-disrupting factors increase acto-myosin 
contractility and centripetal tension, which function to weaken intercellular adhesion, 
resulting in cellular retraction and formation of intercellular gaps [378,379]. Our finding 
that VEGF- or thrombin-induced phosphorylation of MLC2 (S19) was decreased 
following loss of Abl kinase function suggests that Abl kinase inhibition may impair 
endothelial permeability by attenuating the barrier-destabilizing effects of acto-myosin 
contractility. MLC2 (S19) phosphorylation is an important regulator of cellular 
contractility, as phosphorylation of this site promotes contractility by increasing myosin 
ATPase activity [98]. Previous work has linked the Abl kinases to regulation of acto-
myosin contractility through phosphorylation of p190RhoGAP [321] . Abl/Arg-mediated 
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phosphorylation stimulates p190RhoGAP inhibitory activity [321], leading to reduced 
levels of active RhoA and decreased acto-myosin contractility [322,323]. Conversely, 
increased acto-myosin contractility, resulting in adherens junction destabilization, was 
observed following extended Abl kinase inhibition in epithelial cells [294]. In contrast, 
we did not observe any difference in thrombin-induced Rho activation in imatinib-
treated endothelial cells, suggesting that the Abl kinases may play differential roles in 
the regulation of basal versus agonist-induced Rho activation and acto-myosin 
contractility in various cell types. 
5.4.2.2 Calcium Signaling 
Our observation that Abl kinase inhibition decreased agonist-induced MLC2 
phosphorylation without affecting Rho GTPase activation suggests that loss of Abl 
kinase function may modulate activation of other pathways regulating acto-myosin 
contractility, such the Ca2+/calmodulin-dependent myosin light chain kinase (MLCK) 
[97]. Calcium signaling has a critical role in the regulation of endothelial permeability 
[386]. Endothelial cell stimulation with several permeability-inducing factors, including 
VEGF, thrombin, and histamine, leads to increased cytosolic Ca2+ levels [418,419], 
mediated by release of intracellular Ca2+ stores as well as extracellular Ca2+ entry through 
membrane channels [387,420]. Importantly, blocking this increase in cytosolic Ca2+ levels 
impairs induction of endothelial permeability [195,421,422,423,424]. In addition to 
promoting acto-myosin contractility through activation of MLCK, Ca2+ regulates the 
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activity of other enzymes important for endothelial permeability responses, including 
PKCα and eNOS [92,93,387,425,426]. 
Notably, we observed diminished Ca2+ mobilization in response to the 
permeability-inducing factors VEGF, thrombin, and histamine in the presence of the Abl 
kinase inhibitors imatinib or GNF-2. In the case of VEGF stimulation, this attenuated 
increase in cytosolic Ca2+ levels may result in part from delayed phosphorylation/ 
activation of PLCγ, which mediates release of Ca2+ from intracellular (ER) stores by 
catalyzing IP3 production [387]. Interestingly, we also observed delayed 
phosphorylation of the VEGF receptor (VEGFR2) on tyrosine 1175, which is required for 
activation of PLCγ [82]. Further studies will be required to determine whether the Abl 
kinases can directly phosphorylate VEGFR2, as has been shown for the PDGF and EGF 
receptors [58,59], as well as whether phosphorylation of additional VEGFR2 tyrosine 
residues is affected by loss of Abl kinase activity. Interestingly, altered endosomal 
trafficking of VEGFR2 has been linked to protein tyrosine phosphatase (PTP)1b-
mediated dephosphorylation of the Y1175 residue [427]. The Abl kinases have been 
implicated in EGF receptor endocytosis [392] and Notch receptor endocytic trafficking 
[413]. Thus, it is possible that the observed delay in VEGFR2 Y1175 phosphorylation 
may result from altered receptor localization/trafficking in the absence of Abl kinase 
activity. 
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While VEGF-mediated IP3 production is mediated by VEGFR2-induced PLCγ 
activation, thrombin- and histamine-induced Ca2+ mobilization is regulated by G 
protein-mediated activation of PLCβ [387]. Thus, distinct mechanisms are likely to 
underlie the imatinib- and GNF-2-mediated inhibition of Ca2+ mobilization by these 
factors. Interestingly, Abl kinase inhibition also decreased Ca2+ mobilization in response 
to thapsigargin (Figure 5.4A), which inhibits sarcoplasmic/endoplasmic reticulum Ca2+ 
ATPase (SERCA) enzymes [428], resulting in increased cytosolic Ca2+ levels through 
passive depletion of ER stores. This finding suggests that the Abl kinases may regulate 
Ca2+ mobilization through IP3-independent mechanisms. In this regard, previous studies 
have suggested a role for tyrosine kinases in regulating extracellular calcium entry 
through plasma membrane channels following depletion of intracellular Ca2+ stores 
(store-operated Ca2+
To examine the relative effects of Abl kinase inhibition on release of intracellular 
Ca
 influx) [387]. 
2+ stores versus extracellular Ca2+ entry, we evaluated VEGF-induced Ca2+ 
mobilization using a two-step protocol, in which VEGF stimulation is performed in the 
absence of extracellular Ca2+ (to examine release of intracellular Ca2+ stores), followed by 
the re-addition of extracellular Ca2+  (to examine extracellular Ca2+ entry). Interestingly, 
while VEGF-induced Ca2+ mobilization was markedly impaired by Abl kinase inhibition 
in the absence of extracellular Ca2+, no consistent effect was observed on cytosolic Ca2+ 
levels following re-addition of extracellular Ca2+ (Figure 5.4B and data not shown). 
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These findings indicate that Abl kinase inhibition primarily impairs VEGF-induced 
release of Ca2+ from intracellular stores, rather than extracellular Ca2+ entry. Notably, 
thapsigargin-induced Ca2+ mobilization similarly was inhibited upon imatinib treatment 
in the absence of extracellular Ca2+ (Figure 5.4C), suggesting that the diminished VEGF-
induced ER Ca2+ release upon Abl kinase inhibition may not simply result from 
decreased IP3 generation.  
 
Figure 5.4 Altered Release of Intracellular Ca2+
(A) Quantification of intracellular Ca
 Stores Following Abl Kinase 
Inhibition 
2+ levels in HMVECs stimulated with thapsigargin 
(1µM) with or without imatinib (10µM) pre-treatment. Values are expressed as increases 
in intracellular Ca2+ levels, relative to levels in unstimulated cells. Arrow indicates timing 
of thapsigargin treatment. Data are presented as means +/- SD of 35 cells per treatment 
and are representative of 3 independent experiments. (B and C) Analysis of intracellular 
Ca2+ levels in HMVECs treated with either (B) 100ng/mL VEGF or (C) 1µM thapsigargin, 
+/- imatinib (10µM) pre-treatment. Cells were stimulated with VEGF or thapsigargin in 
HBSS without Ca2+ for 5 minutes, followed by re-addition of 1mM extracellular Ca2+. 
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Arrows indicate timing of VEGF/thapsigargin treatment. Values are expressed as 
increases in intracellular Ca2+ levels, relative to levels in unstimulated cells. Data are 
presented as means +/- SD of 35 cells per treatment and are representative of at least 3 
independent experiments. (D) Assessment of intracellular Ca2+ levels in HMVECs 
treated with 10µM imatinib, 15µM GNF-2, or DMSO vehicle control (UT) for 15 minutes. 
Values are expressed as increases in intracellular Ca2+ 
 
levels, relative to levels in 
unstimulated cells. Data are shown as means +/- SD (35 cells per treatment) and are 
representative of 3 independent experiments. (*P<0.05; ***P<0.001). 
This finding further raises the possibility that Abl kinase inhibition may alter the 
overall content of the ER Ca2+ stores. In this regard, transient inhibition of the Abl 
kinases with either imatinib or GNF-2 rapidly (within 15 minutes) led to mildly 
increased levels of intracellular Ca2+ (Figure 5.4D). It remains to be determined if this 
increase in cytosolic Ca2+ levels results from stimulation of extracellular Ca2+ entry or, 
perhaps more intriguingly, from Ca2+ leakage from intracellular stores. It also would be 
important to demonstrate that these effects on Ca2+ levels are a result of Abl/Arg kinase 
inhibition (for instance, through expression of imatinib-resistant Abl and Arg proteins 
and/or Abl/Arg depletion), rather than off-target effects of the pharmacological 
inhibitors. Thapsigargin-induced depletion of ER Ca2+ stores has been linked to 
induction of ER stress [429,430]. Imatinib treatment leads to an ER stress response in 
cardiomyocytes [350], as well as in BCR-ABL1-expressing 32Dcl3 myeloid precursor 
cells [431], which contributes to increased cell death. Thus, it is tempting to speculate 
that this imatinib-induced ER stress may result from altered ER calcium homeostasis; 
however, further experimentation will be required to test this possibility. 
 169 
Regardless of the mechanism whereby Abl kinase inhibition alters agonist-
induced Ca2+ mobilization, it also will be important to examine whether the observed 
decrease in cytosolic Ca2+ levels inhibits activation of Ca2+-regulated enzymes involved in 
endothelial barrier dysfunction, such as MLCK and PKCα [387]. Notably, imatinib did 
not inhibit endothelial permeability induced by the PKC activator PMA (phorbol 12-
myristate 13-acetate) (Figure 5.5), suggesting that PKC may function downstream of Abl 
in pathways regulating endothelial permeability. Alternatively, the induction of 
permeability by PMA may occur through Abl-independent pathways distinct from those 
activated by VEGF and inflammatory mediators.  
 
Figure 5.5 No Effect of Abl Kinase Inhibition on Endothelial Permeability Induced by 
PMA Treatment 
Evaluation of permeability of HMVECs to fluorescein-labeled dextran following 
treatment with PMA (100nM) for the indicated times, +/- 10µM imatinib. Data are shown 
as fold-changes in permeability, relative to unstimulated cells, +/- SEM (n=3). 
 
In addition to affecting cellular Ca2+ levels, Abl may regulate MLCK activation 
through phosphorylation. Abl-mediated phosphorylation of MLCK (Y464) has been 
observed following S1P treatment of endothelial cells [346]; tyrosine phosphorylation of 
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MLCK has been linked to enhanced enzymatic activity at lower Ca2+ concentrations 
[391]. It remains to be determined whether Abl kinase activation by endothelial 
permeability-inducing mediators similarly may contribute to MLCK phosphorylation 
and activation. It is possible that decreased intracellular Ca2+ levels in cells with reduced 
Abl kinase activity might contribute to impaired agonist-stimulated MLCK activity, 
leading to the observed reduction in MLC2 phosphorylation. Further investigation is 
needed to characterize fully the effects of Abl kinase inhibition on MLCK activity, along 
with other Ca2+
5.5 Implications for Clinical Use of Abl Kinase Inhibitors? 
-regulated mediators of endothelial permeability. 
In all, our work has demonstrated important roles for the Abl kinases in the 
regulation of endothelial cell function both in vitro and in vivo, including growth factor-
mediated survival responses as well as induction of endothelial permeability by a 
diverse group of agonists. As previously discussed, our finding that Abl kinase 
inhibition impaired endothelial barrier dysfunction suggests that pharmacological 
targeting of the Abl kinases may have beneficial effects in treatment of disorders 
involving pathological vascular leakage. In addition to decreasing pulmonary edema in 
murine models of sepsis/ALI [344,345], Abl kinase inhibitors could potentially protect 
against VEGF-induced edema and tissue damage following infarction and/or ameliorate 
the increased vessel leakiness and elevated interstitial fluid pressure observed in tumors 
[32]. In this regard, imatinib treatment was previously shown to decrease interstitial 
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fluid pressure in lung and colon cancer models, resulting in improved tumor 
oxygenation and drug delivery [340,341,342]. 
In contrast, we found that loss of endothelial expression of the Abl family kinases 
resulted in late-stage embryonic and perinatal lethality in mice, as well as localized 
vascular loss and tissue damage, suggesting deleterious vascular effects of loss of Abl 
kinase function. However, it is important to note several distinctions between the loss of 
Abl function in the mouse model of endothelial Abl depletion and the clinical use of Abl 
kinase inhibitors. First, in our knockout mice, endothelial cells lacked Abl kinase 
expression from the onset of vascular development. Thus, the phenotypes observed in 
AblECKO; Arg-/- embryos and AblECKO; Arg+/- adult mice may result from abnormalities in 
embryonic vascular development and/or effects of chronic loss of Abl kinase function. 
Examining the effects of loss of endothelial Abl kinase expression in adulthood, which 
would be more representative of the context in which Abl kinase inhibitors are used 
clinically, would require the generation of an inducible endothelial Abl knockout model 
(i.e, VE-cadherin-CreERT2, Tie2-CreERT2 or Pdgfb-iCreER-mediated Abl inactivation 
[394,395,396,397]). Second, endothelial Abl depletion results in complete absence of Abl 
protein expression, which leads to loss of the scaffolding functions of the Abl kinase in 
addition to loss of its kinase activity. Endothelial-specific knock-in of a kinase-inactive 
mutant Abl allele (Abl-K290R, [432]) could allow for the assessment of the role of Abl 
tyrosine kinase activity in endothelial function. Alternatively, generation of tissue-
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specific knock-in mice expressing an imatinib-resistant Abl kinase (Abl-T315I mutation, 
[414]) would enable the assessment of the contribution of Abl kinase inhibition in 
endothelial cells (or cardiomyocytes) to the cardiovascular complications of imatinib 
therapy. 
However, despite reports of adverse cardiovascular effects in a subset of 
imatinib-treated patients [350,351,352], incidence of these complications appears to be 
low, and imatinib is generally well tolerated [368]. Similarly, overt cardiovascular 
phenotypes were observed only in a subset of adult AblECKO; Arg+/-
In summary, the current studies have demonstrated a requirement for 
endothelial expression of the Abl family kinases in vascular development and function 
 mice, suggesting that 
additional factors (genetic and/or environmental) are required for development of 
pathological cardiovascular phenotypes. Accordingly, genetic and environmental 
differences in patients are likely to underlie the observed clinical variability in 
cardiovascular complications of imatinib. Thus, it would be of interest to determine how 
genetic differences may modify the effects of endothelial Abl loss-of-function in our 
mouse model, as well as whether loss of endothelial Abl kinase function may modify the 
progression of cardiovascular pathologies such as diabetes and atherosclerosis. These 
studies could be particularly relevant, given that the requirement for chronic use of Abl 
kinase inhibitors likely will increase the proportion of patients treated with these drugs 
in the context of cardiovascular co-morbidities. 
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in vivo, as well as in mediating endothelial cell survival and permeability responses to a 
variety of soluble mediators. Further studies will be needed to examine the potential 
utility of pharmacological targeting of the Abl kinases for treatment of disorders 
involving deregulated vascular permeability and angiogenesis, as well as to understand 
the precise mechanisms underlying the adverse effects of depletion of the endothelial 
Abl kinases on in vivo vascular function. An improved understanding of these 
contrasting beneficial and deleterious effects of loss of endothelial Abl kinase function 
will be useful for optimizing the clinical use of Abl kinase inhibitors, in order to reduce 
potential cardiovascular complications. 
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